CHARACTERIZING RISK & BURDEN OF LOWER CRANIAL NEUROPATHY (LCNP)  AS LATE EFFECT AMONG OROPHARYNGEAL CANCER SURVIVORS by AGGARWAL, PUJA
The Texas Medical Center Library 
DigitalCommons@TMC 
UT School of Public Health Dissertations (Open 
Access) School of Public Health 
Spring 12-2019 
CHARACTERIZING RISK & BURDEN OF LOWER CRANIAL 
NEUROPATHY (LCNP) AS LATE EFFECT AMONG 
OROPHARYNGEAL CANCER SURVIVORS 
PUJA AGGARWAL 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/uthsph_dissertsopen 
 Part of the Community Psychology Commons, Health Psychology Commons, and the Public Health 
Commons 
 
 
 
 
 
CHARACTERIZING RISK & BURDEN OF LOWER CRANIAL NEUROPATHY (LCNP) 
AS LATE EFFECT AMONG OROPHARYNGEAL CANCER SURVIVORS 
 
by 
 
PUJA AGGARWAL, B.D.S (DENTISTRY) M.P.H (EPIDEMIOLOGY) 
 
 
APPROVED: 
 
 
 
 
Dr. Xianglin L. Du, MB MS PhD 
 
 
 
 
 
Dr. Katherine A Hutcheson, PhD 
 
 
 
 
 
                                                                       Dr. Linda B. Piller, MD MPH 
 
  
 
 
Dr. Michael Swartz, PhD 
 
 
 
 
 
DEAN, THE UNIVERSITY OF TEXAS 
SCHOOL OF PUBLIC HEALTH 
                                                    
 
 
 
Copyright 
 
by 
 
PUJA AGGARWAL B.D.S (DENTISTRY) M.P.H (EPIDEMIOLOGY) 
2019
 
 
 
DEDICATION 
To my dad late Dr. Vijay Prakash, mom Dr. Aruna Prakash, Rohit, Sameer, and my brother 
Dr. Prashant Prakash. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHARACTERIZING RISK & BURDEN OF LOWER CRANIAL NEUROPATHY 
(LCNP) AS LATE EFFECT AMONG OROPHARYNGEAL CANCER SURVIVORS 
 
 
by 
 
PUJA AGGARWAL, B.D.S (DENTISTRY) M.P.H (EPIDEMIOLOGY) 
 
 
 
Presented to the Faculty of The University of Texas 
School of Public Health 
in Partial Fulfillment 
of the Requirements 
for the Degree of 
 
DOCTOR OF PHILOSPHY 
 
 
THE UNIVERSITY OF TEXAS  
SCHOOL OF PUBLIC HEALTH 
Houston, Texas 
December, 2019 
 
 
 
 
 
 
 
PREFACE 
 “I don’t have a choice as to my “new” normal, so I do what I can to continue to find 
enjoyment and fulfillment in life.”  –Ed Steger, head and neck cancer survivor 
My dad, late Dr Vijay Prakash (Professor, Internal Medicine & Cardiology) and my mother 
Dr. Aruna Prakash (Gynecology & Obstetrics) devoted their entire life to the service of their 
patients and their immense dedication has inspired me the most in my journey as an 
epidemiologist with training in dentistry to pursue head and neck cancer research. Working 
as a dentist in India with oral cancer patients, losing beloved family members and friends to 
cancer and having witnessed the immense suffering that cancer brings to the patient and their 
families has further fueled my passion to pursue to pursue head and neck cancer research. 
Lower cranial neuropathy (LCNP) is a clinical condition of great concern, often accompanied 
with late radiation-associated dysphagia, which may enhance risk of aspiration pneumonia 
and contribute to debilitating functional morbidity with increased feeding tube dependence, 
hospitalization, weight loss, and life-threatening complications. During data abstraction, I 
have often observed LCNP patients describe their anguish with problems eating, swallowing, 
and embarrassment in eating in social settings contributing to feelings of social isolation 
which can be exacerbated sometimes by speech and hearing problems. It is my hope that this 
dissertation research will improve our understanding of late LCNP, to inform ongoing 
surveillance recommendations, targeted prevention, supportive care, and treatment 
interventions for patients with late LCNP to prevent functional decline and improve quality 
of life in these patients. 
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ABSTRACT 
 
Background: Lower cranial neuropathy (LCNP) is a rare but potentially disabling late effect 
of radiotherapy (RT) and other head and neck cancer therapies. Survivors who develop late 
LCNP may experience profound functional impairment with deficits in swallowing, speech, 
and voice. The aims of this research were: 1) to quantify the cumulative incidence of late 
LCNP and identify clinical predictors of late LCNP; 2) to investigate the impact of late 
LCNP on severity of cancer treatment-related symptoms, general functional impairment 
(GFI), and single item scores of the most severe symptoms; and 3) to quantify the association 
of late LCNP with swallowing-related quality of life (QoL) and functional status among 
long-term oropharyngeal cancer (OPC) survivors. 
 Methods: For the first aim of this dissertation the study population included 2,021 OPC 
survivors (median survival: 6.8 years) who received primary treatment at MD Anderson 
Cancer Center from 2000 to 2013. A retrospective cohort study was conducted and late 
LCNP events for all three studies were defined by neuropathy of the glossopharyngeal (IX), 
 
 
 
vagus (X), and/or hypoglossal (XII) nerves ≥3-months after cancer therapy and abstracted 
from medical records along with other study variables. For the second and third study, a 
cross-sectional survey analysis among 889 OPC survivors nested within a retrospective 
cohort of OPC survivors treated during January 2000 -December 2013 at MD Anderson 
Cancer Center was conducted (56% response rate). The survey included MD Anderson 
Symptom Inventory Head and Neck Cancer Module (MDASI-HN) and MD Anderson 
Dysphagia Inventory (MDADI) among other items. For the first study, cumulative incidence 
of LCNP was estimated using the Kaplan Meir method with adjustment for competing risks 
using time to event as the underlying metric. Log-rank test was used to assess differences 
between groups by LCNP status, and multivariable Cox proportional hazard models were fit. 
For the second study, the primary outcome variable was the mean of the top 5 most severely 
scored symptoms from MD Anderson Symptom Inventory Head and Neck Cancer Module 
(MDASI-HN) out of all 22 core and HNC-specific symptoms. Secondary outcomes included 
mean MDASI-HN interference scores and single item scores of the most severe symptoms. 
Multivariate models regressed MDASI-HN scores on late LCNP status adjusting for clinical 
covariates. Finally, for the third study, multivariate models regressed MDADI scores on late 
LCNP status adjusting for clinical covariates. 
Results: For the first study; 4.4% (n=88) OPC survivors were diagnosed with late LCNP 
with median time to LCNP onset after treatment of 5.4 (range, 0.3-14.1; IQR: 1.6-8.5) years 
post-treatment. Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI: 
0.02-0.03), 0.06 (95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and 
18 years of follow-up, respectively. Multivariable Cox regression identified T4 stage vs T1 
 
 
 
stage (HR: 3.82; 95%CI: 1.85-7.86, p=0.000) and accelerated RT fractionation vs standard 
RT fractionation (HR 2.15, 95%CI 1.34-3.45, p=0.002) independently associated with late 
LCNP status, adjusting for age, subsite, T-stage, smoking and therapeutic modality.  
In the second and third, cross-sectional survey analysis study overall, 4% (n=36) of 889 OPC 
survivors (median survival time: 7 years) developed late LCNP with median time to onset of 
5.25 years post-treatment. Late LCNP was significantly associated with worse mean top 5 
MDASI-HN symptom scores (coefficient, 1.54; 95%CI, 0.8, 2.2) adjusting for age, survival 
time, sex, therapeutic modality, T-stage, subsite, type of radiotherapy, smoking, and normal 
diet prior to treatment. Late LCNP was also associated with single item scores for difficulty 
swallowing/chewing (coefficient, 2.25; 95%CI, 1.3, 3.1), mucus (coefficient, 1.97; 95%CI, 
1.0, 2.9), fatigue (coefficient, 1.35; 95%CI, 0.4, 2.2), choking (coefficient, 1.53; 95%CI, 0.6, 
2.4), and voice/ speech symptoms (coefficient, 2.3; 95%CI, 1.6, 3.0) in multivariable models. 
However late LCNP was not significantly associated with mean interference scores after 
correction for multiple comparisons. LCNP cases reported significantly worse mean 
composite MDADI (LCNP: 68.0 vs. no LCNP: 80.2, p<0.001). Late LCNP independently 
associated with worse mean composite MDADI (β= -6.7, p=0.015, 95%CI: -12.0, -1.3) as 
well as all MDADI domains after multivariate adjustment. Finally, LCNP cases were more 
likely to have a feeding tube at time of survey (OR= 20.5; 95%CI, 8.6 to 48.9), history of 
aspiration pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), and tracheostomy (OR= 26.9; 95%CI, 
6.0 to 121.7). 
 
 
 
 
Conclusion: Risk of late LCNP progressed over time to exceed 10% cumulative risk over 
survivors’ lifetime even though it is considered a rare late effect. Our prediction model 
enabled identification of OPC survivors who had T4 tumors and those who received 
accelerated fractionation RT treatment as having higher risk of late LCNP. In the large 
survey study, OPC survivors with late LCNP reported significantly worse cancer treatment-
related symptoms, significantly poorer swallowing-related QOL and had significantly higher 
likelihood of poor functional status demonstrating the impact of late LCNP on both symptom 
severity and functional burden. Further, efforts are necessary to investigate the risk and 
predictors for this disabling late effect of cancer treatment, address severity of treatment-
related symptoms and optimize swallowing outcomes to improve QoL among growing 
numbers of relatively younger OPC survivors, who are expected to survive decades after 
treatment. 
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BACKGROUND 
Oropharyngeal Cancer (OPC) 
The incidence of OPC is increasing by 5% each year and it is projected that by 
2030 about half of head and neck cancers (HNC) will be OPC.1 This phenomenon is 
attributable to the  epidemic of HPV-associated OPC which is usually diagnosed in patients, 
who are middle aged, male, white, non-smokers and non-drinkers and have a higher 
socioeconomic status relative to individuals diagnosed with tobacco-related head and neck 
cancers.1-4 They also tend to have a history of higher number of sexual partners and are often 
diagnosed at a more advanced stage.1-4 As a consequence of modern regimens of organ 
preserving radiotherapy, favorable biology, and improved prognosis due to better response to 
treatment among HPV associated OPC patients, these patients have good survival rates and 
are often expected to live for  decades despite advanced stage disease.2-4 HPV associated 
HNC patients have a 3-year overall survival rates of 82%, in comparison to 57% among HPV 
negative HNC patients (with tobacco related cancer).2 HPV positive HNC also have better 5-
year overall survival (RR=0.4; 95%CI 0.2-1.08) than non-HPV related tumors.3 Further HPV 
associated HNC are more likely to occur in the oropharynx, especially base of tongue or 
tonsil and HPV positive tonsillar tumors at time of diagnosis. Primary tumors are more likely 
to be smaller with regional lymph node metastasis making most stage IV at presentation.4  
As the lifespan of OPC survivors increase, they are more likely to experience severe 
side-effects over time due to delayed or late adverse effects of tumor and cancer treatment. 
OPC survivors experience excess morbidity and disability compared to other cancer 
survivors, as these side-effects lead to problems in swallowing, eating, breathing, and 
 
2 
 
speaking. According to a survey study in 2004, 52% of HNC patients of mixed sites 
experience disability due to cancer treatment and are unable to work due to these problems.5  
  
Cranial Nerves 
Cranial Nerves (CN) comprise of 12 pairs of nerves that emerge from the brainstem. 
They regulate smell, sight, speech taste, movement of eyes, eye muscles, facial muscles, 
shoulder and neck muscles, and many other physiologic processes in the body.6-8These 
nerves are numbered using roman numerals, in the order they emerge from the brainstem and 
their names convey their function.6-8 
CN carry sensory or afferent fibers that conduct neural information from sensory 
receptors in the head and neck region to the brain and terminate in sensory cranial nerve 
nuclei. These nuclei are generally located laterally in the brainstem.8, 9The sensory 
component of CN includes general sensory, visceral sensory, and special sensory fibers 
which conduct smell, sight, taste, balance, and hearing signals to the brain.8, 9CN also carry 
motor or efferent fibers, which conduct regulatory neural input back from brain to target 
receptors (muscles) and other parts of the body. The neuronal cell bodies of these fibers are 
present in the motor cranial nerve nuclei, located more medially in the brainstem.8, 9 Further 
CN also transmit somatic motor, branchial motor, and parasympathetic motor fibers which 
supply voluntary muscles (skeletal muscles), involuntary muscles, and provide 
parasympathetic innervation to the viscera respectively.8,9 Most cranial CN are mixed, 
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carrying both sensory and motor nerve fibers but some only carry sensory or only motor 
fibers.8,9 
 
Lower cranial nerves (LCN) 
Lower cranial nerves (LCN) include glossopharyngeal (IX), vagus (X), accessory (XI) and 
hypoglossal (XII) nerves which provide innervation to the pharynx, larynx, and shoulder, 
neck and tongue muscles respectively.10  
 
Glossopharyngeal Nerve (IX) 
Glossopharyngeal Nerve (IX) is a mixed sensory and motor nerve, which innervates 
the tongue and the pharynx.8, 9 General sensory fibers of CN IX provide general sensory 
input from the soft palate, pharynx, oropharynx, tympanic membrane, Eustachian tube, and 
the posterior third of the tongue (also supplied by special sensory fibers of CN IX which 
provide taste sensation).8,9These fibers descend in the spinal trigeminal tract and the sensory 
fibers from tongue, tonsils, soft palate, and pharynx terminate in the spinal trigeminal 
nucleus.8,9 The sensory fibers from the tympanic nerve carry pain signals and also terminate 
in the spinal trigeminal nucleus.8,9 Visceral sensory fibers from CN IX conduct neural 
information from carotid body and sinus, to monitor blood pressure and arterial oxygen in the 
internal carotid artery.8,9 They pass through the jugular foramen, enter the medulla, descend 
in the tractus solitarius and terminate in the nucleus solitarius.8,9 Special sensory fibers from 
CN IX carry taste signals from the taste buds in posterior one-third of the tongue, pass 
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through the jugular foramen, enter the medulla, ascend in the tractus solitarius and terminate 
in the rostral gustatory part of nucleus solitarius.8,9 
Parasympathetic preganglionic motor CN IX fibers are located in the inferior 
salivatory nucleus and the nucleus ambiguus in the medulla.8, 9 Nerve axons from inferior 
salivatory nucleus exit the cranial cavity via foramen ovale, synapse on the otic ganglion to 
supply the parotid gland and regulate its secretory function.8Axons from the nucleus 
ambiguus innervate the carotid body and sinus and regulate the vasodilation of blood 
vessels.8 
Branchial motor fibers of CN IX emerge from the nucleus ambiguus, where the 
synapse between upper motor neurons passing through the corticobulbular tract and lower 
motor neurons occurs.8 These lower motor neuron axons exit the cranial cavity through the 
jugular foramen.8 They innervate the stylopharyngeus muscle, which plays a role in 
pharyngeal elevation to mediate swallowing and speech.8 This muscle facilitates swallowing, 
by elevating pharynx and larynx, to allow bolus of food to pass. 6, 7 
 
CN IX Injury: CN IX exits the medulla of the brain stem along with CN X and XI, via the 
jugular foramen. Thereby tumor-related and treatment-related toxicity can affect all three 
nerves together and lead to nerve impairment.8, 9 CN IX injury can lead to swallowing 
impairment, from the loss of function of the stylopharyngeus and also contribute to ipsilateral 
loss of taste sensation over the posterior third of tongue.8, 9 
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Vagus Nerve (X) 
Vagus Nerve is a mixed sensory and motor nerve. It innervates major areas of the 
body from the brainstem to the splenic flexure in the transverse colon.8, 9 General sensory 
fibers of CN X conduct somatosensory information including touch, temperature, and pain 
from the larynx, laryngopharynx, concha, external auditory canal, tympanic membrane, and 
the posterior meninges.8, 9 These fibers pass through the jugular foramen, enter the medulla, 
ascend in the spinal trigeminal tract and synapse in the spinal trigeminal nucleus.8, 9 From 
this nucleus, second-order axons carry neural information to the thalamus and the sensory 
cortex.8 Visceral sensory fibers of CN X, conduct visceral neural input from the aortic arch 
baroreceptors, aortic body chemoreceptors, the larynx above the vocal cords (via internal 
laryngeal nerve),the larynx below the vocal cords (via recurrent laryngeal nerve), epiglottis, 
and base of tongue.8 These afferent fibers pass through the jugular foramen, enter the 
medulla, descend in tractus solitarius and synapse in the nucleus solitarius.8 Neural signals 
from the nucleus are relayed to the reticular formation and the hypothalamus, and help to 
regulate numerous cardiac, respiratory and gastrointestinal functions.8 Branchial motor fibers 
of CN X emerge from nucleus ambiguus, where the bilateral corticobulbular fibers carrying 
upper motor neuron axons synapse.8These fibers exit the cranial cavity through the jugular 
foramen and branch out into the pharyngeal, superior laryngeal, and recurrent laryngeal 
nerves.8 
 
Pharyngeal Branch of CN X: The pharyngeal branch via the pharyngeal plexus, provides 
innervation to all the muscles of pharynx, soft palate (excluding stylopharyngeus, supplied by 
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CN IX and tensor veli palitini by CN V), and the palatoglossus muscle in the base of tongue.8 
The Palatoglossus; contracts to either lower the soft palate or raise the posterior part of the 
tongue.11,12 The levator veli palatine; elevates and retracts the soft palate, the 
palatopharyngeus; narrows the oropharynx, elevates the pharynx and guides the food bolus 
down to lower pharynx and also produces some laryngeal elevation.11,12 The muscularis 
uvulae; shortens and elevates the uvula.11,12  
 
Superior laryngeal Nerve (Branch of CN X): This nerve supplies the cricothyroid muscles 
and inferior pharyngeal constrictor.8, 9The cricothyroid muscles help to elongate and tighten 
the vocal cords and thereby contribute to phonation.13The inferior pharyngeal constrictor 
comprises of thryopharyngeus and cricopharyngeus, and the latter relaxes during swallowing 
to enable food bolus to pass downwards towards the esophagus.6, 7 
 
Recurrent laryngeal nerve (Branch of CN X): This nerve supplies the other intrinsic 
muscles of the larynx, which contribute to phonation by altering the shape of the glottis and 
altering the length and tension of the vocal cords.8, 9, 11-13 
The parasympathetic motor fibers of CN X, emerge from the cell bodies in the dorsal 
motor nucleus of CN X and medial part of nucleus ambiguus.8 These efferent fibers exit the 
cranial cavity through the jugular foramen and innervate the pharynx, larynx, viscera of the 
thorax and abdomen, cardiac muscle and the aortic bodies.8 They help to regulate numerous 
cardiac, respiratory and gastrointestinal physiological functions.8, 9 Overall CN X plays a 
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critical role in swallowing, as it regulates the posterior elevation of tongue, soft palate 
movement, velar elevation, closure of glottis and pharyngeal constriction allowing bolus 
transport into the esophagus. It contributes to phonation by regulating intrinsic movements of 
larynx.11, 12  
 
CN X Injury: CN X is very similar to CN IX in structure, function and they arise from the 
same cranial nerve nuclei in the brain stem and exit the skull base together through the 
jugular foramen accompanied by CN XI.8, 9 Therefore, these nerves are likely to be injured 
concurrently.8, 9 
Damage to CN X, can lead to paralysis of the pharyngeal muscles, larynx and vocal 
cords, and thereby contribute to dysphagia and speech impairment.8-10 Unilateral vagal injury 
can lead to reduced pharyngeal muscle movement, which can cause loss of adequate soft 
palate elevation, dysphagia, palatal droop on the affected side. Palatal drooping can result in 
passage of food into the nasal cavity during swallowing and thereby cause aspiration8, 9It can 
also cause reduced vocal cord vibration, leading to hoarseness and reduced pitch of voice.8, 9 
Thereby bilateral CN X injury, can cause bilateral pharyngeal paresis, severe dysphagia, 
bilateral paralysis of vocal cords and severe speech impairment.8, 9 
 
Hypoglossal (XII) nerve 
Hypoglossal (XII) nerve is a motor nerve and only carries somatic efferent 
fibers.13These fibers emerge from the hypoglossal nucleus in the tegmentum of the medulla, 
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from which neural information is relayed by the corticobulbular tract to the cortex.8 Efferent 
fibers of CN XII exit the cranial cavity, through the hypoglossal foramen and pass medially 
to CN IX, X and XI.8 They innervate the extrinsic tongue muscles (except palatoglossus) 
which regulate tongue movement.8,11,12 The genioglossus mediates  tongue protrusion, tongue 
retraction, and draws the tongue downward, thereby helping in food bolus transport.11,12 The 
hyoglossus retracts and depresses the tongue and elevates the hyoid bone, whereas 
styloglossus is responsible for upward and backward movement of the tongue.11,12 These 
efferent fibers also provide nerve supply to all the intrinsic tongue muscles which alter the 
shape of the tongue.8,11,12 These muscles include the superior longitudinal; which shortens the 
tongue and turns its tip upward, the  inferior longitudinal; which shortens the tongue and 
turns its tip downward, the transverse; which narrows and elongates tongue, and the vertical; 
which flattens tongue.11,12 
 
CN XII Injury: The hypoglossal nuclei are in close proximity to each other, therefore 
tumor-related and treatment-related toxicity contributing to nuclear injury, is likely to affect 
both nuclei leading bilateral nerve impairment of the tongue.8, 9 
Lesions of hypoglossal nuclei in the brainstem and unilateral lesions of CN XII can 
cause ipsilateral tongue paralysis, atrophy of tongue muscles, wrinkled tongue appearance, 
tongue fasciculations, and mild speech impairment.8,9 In cases with ipsilateral paralysis of 
CN XII,  when the tongue is protruded it deviates towards the affected side, due to the 
genioglossus action on the unaffected side, which can over time lead to tongue fasciculations 
and atrophy.8,9 Bilateral CN XII injury leads to bilateral tongue paresis, inability in tongue 
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protrusion, atrophy, fibrillations, severe dysphagia, and speech impairment. Reduced lingual 
motion may contribute to swallowing apraxia, oral residue, bolus formation problems, and 
reduced bolus movement, thereby leading to extensive swallowing toxicity.8-13 
In summary injury to lower cranial nerves can lead to profound functional impairment 
in terms of dysphagia, vocal cord paresis with or without accompanying lingual weakness 
14,15 often with co-existing problems in speech and voice and shoulder impairment .10,14,16,17 
Therefore lower cranial nerve injury can have an adverse impact on swallowing-related QoL 
among OPC patients.16,18 
 
Lower Cranial Neuropathy (LCNP) 
Lower cranial neuropathies (LCNP) are a rare, but severe late effect induced by 
damage due to radiotherapy or surgery.14,15,19 LCNP can occur both unilaterally and 
bilaterally and can affect glossopharyngeal (IX), vagus (X), accessory (XI), and hypoglossal 
(XII) nerves.14,15,18,19These nerves are critical to the oropharyngeal phase of swallowing 
mechanism and speech production and shoulder movement. 14-16, 18, 19  
According to a recent report, the incidence of late LCNP among 59 OPC survivors 
was 5% at 5.7years (Hutcheson, et al).15 Nerve palsies have delayed occurrence.14, 
15,19According to a previous study among NPC patients, late LCNP was reported 12 months 
to 240 months after radiation treatment.19 Therefore, there is need for long-term surveillance 
of late LCNP among HNC and OPC patients.14, 15, 19 
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Previous studies have suggested that, malignant tumor invasion may cause upper 
cranial nerve neuropathy, whereas radiation associated injury is more likely to cause lower 
cranial nerves neuropathy (LCNP).20 Therefore, competing causes of nerve palsy, like second 
primary, recurrent, and metastatic tumors need to be assessed, and such patients need to be 
excluded, in order to identify patients with treatment-associated late LCNP. 
 
Mechanism of Nerve Injury 
Radiation injury to cranial nerves can be acute; days after exposure to radiation or 
late; which occurs months and years after exposure to radiation.21 Acute radiation injury is 
rare with standard fractionation RT treatment among HNC patients, and late radiation 
toxicity is more commonly reported. According to previous literature, different theories 
postulate that, late LCNP can be caused by peripheral nerve and brainstem injury.15, 21-23 
 
Peripheral Nerve Injury Theory 
Peripheral nerves including cranial nerves and spinal nerves are considered to be 
relatively resistant to radiation injury.15, 21-23 Literature suggests however, that radiotherapy 
may contribute to peripheral nerve injury by axonal degeneration, suppression of Schwann 
cell proliferation, and fibrosis of connective tissues. 15, 21-24  
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Axonal Degeneration 
Radiotherapy (RT) can cause cranial nerve injury directly by axonal 
degeneration.24This axonal injury may contribute to local demyelination, membrane 
instability or vascular endothelial injury which may lead to ischemia, fibrosis, secondary 
neural injury, and eventually myokymia.21, 25  
Myokymia is clinically observable continuous rippling or undulating involuntary 
muscular movement, which can be mistaken for fasciculations and has been documented 
among neuropathies with nerve compression or entrapment.25, 26 Myokymia can occur in 
some muscles innervated by cranial nerves and is often a clinical symptom of radiation 
associated LCNP.15 
 
Vascular Injury  
Radiotherapy(RT) may contribute to cranial nerve injury indirectly by causing 
vascular endothelial injury.21 Endothelial cells in capillaries are extremely radiation sensitive 
and RT injury can cause thrombosis, obstruction, and capillary destruction.21 It has been 
suggested that at standard fractionation schedule, RT dose of 50-60 Gy can cause arterial 
damage.27 However capillary injury can occur at RT doses > 40 Gy.27 This vascular injury 
can lead to ischemia and fibrosis of surrounding connective and soft tissues adjacent to 
nerves.21,27 Thereby damage to blood vessels can contribute to axonal degeneration and 
cranial nerve injury.15,21 
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Fibrosis 
It is postulated that connective tissue and soft tissue fibrosis may lead to nerve 
compression injury or loss of vascular supply to the nerve sheath. 21,26,28 Tissue pressure due 
to fibrosis, can cause blood supply interference or direct neural vascular damage, extensive 
vascular sclerosis, and microvascular damage contributing to axonal degeneration leading to 
fibrosis induced nerve infiltration, compression, and thereby nerve injury.15,17,24,27-29 
According to a previous study among NPC patients, 12/19 (63%) patients with radiation-
related cranial nerve palsy reported fibrosis of neck muscles and other studies have supported 
this association.17 The authors postulated, neck fibrosis may cause compression of cranial 
nerves passing through the neck, leading to cranial nerve palsy.17 This idea was supported by 
the fact, that CN XII, CN X, and recurrent laryngeal nerve (branch of CN X) were most 
frequently damaged in this study and these nerves pass through the anterior portion of the 
neck, which receives substantial amounts of RT.17 Other studies have shown similar 
results.30-32 Another study reported 6/7 NPC patients, treated with parapharyngeal radiation 
boost developed CN XII palsy on the boosted side.33 Other studies have speculated that 
neurovascular fibrosis in the parapharyngeal region and fibrosis of the retroparotid space may 
contribute to neuropathy of CN IX, X, XI, XII though exact mechanism was not described. 
15,16,32 
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Schwann cell Depletion 
Schwann cells play a prominent role in the peripheral nervous system. They provide 
support to neurons, produce the myelin sheath around axons, and help in axon regeneration 
and neuronal survival.34 RT toxicity of cells, can cause increased expression of vascular 
endothelial growth factor (VEGF), which can contribute to enhanced permeability of blood 
vessels.34 Consequently interstitial edema may occur, leading to fibroblast cell growth 
causing axonal compression, which in combination with hypoxia may contribute to axonal 
degeneration and subsequent Schwann cell proliferation.34 This Schwann cell accumulation, 
may lead to increased cellular expression of RT injury and contribute to their cell death 
(leading to depletion of Schwann cell), which in turn may trigger myelin loss and additional 
axonal degeneration.34 Thereby Schwann cell depletion, may contribute to loss of nerve 
fibers, nerve cell injury and eventually impairment of peripheral nerves.34 
 
Wallerian Degeneration  
RT-induced peripheral nerve injury can also lead to Wallerian Degeneration, which 
involves axonal skeleton breakdown distal to injury site. 21,34,35 Schwann cells reject the 
myelin component of their plasma membrane leading to disintegration of the myelin sheath.35 
This degenerated myelin contains myelin-associated glycoprotein, which further suppresses 
regeneration of damaged axons.35 Wallerian Degeneration may also lead to initiation of 
inflammatory mechanisms and it has been suggested that the release of pro-inflammatory 
cytokines and growth factors, may mediate biological processes including inflammation and 
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fibrosis, which can cause  late radiation nerve damage.21,34,35Thereby this degenerative 
process, has been reported after RT in some studies and may contribute to nerve impairment 
in both the peripheral and the central nervous system.11 
It has also been suggested that if surgery or tumor invasion damages the vascular 
supply of cranial nerves, they may become more susceptible to radiation injury. 21 
In summary, RT may contribute to extensive injury and ischemia of nerves, causing 
functional nerve impairment, and late LCNP.15, 17  
 
Brainstem Injury Theory  
A complementary theory suggests, that high RT dose to malignant lesions or RT 
targets near the base of the skull or the bulbar region can lead to brain stem injury, which in 
turn can cause lower cranial nerve dysfunction.21, 36 This theory is supported by 
documentation of LCNP among NPC, which is close to the skull base and brain stem.23 It is 
postulated  that base of skull irradiation, can lead to a different combination of CN X, XI, and 
XII palsies.23 This is especially relevant with IMRT, which may lead to unintended higher 
RT dose to non-target regions, like the brainstem relative to older RT planning methods.  
Radiation field overlap may contribute to formation of “hot-spots” and could cause 
development of radiation associated late LCNP.23, 37  
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Brainstem 
The brainstem is located in the posterior cranial fossa and is an extremely important 
sensitive region of the brain containing sensory and motor neural pathways, that connect the 
brain with rest of the body.9, 21 It comprises of the midbrain, the pons, and the medulla 
oblongata.21 It also contains the corticospinal tract, posterior column medial lemniscus 
pathway, and the spinothalamic tract and numerous cranial nerve nuclei.21  
All the cranial nerves except CN III (oculomotor) and CN IV (trochlear), emerge 
from their nuclei located within the tegmentum of the brainstem.9, 21The nuclei of CN IX, X, 
XI, and XII are located in close proximity to each other in the medulla, whereas the nuclei of 
CN V, VI, VII, and VIII are located in the pons.21 Thereby, it is postulated that high radiation 
dose to brainstem, may cause injury to the cranial nerve roots and the nuclei.21 This theory 
may be supported by Bulbar palsy, which includes CN IX, X, XI, and XII dysfunction which 
is suggested to be caused by brainstem lesions in cranial nerve nuclei or lower cranial nerve 
injury outside of brainstem.38 
It has also been suggested that, brainstem damage may depend on volume of 
brainstem tissue being irradiated, during fractionated radiation treatment rather than 
maximum radiation dose received.21 A previous study reported that, RT dose of 60, 53 and 
50 Gy when 1/3, 2/3 and 3/3 of the brainstem is irradiated at a fractionation of 2Gy/fraction 
had a 5% brainstem injury risk after 5 years of RT exposure.39  Another study reported that, 
total volume brainstem irradiation with a RT dose ≥ 65 Gy resulted in a 50% increased risk 
of treatment related toxicity after 5 years post-RT.21 A multivariate analysis also revealed that 
brainstem volume irradiated with > 60 Cobalt-Grey equivalent (CGE), was significantly 
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associated with brainstem damage. In fact, if greater than 0.9cc of the brainstem was 
irradiated with > 60 CGE, there was a significant increase in risk of brainstem injury.21 
It has also been suggested that, radiation associated risk of brainstem toxicity may 
increase if targeted tumor is large, is in close proximity to the brainstem and radiation dose is 
high.21 Further as cranial nerves are considered to be radiation resistant, it has been suggested 
that RT dose of radiation to the brainstem may be a more influential factor leading to cranial 
nerve injury.21Therefore, brainstem injury due to cancer treatment, may be a potential risk 
factor for late LCNP and needs to be investigated in future prospective studies.15, 21 
 
Neuromuscular Junction and Muscle Contraction  
Neural transmission of signals from the nerve to the muscle occurs at the 
neuromuscular junction, which is initiated by the conduction of action potential to the axon 
terminal.21, 40This leads to its depolarization, which enables the opening of voltage-dependent 
calcium channels, to allow influx of Calcium ions into the axon terminal. These ions trigger 
the release of neurotransmitter Acetylcholine (ACh) into the synaptic cleft. ACh in turn binds 
to Nicotinic Acetycholine receptors located in post-synaptic membrane, leading to opening of 
ion channels to enable sodium ion influx into muscle cell. This produces a muscle action 
potential, which is transmitted by a chain of processes including, depolarization of 
sarcolemma, excitation-contraction coupling and leads to myofibril contraction and 
eventually target muscle contraction.21, 40 Muscle contraction and relaxation, is thereby 
regulated by neural input from the cranial nerves.21,40 Therefore, RT can also potentially 
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cause damage to the neuromuscular junction and lead to treatment related toxicities like late 
LCNP. 
 
Potential Risk Factors of LCNP 
According to previous literature, potential factors which may predispose patients to 
treatment associated late LCNP include radiation dose, radiation field, radiation 
fractionation, surgery, systemic therapy, and individual sensitivity to treatment.15, 18 
 
Radiation Dose 
Radiation dose is most commonly suggested in literature as the chief predisposing 
factor for late LCNP, but the contributing threshold dose is not known.15 According to a 
study among NPC patients cranial neuropathy is rare, but has, typically been reported among 
patients treated with daily RT dose of 180-200 centigrays per day, which is the current 
standard fractionated dose for OPC.17 Cumulative radiation dose to nasopharynx >70Gy was 
identified as a significant predictor for cranial neuropathy (RR = 1.961, p =0.009) and lower 
cranial neuropathy (RR= 3.088, p < 0.001), as it could potentially lead to muscle fibrosis and 
subsequent nerve toxicity.20 Similarly, a previous study of late LCNP reported a total 
radiation dose of about 70 Gy and higher among 3 among OPC survivors with LCNP.15,14 
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Regional Dose along Nerve Tracts: It has been suggested that the dose to regions-of interest 
(ROI) in the RT field, containing nerve tracts may play a more pivotal role in late treatment-
related toxicity than total RT dose.41 The superior pharyngeal constrictor (SPC) region, 
comprises of minor nerve tracts and the constrictor and longitudinal pharyngeal muscles, 
which are important for pharyngeal shortening during swallowing for bolus propulsion into 
the esophagus.41 A small retrospective case-control study of 38 OPC patients, reported that 
mean SPC dose was significantly associated with cranial neuropathy and late radiation 
associated dysphagia, controlling for T-stage and total RT dose.41 Majority (8/10) of LCNP 
cases in the study, received a mean SPC dose of ≥ 70 Gy.41 The authors reported that a mean 
threshold dose of 62 Gy to the SPC region can differentiate between OPC survivors with 
LCNP versus those without LCNP. 41Mean SPC dose was also associated in numerous other 
small clinical studies, with radiation associated dysphagia, use of feeding tubes during RT, 
and oropharyngeal swallowing efficiency after chemoradiation.42-44 Thereby it has been 
suggested that high mean SPC dose may have a detrimental impact on swallowing and 
functional outcomes years after treatment, and can contribute to late toxic effects including 
late LCNP among OPC survivors.41 
 
Radiation Fields 
HNC and OPC patients, may include irradiation fields comprised of healthy tissues, 
lower cranial nerves, and pharyngeal mucosa, and ionizing RT treatment can cause nerve 
injury, swallowing toxicity and speech impairment.39,45 Thereby RT field may be a 
predisposing factor for late LCNP.15,39,45 Among NPC patients, incorporation of facial-
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cervical RT fields was suggested to be associated with lower radiation associated cranial 
neuropathy incidence and longer latency in comparison to use of facial-cervical split 
fields.16,46 Further overlap of radiation fields during IMRT treatment may lead to 
development of “hot spots” as described earlier, and may contribute to late LCNP.15, 23 Some 
studies have documented a higher risk of LCNP among patients, who receive irradiation 
involving the carotid sheath, the parapharyngeal space and large subdigastric and 
retropharyngeal lymph nodes.15 It has also been suggested that CN XII injury only and CN X 
injury only, may be due to RT toxicity to submandibular space and carotid sheath 
respectively. 23 
 
Path of Lower Cranial Nerves and Nerve Injury: Path of lower cranial nerves in the head 
and neck region, may make them more susceptible to injury. NPC and OPC tumors may 
cause compression of lower cranial nerves in the suprahyoid neck.42 NPC tumors can also 
affect the carotid space and compress CN XII as it exits the Hypoglossal canal, and thereby 
affect CN IX to CN XI as they pass through the jugular foramen.42 RT dose of ≥ 70Gy to the 
carotid sheath, may result in lower cranial nerve injury, as CN XII passes through this region 
to innervate the hyoglossus muscle and the tongue.18, 28 It is postulated that, proximity of CN 
XII to the base of the tongue, which receives high RT dose, as well pressure from laryngeal 
airway masks can lead to fibrosis, loss of vascularity, nerve entrapment, and damage.16, 43 
Therefore LCNP among NPC patients can occur due to malignant tumor invasion, and at 
lower doses of radiation treatment to the brain stem and oral cavity.28  
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Chemotherapy 
Chemotherapy drugs are cytotoxic as they can destroy cancer cells, and modify radio 
sensitivity of cells either by, altering their cell-cycle phase or by interfering with repair of 
radiation initiated double-strand DNA breaks.21 An earlier study among NPC patients, 
reported that chemotherapy was significantly associated with development of cranial 
neuropathy (RR=1.42, p=0.021).20 A clinical trial among stage III and stage IVB NPC 
patients, revealed that late cranial neuropathy was significantly increased among patients 
treated with RT and concurrent adjuvant chemotherapy (p=0.042) than those treated with RT 
only.44 Similarly, in another study 6.3% of HNC patients, who received intra-arterial 
Cisplatin therapy developed cranial neuropathy shortly after treatment.42 This is not a 
standard procedure for cisplatin administration, and other studies have not reported similar 
associations.42 Chemoradiotherapy, is standard multi-modality treatment for stage III-IV 
HNC and OPC, but combined effects of RT and chemotherapy may contribute to increased 
treatment-related toxicity. Therefor future studies need to assess chemotherapy, as a predictor 
of late LCNP among HNC and OPC survivors.  
 
Fractionation Schedule 
Radiation dose fraction may also influence late LCNP. It has been suggested that 
among NPC patients, if fractionation dose is increased from 180cGy to 420 cGy there may be 
an increased risk of cranial nerve toxicity.17 A previous study among NPC patients, reported 
that RT fractionation schedule was a significant predictor of upper cranial nerve neuropathy 
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and not significantly associated lower cranial nerve neuropathy.20 The authors suggested that 
the lack of significant association between lower cranial nerve neuropathy and RT 
fractionation schedule, maybe due to lower cranial nerves being more affected by fibrosis.20 
An earlier randomized trial among NPC patients, reported that accelerated hyper-
fractionation radiation treatment, was associated with higher late LCNP incidence than 
conventional fractionation (13.0% vs 8.7%) over a median follow-up of 59.2 
months.33,47Therefore, fractionation schedule of RT needs to be assessed in future studies, as 
a predisposing factor for LCNP among OPC survivors. 
 
Surgical Treatment 
Surgical treatment along the course of cranial nerves may cause nerve damage and 
contribute to late LCNP. It has been suggested that, if surgery causes damage to vascular 
supply of cranial nerves, they may become more susceptible to radiation injury.21 Also 
depending on the operating field, isolated cranial nerve palsy or multiple cranial nerve injury 
may occur.42 Further, if surgery involves the sublingual region, hypoglossal nerve injury may 
occur.35 Neck Dissection has also been documented to lead to paralysis of CN VII, CN X, 
CN XI, and CN XII.33 Reports suggest CN XI paralysis is most common treatment related 
toxicity related to radical neck dissection with an incidence of about 62%.34, 35 
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Genetic Susceptibility  
A previous study postulated that individual sensitivity possibly due to genetic 
susceptibility, may contribute to CN XII palsy among NPC patients treated with standard RT 
dose of 66 Gy.28The authors supported their idea by reporting that 4/14 patients in the study, 
with radiation-related neuropathy did not receive high dose of radiation.28 In another 
retrospective study among 130 OPC patients, ERCC4 T2505C polymorphism was suggested 
to be associated with enhanced recovery from toxicity due to radiation treatment.49 ERCC4 is 
a gene which plays a role in repairing cell damage, due to ionizing effects of radiation.48 This 
gene, is involved in recognition of site of injury, recombination repair, and mismatch 
repair.48 ERCC4 T2505C polymorphism is reported with a allele frequency of about 36% and 
was associated with lower risk of long term feeding tube placement (OR=0.2; 95% 
confidence interval, 0.06-0.67) controlling for age, chemotherapy, T and N stage.48 Other 
reports have suggested a positive association between genetic markers and risk of radiation 
related tissue toxicity, and future genetic studies are needed to explore this association. 20, 49 
In summary, earlier studies have suggested that radiation dose, radiation field, 
radiation fractionation, surgery, systemic therapy, and individual sensitivity to treatment may 
influence risk of late LCNP among NPC patients.7 Thereby these variables were assessed in 
our study and investigated as potential predictors of late LCNP among OPC survivors. 
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Latency Period for Cranial Neuropathy 
A previous study among 59 OPC survivors by Hutcheson et al., reported a latency 
period from time of RT treatment to presentation of late LCNP with a median of 5.7 years 
and range of 4.6-7.6 years.15 An inverse relationship between the length of latency period 
between radiation treatment and presentation of late LCNP symptoms and dose of treatment 
has been suggested.16,20 This association has also been reported in clinical studies of injury of 
brachial plexus and experimental animal studies.23 It has been suggested that more precise 
information about nerve palsy onset, may lead to a stronger association between latency 
period and dose.23 Case reports have also suggested that, though there may be a substantial 
delay in appearance late LCNP symptoms, but once nerve palsy occurs consequential decline 
in functional status is progressive and rapid over subsequent months.15,25 
 
Progression of late LCNP 
Late LCNP is a progressive disease. An earlier prospective study among 3 OPC 
survivors with LCNP, suggested that these patients could experience severe decline in 
function overtime, as per patient reported MDADI scores.15 Long-term deterioration of 
swallowing function was also noted using clinician rated modified barium swallow (MBS) 
scores as per validated Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria, 
as well as diet score rated on the Performance Status Scale of Head and Neck Cancer (PSS-
HN).15 An earlier study among NPC patients had reported a late LCNP cumulative incidence 
of 5.7%, 17.4%, 27.1%, and 37.3% over a 5, 10, 15, and 20-year follow up respectively.20 
 
24 
 
Therefore, the risk of cranial nerve damage increases overtime and as a late treatment-
associated toxicity, LCNP has long term implications on the functional status of survivors. 
Further, as survival probabilities improve for OPC late-effects like neuropathy are more 
likely to occur, and patients should be followed for extended periods of time to assess and 
treat these late complications. 
 
Late LCNP and Late Radiation-Associated Dysphagia (late RAD)  
Late Radiation Associated Dysphagia (late RAD) is a severe form of dysphagia, 
which occurs among HNC patients many years after RT. It may contribute to severe 
problems in swallowing, eating, and extreme functional impairment in pharyngeal phase of 
swallowing, which may cause swallowing inefficiency, pharyngeal residue, and silent 
aspiration.19 Overtime about 85% of OPC survivors with late-RAD, develop pneumonia and 
more than 60% of them required long-term gastronomy tube placement.19, 41 
OPC patients in recent times tend to be middle-aged and are expected to survive 
decades after treatment, thereby it is more likely that these patients may develop late 
toxicities like late RAD.1, 19This idea is supported by findings from a recent study, which 
reported that that 86% patients with late-RAD were OPC survivors.19 
The prevalence of Late RAD is low with an estimated rate of 12%.19, 22 However as 
majority of OPC patients survive and eventually transition from oncologic management to 
care of primary care physicians, they may be lost to follow-up. Therefore, lack of adequate 
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surveillance may contribute to lower prevalence estimates of late toxicities like late RAD and 
even late LCNP. 
Patients with late RAD also often present with lower cranial neuropathies.19 It is 
postulated that LCNP potentially leads to the accelerated functional decline among patients 
with late RAD.19 Late RAD patients often have unilateral paralysis, muscle wasting leading 
up to atrophy of lingual and pharyngeal musculature implicating a prominent role of nerve 
injury in the functional decline experienced by these patients.47 In an earlier case series 48% 
of patients with late RAD had clinically-detectable cranial neuropathies, and cranial nerve 
XII and X palsies were most commonly reported.48 Further, another study reported that 90% 
of patients with late RAD displayed evidence of some evidence of loss of innervation to 
suprahyoid muscles in the pharynx when tested by EMG.50 
Bulbar Palsy along with neuromuscular fibrosis, is suggested to contribute to  
functional impairment among late RAD patients.19 A recent case report indicated that 
treatment-related LCNP may play a major role in late RAD, and precipitate delayed but 
extreme chronic oropharyngeal impairment and increased pharyngeal impairment, as 
recorded by modified barium swallow (MBS) studies.14 It was reported that Late LCNP 
patients with late-RAD, experienced deterioration of diet and speech scores, as reflected by 
Performance Status Scale for Head and Neck cancer (PSS-HN) scores.14 They reported low 
scores with MD Anderson Dysphagia Inventory (MDADI), which reflected overall 
impairment of swallowing related quality of life.14 Further, the functional status of cases 
emulated the trajectory of neuropathy experienced by patient i.e. if the late LCNP remained 
stable, physiologic impairment experienced by patient remained steady and if the late LCNP 
 
26 
 
was progressive then patient experienced severe decline in function, and decline in body 
weight.14 Most importantly late-RAD patients including those with late LCNP, do not 
typically respond well to treatment and experience excess disease morbidity and functional 
impairment overtime.14, 41 
Late LCNP may have a significant impact on dysphagia experienced by OPC 
survivors, many years after treatment and cause extensive functional impairment and result in 
poor swallowing related QOL. The functional impact of late LCNP has not been studied in a 
study with substantial numbers of OPC survivors and given that it is an area of concern 
among late LCNP patients, we investigated the impact of late LCNP on dysphagia and 
swallowing related QOL among OPC survivors. 
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Gap in Knowledge/Unmet Need: Previous studies examining late radiation-associated 
LCNP have mostly been case reports of nasopharyngeal cancer survivors. Few studies have 
addressed late LCNP among OPC survivors, the largest to date comprising only 3 late LCNP 
cases in a cohort of 59 OPC survivors.15With a rapidly growing pool of OPC survivors who 
have received curative doses of radiotherapy, there is urgent need to investigate this disabling 
late effect of therapy. Late LCNP is a debilitating, permanent condition, and can have a 
profound impact on QOL of OPC survivors yet we know little to predict or understand the 
continuum of associated toxicities.14 For the growing numbers of OPC survivors at risk for 
and experiencing late LCNP, needed to identify risk profiles of those most vulnerable to late 
LCNP and subsequent late effects to help in the development of more targeted preventive 
strategies and interventions. 
The overall objective of this research plan was to characterize risk and burden of late 
LCNP among OPC survivors. 
This research is expected to contribute to a comprehensive understanding about late LCNP in 
terms of incidence, predictors of risk, and impact on functional outcomes including 
swallowing-related QOL, symptom burden, and functional impairment and among OPC 
survivors.  
The contribution of the proposed research will be significant because once we identify 
predictors of late LCNP and associated late toxicities; we can identify high-risk populations 
who are most vulnerable for future implementation of targeted preventive interventions to 
alleviate late effects of cancer treatment among OPC survivors. Also, our study may provide 
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support for recommendations for ongoing surveillance of late-toxicities experienced by OPC 
survivors to promote timely treatment of side-effects. 
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Public Health Significance 
This research will support future research of late effects experienced by OPC 
survivors by providing information about late LCNP which has not been previously studied 
among a large cohort of more than 2,000 OPC survivors and its impact on morbidity and 
decline in function among these patients. Late LCNP experienced by OPC survivors may 
lead to placement of feeding tubes, tracheostomy tubes, and aspiration which can lead to 
pneumonia. Therefore, patients may be hospitalized and such adverse consequences lead to 
increase in medical costs.  
The results from this study have the potential to inform the development and 
implementation of ongoing surveillance, risk-reduction, and preventive interventions which 
could be implemented early and be personalized to meet individual needs to allow for more 
strategic allocation of resources and lower health care cost. 
OPC patients have excellent prognosis in terms of survival therefore de-escalation of 
treatment may be a viable option to reduce treatment-associated late toxicities like LCNP. 
Risk-based OPC treatment planning, use of targeted therapies, nerve-sparing RT planning to 
decrease irradiation of vital structures which play an important role in swallowing, or 
sequential chemoradiotherapy may help to alleviate late effects like LCNP and improve 
function among survivors. Knowledge about predictors of late LCNP and its consequent 
impact on swallowing function and overall symptom severity will allow more effective 
delineation of de-escalation targets. 
Among NPC patients, neuro-nutritional agents, glucocorticoids, and hyperbaric 
oxygen can be administered early to alleviate functional symptoms and prevent progression 
of nerve damage and such treatment, if viable, might be suggested to OPC patients with late 
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LCNP.44 Further, as among NPC patients, laryngoplasty, tracheostomy, and gastrostomy tube 
placement may help manage voice hoarseness, respiratory function, and maintain adequate 
nutritional intake and thereby have the potential to improve QOL in such patients.19 Similar 
options can be explored for OPC patients and more informed treatment decisions can be 
made with better understanding of the continuum of late LCNP and its associated functional 
implications. 
  The study identified predictors of LCNP, which can inform future research in terms 
of reducing treatment exposure. Currently, treatment of OPC does not vary by HPV status 
and this study has the potential to inform future clinical trials investigating de-escalation of 
OPC treatment based on HPV status. Further, this study has the potential to inform future 
screening and surveillance recommendations among OPC survivors, given the delayed 
progression of late LCNP. As neuropathies may be experienced among patients with other 
head and neck cancers, findings from this study may be extrapolated to inform survivorship 
research for such patients. The study will thereby address tertiary cancer prevention among 
OPC patients and help alleviate disease morbidity experienced by OPC patients over time. 
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SPECIFIC AIMS 
The incidence of oropharygeal cancer (OPC) is increasing by 5% each year and it is 
projected that by 2030 about half of head and neck cancers (HNC) will be OPC.1This 
phenomenon is attributable to the to the epidemic of HPV-associated OPC which is usually 
diagnosed in patients who are middle aged, and despite advanced-stage have biologically 
favorable disease with excellent prognosis for long-term survival. Survivors may experience 
severe side-effects over-time due to cancer treatment and thereby experience excess 
morbidity and disability compared to other cancer survivors. It has been estimated that 20%-
50% HNC survivors experience disability from treatment toxicities and are unable to work.2-5 
Late lower cranial neuropathies (LCNP) are a rare, but potentially severe late effect induced 
by damage due to radiotherapy (RT). Fibrosis of nerve tracts or adjacent soft tissues may lead 
to delayed but progressive neuro-vascular damage and eventually neuropathy which over 
time causes profound functional impairments.16 According to a recent report, the incidence of 
delayed LCNP among 59 OPC survivors was 5% at 5.7years (Hutcheson, et al).15 While a 
rare late effect, case reports suggest substantial functional burden including  profound 
impairment in swallowing, speech, voice and shoulder function and overall low quality of 
life in survivors who develop LCNP.14-16,19 
  
Gap in Knowledge/Unmet Need: Previous studies examining late radiation-associated 
LCNP have been case reports or small cohorts of predominantly nasopharyngeal cancer 
(NPC) survivors. Few studies have addressed late LCNP among OPC survivors. With an 
ever-growing pool of OPC survivors who have received curative doses of radiotherapy likely 
sufficient to induce LCNP, there is urgent need to investigate this disabling late effect of 
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therapy. Late LCNP is a permanent condition and may have a profound impact on quality of 
life (QoL) of OPC survivors yet we know little to predict or understand the continuum of 
associated toxicities.14-16 For the growing numbers of OPC survivors at risk for and 
experiencing LCNP, we must identify risk profiles of those most vulnerable to LCNP and 
subsequent late effects to help in the development of more targeted preventive strategies and 
interventions. 
 
Objective: The overall objective of this application was to characterize risk and burden of 
late LCNP among OPC survivors.  
 
Central Hypothesis: Our central hypothesis was that OPC survivors with late LCNP will 
experience higher levels of functional burden and symptom burden that impact their quality 
of life (QoL) relative to survivors without LCNP, and that significant predictors of late 
LCNP can be identified in this study to help target the high-risk populations for risk 
reduction strategies. 
 
Rationale: The rationale for this research was that once we identify predictors of late LCNP 
and associated burden, we can identify high-risk populations who are most vulnerable for 
future implementation of targeted risk reduction strategies to alleviate late effects of cancer 
treatment and improve QoL among OPC survivors. 
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Our study population comprised a cohort of disease-free OPC survivors diagnosed and 
treated at MD Anderson Cancer Center, January 2000 -December 2013 with a nested cross-
sectional survivorship survey.  
 
Specific aims: 
Aim1: To estimate the risk of late lower cranial neuropathies (LCNP) in patients with 
oropharyngeal cancer (OPC) and identify clinical predictors for late LCNP. 
Aim 1(a): To estimate the cumulative incidence of late LCNP among OPC survivors. 
Hypothesis: Based on preliminary data, we expected the 5-year incidence rate of late LCNP 
will be estimated at 5%. 
Aim 1(b): To identify clinical predictors for late LCNP among OPC survivors. 
Hypothesis for Aim 1(b):  We hypothesized that risk of LCNP, will be correlated with 
tumor subsite and stage, radiation dose, fractionation schedule, smoking status, and systemic 
therapy. 
 
AIM 2: To compare severity of treatment related symptoms and swallowing-related 
QoL by LCNP status among oropharyngeal cancer (OPC) survivors. 
AIM 2(a): To compare the severity of treatment-related symptoms and subsequent 
impact on General Functional Impairment (GFI), by LCNP status among 
oropharyngeal cancer (OPC) survivors. 
We assessed the impact of late LCNP on severity of treatment-related symptoms and general 
functional impairment using the MD Anderson Symptom Inventory Head and Neck Cancer 
Module (MDASI-HN) survey after end of cancer treatment. 
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Hypothesis: We hypothesized that LCNP status among OPC survivors, will be associated 
with higher symptom scores (per mean of top 5 most severe core and head and neck specific 
scores on MDASI-HN survey) and significantly higher levels of GFI (per mean interference 
scores on MDASI-HN survey) than those without LCNP. 
AIM 2(b): To compare swallowing-related QoL by LCNP status among oropharyngeal 
cancer (OPC) survivors. 
Impact of late LCNP on swallowing-related QOL was assessed using the MD Anderson 
Dysphagia Inventory (MDADI) survey after end of cancer treatment. 
Hypothesis for Aim 2(a): We hypothesized that LCNP status among OPC survivors will be 
associated with significantly worse swallowing-related QOL (per MDADI survey) than those 
without LCNP. 
 
Expected Outcomes:  
It was anticipated that the aims will yield a comprehensive understanding about late LCNP in 
terms of incidence, predictors of risk and impact on functional outcomes, symptom burden, 
functional impairment and QOL among OPC survivors. We hope to inform the development 
of effective risk reduction and management strategies for this rare but devastating late effect 
of therapy. 
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Figure 1: Overall Late LCNP Risk & Burden Study Aims 
 
 
Figure 1: Overall Late LCNP Risk & Burden Study Aims. 
OPC – Oropharyngeal Cancer, LCNP – Lower Cranial Neuropathy, MDADI – MD Anderson 
Dysphagia Inventory, MDASI-HN - MD Anderson Symptom Inventory for Head and Neck Cancers 
(MDASI-HN)  
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GENERAL STUDY METHODOLOGY FOR SPECIFIC AIM 1 AND 2 
Definition of Late LCNP  
Late LCNP was defined as swallowing-associated neuropathy of glossopharyngeal 
(IX), vagus (X) and hypoglossal (XII) nerves, which are critical to the oropharyngeal phase 
of swallowing mechanism and speech production. The degeneration of these nerves 
potentially results in substantial amounts of dysphagia and functional impairment, based on 
case report evidence (Hutcheson, et al).14-16,18,19 CN XI or Accessory Nerve palsy was rare 
and reports suggested that it occurs less frequently than CN X and CN XII palsy. It has been 
suggested that this may be due to the course of CN XI, in the posterior part of the neck, 
which may not receive as much radiation as the anterior part. Further, this nerve may also be 
protected from radiation damage by the cervical nerve. 28 CN XI palsy was also 
inconsistently recorded in medical charts. Thereby, CN XI was omitted from LNCP analysis 
in this research, with the intent to focus on swallowing-associated LCNP.  
 
Late effects of cancer treatment are often defined as severe treatment associated toxicities 
which occur 3 months or more after end of cancer treatment. 51 
Therefore, late LCNP due to treatment in our study was assessed 3 months or more after 
the end of cancer treatment to focus on late effects of therapy as opposed to neuropathy 
which may be tumor associated or an acute effect of treatment. 
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Descriptive Analysis Methodology: Descriptive statistics (e.g., means, ranges, standard 
deviations) and graphical methods (box-plots, histograms and scatter plots) were computed to 
explore relationship between variables of interest. Normality of continuous variables was 
tested, when normality assumption was met independent T-tests otherwise, Wilcoxon rank‐
sum test or Kruskal Wallis test was used to test for differences between groups. For 
categorical variables, contingency tables, chi-square (X2) test and Fisher’s exact test were 
used. 
 
Clinically important covariates: included age, t-stage, subsite, treatment modality and 
smoking. 
 
HPV Status: HPV status was not available in about half of the cohort, as HPV testing was 
not conducted consistently till 2007. But we classified patients as HPV – and HPV + based 
on test results. Only exploratory analysis of HPV status was conducted; therefore, HPV 
status information was not taken into consideration for our power analysis estimates. 
Analysis Software: Data was be analyzed using the statistical software package Stata and 
SAS. 
Hypothesis Testing: All reported p-values were two-sided and were considered to be 
statistically significant at p value of < 0.05.  
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Human Subjects  
This dissertation research was a secondary analysis of existing oropharyngeal cancer 
data. Informed consents were signed by participants prior to participating in the cross-
sectional patient reported outcome survey and in the tumor registry data. There were no 
benefits or risks for study participants in the conduct of the study. Only adults at least 18 
years of age were recruited for this study and children were excluded. 
 
Personal identifiers were used by selected study personnel for data abstraction and all 
study personnel participated in institution approved human subjects training course. 
Abstracted data was stored on a study database and access to database was protected by 
passwords. Survey forms were stored in locked cabinets and on a password protected 
database. Only de-identified data was used for analysis and was stored on encrypted 
institution approved computers and devices. 
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METHODS 
Research and Methods for Specific Aim 1(a) & 1(b): Cumulative Incidence & Risk 
Prediction 
 
Study Design 
This study was a retrospective cohort study. 
 
Study population 
This study included oropharyngeal cancer (OPC) patients diagnosed and treated at MD 
Anderson Cancer Center, January 2000 - December 2013.  
 
Exclusion criteria  
1. Patients who were deceased, had a secondary primary malignancy (SPM) or recurrent 
malignancy of the head and neck before 3 months of follow-up after end of cancer 
treatment. 
2. Patients diagnosed with LCNP before starting cancer treatment i.e. LCNP at baseline 
or before treatment. 
3. Patients who received cancer treatment with palliative intent. 
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Research and Methods for Specific Aim 1(a) Cumulative Incidence 
Data Collection 
Primary Outcome Variable: The primary outcome variable for this aim is late LCNP 
among all eligible OPC survivors in our study population. 
 
Diagnosis of Lower Cranial Neuropathy (LCNP): LCNP status among patients was 
assessed by clinical examination of cranial nerves by head and neck surgeon, radiation 
oncologist and speech pathologist and is recorded in the charts of patients.  
 
Data Abstraction from Medical Records: Medical records were reviewed to identify cases 
of LCNP. Case status was verified by head and neck specialized physician review. Time to 
event of LCNP diagnosis was also be collected. 
. 
Variables: Demographic, clinical information, treatment related factors, health behaviors 
and HPV status were abstracted from medical charts using a structured study forms. 
Demographic Variables: included age, sex, race and education.  
Clinical Variables: included T and N staging, sub-site, OPC treatment modality, RT dose, 
mode of RT, RT fractionation schedule, chemotherapy, surgery, lack of solid food diet at 
baseline (as a surrogate of baseline dysphagia), and smoking status. 
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Power Analysis  
The power analysis of this aim addressed the precision of our cumulative incidence 
estimate, by calculating 95% confidence intervals using late LCNP event rates between a 
range of 0.02 – 0.10. An earlier study among 59 OPC survivors, treated on clinical trials at 
MDACC by Hutcheson et al has suggested a LCNP cumulative incidence of 2.1% at 6-year 
follow-up of (95% CI: 0.2%,10%) which suggests our assumption to detect a 5- year 
incidence of LCNP of 5% is reasonable.7 
On the basis of tumor registry estimates, assuming that 95% OPC patients are alive at 
3 months such that late LCNP outcome can be assessed among these patients, as well as loss 
to follow-up and missing data rate of 20%, 52 we will have a sample size of 2683. 
About half of our cohort has missing information for HPV status. As we did not believe HPV 
status influences risk of late LCNP, only exploratory analysis of HPV status was conducted 
in our study and was not be the focus of any of our power analysis estimates. 
We used the following formula to calculate the 95% confidence interval of our cumulative 
incidence estimates of 0.02-0.10. 
Formula of 95% Confidence Interval for Incidence Proportion 
95%CI = P ± 1.96 √ (P (1-P) / N) 
Where P= incidence proportion and N= sample size 
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Confidence Interval and Precision of Estimate of Incidence N= 2683 
LCNP Event 
Rate 
 
95% Lower 
Bound CI 
95% Upper 
Bound CI 
0.02 .015 
 
.025 
 
0.03 .023 
 
.036 
 
00.04 .032 
 
.047 
 
0.05 .042 
 
.058 
 
0.06 .051 
 
.069 
 
0.07 .061 
 
.079 
 
0.08 .070 
 
.090 
 
0.09 .080 
 
.101 
 
0.10 .096 
 
.104 
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Literature Review, Research and Methods for Specific Aim 1 (b): Risk Prediction 
 
Literature Review Specific Aim 1 
Earlier studies have revealed that age, tumor subsite, tumor stage (T-stage) and pre-
treatment swallowing scores as per MDADI may have an impact on swallowing scores as per 
MDADI overtime. 53-55Similarly another review among OPC patients treated with transoral 
robotic surgery, also reported that pre-treatment swallowing function, T-stage, N-stage, 
primary subsite involving base of tongue and adjuvant chemoradiation may predict 
swallowing outcomes and toxicity.56  
 
Treatment Intensity: HNC patients treated with non-surgical therapy had previously 
reported, that treatment intensity as per patients treated with less <50 Gy had significantly 
better swallowing scores on the MDADI, than those treated with higher RT dose or 
chemoradiation (p< 0.001).57 Therefore patients treated more aggressively with greater 
treatment intensity or combined modality, may be more likely to develop late toxicities like 
late LCNP. 
 
Swallowing scores prior to treatment:  In a previous study, swallowing scores prior to 
treatment explained 13% of the variance in long-term swallowing scores among HNC 
patients.57 Therefore, patients not eating solid food at baseline (prior to treatment) may have 
some pre-treatment swallowing dysfunction, which may be tumor-associated and may 
eventually contribute to development of late LCNP overtime.  
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Tumor Stage (T-Stage): OPC patients withT1 and T2 tumors, have reported significantly 
better swallowing scores as per MDADI (+15.9, p=0.0001 and + 10.9, p=0.0049 
respectively) than patients with T4 tumors.53 This may be due more aggressive treatment of 
advanced OPC tumors, which may have a detrimental impact on long term toxicities like late 
LCNP and late-RAD.  
 
Smoking: Current smokers have also reported significantly worse swallowing scores as per 
MDADI (- 9.4 points, p=0.0007) compared to nonsmokers.53 Further smoking can lead to 
worse functional outcomes and inferior prognosis overtime, for both HPV positive as well as 
negative disease.53 Smokers therefore may experience greater disease morbidity and late 
treatment -related toxicities like late LCNP. 
 
Age: An earlier study reported that younger HNC patients reported worse swallowing scores 
overtime.57 This may be due to higher expectations of younger patients to resume work and 
daily activities after treatment, which when unmet lead to greater dissatisfaction and higher 
disease burden. Given the long latency period for late LCNP, these patients may eventually 
develop late toxicities like late LCNP. 
 
Survival Time: Further long-term survival of OPC patients, may also contribute to higher 
chances of them developing late LCNP. Survival time will refer to difference between time 
of diagnosis and time of last follow-up. 
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In summary, age, T and N staging, sub-site, pre-treatment swallowing dysfunction, 
smoking and survival time may act as potential confounders, contributing to development of 
late toxicities like late LCNP. These variables were evaluated and controlled for in our 
analysis to obtain adjusted effect estimates for predictors of late LCNP in our study.52, 54, 55, 57 
 
Effect Modifiers: There was insufficient evidence in literature to suggest any specific effect 
modifiers, and given that late LCNP was rare, we did not have enough power to explore 
effect modification in this study. We however conducted exploratory analysis of biologically 
plausible interaction terms between treatment variables including RT dose, age, survival time 
and smoking. 
 
Research and Methods 
 
Study Design: Same as Aim 1 a 
 
Study population: Same as Aim 1 a 
 
Exclusion criteria: Same as Aim 1 a 
 
Data Collection 
Primary Outcome Variable: Same as Aim 1 a. The primary outcome variable for this aim 
was late LCNP, among all OPC survivors in our study population. 
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Definition of Late LCNP: Same as Aim 1 and Aim 2  
Diagnosis of Lower Cranial Neuropathy (LCNP): Same as Aim 1 a 
Primary Exposure: Radiation therapy (RT) was the exposure of interest for this aim, as 
most OPC patients receive either RT alone or in combination with systemic therapy and 
exposure to surgery alone or surgery in combination to adjuvant therapy is rare. RT dose 
which has been suggested by the literature as one of the main predictors of LCNP was the 
primary exposure for this aim.14-16 
 
Predictors 
RT dose, mode of RT, RT fractionation schedule, chemotherapy, surgery, eating solid food at 
baseline and smoking are some of the variables based on literature review which may 
influence risk of late LCNP and may act as predictors along with our main predictor RT 
dose.15,17,18,42,46 Thereby these variables were assessed in our proposed study and investigated 
as potential predictors of late LCNP among OPC survivors. 
 
Covariates  
Demographic, clinical information, treatment related factors, health behaviors and HPV 
status were abstracted in Aim 1 a. 
Demographic covariates included age, sex, gender, race and education. 
Clinical covariates included T stage, sub-site, treatment modality, RT dose, mode of RT, RT 
fractionation schedule, chemotherapy, surgery, lack of solid food diet at baseline and 
smoking 
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Survival Time was defined as the number of years a patient survives after diagnosis.  
 
Power Analysis  
The power analysis of this aim addressed the specific hypothesis that risk of LCNP, 
would be correlated with tumor subsite and stage, radiation dose, fractionation schedule, 
smoking status, and chemotherapy. A previous study revealed that the event rate of late 
LCNP among 59 OPC survivors was 5%.15 
We assumed reasonable tumor regression rates and that 95% OPC patients are alive at 
3 months, so late LCNP outcome could be assessed among these patients. We also assumed a 
loss to follow-up and missing data rate of 20%, 52 therefore we would have a sample size of 
2683. Assumptions derived from unpublished pilot data (PA11-0809, PI: Hutcheson), 
included a standard deviation for radiation dose of 2.59. 
A previous study conducted among NPC survivors reported that total radiation dose 
to nasopharynx above 70Gy may be a significant predictor for cranial neuropathy (RR = 
1.961, p =0.009) and lower cranial neuropathy (RR= 3.088, p < 0.001).20 Given the low event 
rate of late LCNP, retrospective study design, loss to follow-up, and possibility of missing 
data we assumed we would find a small effect size of 1.4 according to Cohen’s conventions 
for small effects. Therefore, assuming hazard ratios for late LCNP a range of 1.1 – 1.4 we 
calculated the power for this aim.  
As per the reasons stated above we also assumed that the R square or the variation in 
our primary predictor RT dose explained by the 13 predictors in the cox model would range 
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from 0.2, 0.3 and 0.4. This would allow us to derive power calculations for this study 
capturing a range of effect sizes which fit Cohen’s conventions for medium and large effect 
sizes for multiple R square which was a plausible assumption for this model. 
Proc Power in SAS with assumptions mentioned above was used for the power calculations 
and are listed in the table below. 
R-square Hazard Ratio Power 
 
0.2 1.1 0.725 
0.2 1.2 0.998 
0.3 1.1 0.667 
0.3 1.2 0.996 
0.4 1.1 0.601 
0.4 1.2 0.988 
 
Therefore, we observed that at a modest assumption of R-square of the important 
covariates explaining only 20% of the variation in radiation dose, assuming late LCNP event 
rate of 5%, loss to follow-up and missing data rate of 20%, standard deviation of radiation 
dose of 2.59, hazard ratio range of 1.1 – 1.4 with a R-square range of 0.2 – 0.4 with n=2683, 
we would have 99% power to detect a reasonable hazard ratio of 1.2 for radiation dose and 
late LCNP 
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Research and Methods for Specific Aim 2 (a) & (b): Symptom Burden & Functional 
Burden 
 
Study Design 
This study was a cross-sectional survivorship study.  
 
Study population for Aim 2 
This study will include a sub-cohort (907) of the population in Aim 1, who responded to a 
cross-sectional survivorship survey that was conducted among OPC survivors treated at MD 
Anderson Cancer Center during January 2000 -December 2013.  
 
Key exclusion criteria 
1. Patients who were deceased, had a secondary primary malignancy (SPM) or recurrent 
malignancy of the head and neck preceding the survey administration 
2. Patients lost to follow up or refused contact by MD Anderson prior to survey 
administration 
3. Patients whose primary spoken language is not English.  
4. Patients diagnosed with LCNP or with clinical signs of LCNP before starting cancer 
treatment i.e. LCNP at baseline. 
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Survey Characteristics 
Cross-sectional Survey: A cross-sectional patient reported outcome survey was 
administered to OPC survivors in Fall, 2015, and included the following validated 
instruments and study-specific items: MD Anderson Dysphagia Inventory (MDADI), MD 
Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN), decisional 
regret, and adapted patient-reported version of Performance Status Scale for Head and Neck 
cancer (PSS-HN), EQ5D, and adapted NHANES terminology for head and neck specific 
health problems (osteoradionecrosis, lymphedema, aspiration, thyroid problems, stricture of 
throat or esophagus, pneumonia and hospitalization), as well items pertaining to feeding tube, 
tracheostomy, smoking, and employment status . 
 
MD Anderson Dysphagia Inventory (MDADI) is a validated patient reported outcomes 
(PRO) survey, with 20 questions that quantify perceived limitations in swallowing ability of 
OPC patients and their impact on day to day activities of these patients.58 MDADI was 
validated among HNC patients and has internal consistency scored by Cronbach’s alpha of 
0.96 and was documented to have test-rest reliability correlations ranging from 0.69 to 
0.88.58  
The survey provides subscale scores which are comprised of emotional (based on 6 
questions), physical (based on 8 questions), and functional scores (based on 5 questions). It 
also estimates a global summary score (based on 1 question- “My swallowing limits my day 
to day activities”) and composite score (based on 19 questions). The composite MDADI 
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score is comprised of responses from 19 questions on the survey which are considered to 
reflect overall swallowing related quality of life.54, 58-60 
 
Scoring of MDADI: The questions related to swallowing function are Likert scaled with the 
options strongly agree, agree, no opinion, disagree and strongly disagree, scored on a scale of 
1-5, respectively, with the exception of two questions (E7 and F2) for which reverse scoring 
is calculated. After summation of response scores, mean is estimated and multiplied by 20 to 
estimate total score.54 Total scores range from 20-100 with higher scores reflecting higher 
perceived swallowing-related QOL.54, 58-60We can use MDADI scores as continuous or 
categorical variables. For categorical variables MDADI scores will be classified in the 
following categories:   ≥80 as optimal, 60-79 as adequate and < 60 as poor.53 
 
MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN) is a 
validated patient reported survey used to evaluate severity of cancer treatment related 
symptoms and their subsequent impact on functional status, as well as day to day activities of 
head and neck cancer patients. MDASI-HN comprises 28-items including 13 questions to 
assess core symptoms common across all cancers, 9 questions to assess symptoms specific to 
HNC like presence of mucus, swallowing problems, choking, voice problems, pain, 
constipation, taste issues, presence of sores and oral problems.61-64 The head and neck 
specific items relate to common treatment related toxicity experienced by HNC patients due 
to radiotherapy or chemoradiotherapy .62 Further, there are 6 interference questions to assess 
the impact of symptoms experienced by patient on daily function with respect to “general 
activity”, “walking”, “work”, “mood”, “relations with other people” and “enjoyment of life”. 
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The internal consistency reliability for MDASI-HN has been estimated with Cronbach alpha 
of 0.72 to 0.92.62 
 
Scoring of MDASI-HN: MDASI-HN symptom severity items have a range from 0 to 
indicate “not present” to 10 for “as bad as you can imagine” wherein lower scores on core 
and site-specific domains indicate better function. Interference items also have a range from 
0 to indicate “do not interfere” to 10 for “interfere completely” such that higher scores 
indicate more limitations experienced by patients and indicate lower QOL.61-64 Mean 
subscale scores for core, head and neck and interference domains can be estimated as mean 
intensity of those specific domains. Mean global score is estimated as mean of scores of all 
28 questions on the survey. 61-64  
We can also use symptom and interference scores as categorical variable where scores will 
be categorized as no symptoms (score=0), mild (1–3), moderate (4–6) and any one item rated 
as severe (7–10) symptoms, as per Cleeland et al.64 
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Literature Review, Research and Methods for Specific Aim 2 (a): Symptom Burden 
We will assess the impact of late LCNP on symptom burden using the MD Anderson 
Symptom Inventory Head and Neck Cancer Module (MDASI-HN) survey.  
Literature Review 
 
Symptom Burden 
Symptom burden is a concept which incorporates severity of symptoms experienced 
by patients and the impact of those symptoms on their day-today life.65 Symptom burden 
thereby combines symptom severity and symptom interference (surrogate measure for 
general functional impairment) reported by a substantial proportion of patients suffering from 
a specific disease. Patients may experience symptoms due to disease, recurrence or as a 
consequence of treatment related toxicity, which can be acute and occur during or 
immediately after treatment.65 Patients can also suffer from late-toxicities such as late LCNP 
many years after treatment completion, which can lead to high symptom burden among HNC 
and OPC survivors. It has been suggested that a complex interplay between patient level, 
cancer and treatment related factors may contribute symptom burden.66 
 
Symptom Burden among HNC and OPC Survivors 
HNC patients endure substantial symptom burden, as they often experience 
debilitating symptoms which may compromise their physical appearance, swallowing, 
speech, oral health and respiratory function.65, 67 HNC treatment may lead to multiple 
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complications including mucositis, dry mouth, dysphagia, choking, speech problems, lack of 
taste, pain and neurotoxicity among others which can contribute to excessive symptoms, 
distress, and overall lower quality of life.68, 69  
Patients may also experience fatigue, emotional distress, feel self-conscious, and have 
low self-esteem which may contribute to feelings of social isolation.76, 79 About 22-57% 
HNC patients experience depression and symptoms of anxiety, indicating high levels of 
psychological distress.70, 71 In fact, studies have even reported that HNC patients may have an 
elevated risk for suicide (four times higher) than the general population.72 
Thereby, symptoms of distress experienced by HNC patients may have a negative 
impact on the physical and emotional domains of health-related QOL.73 Prospective cohort 
studies among HNC survivors have reported health related quality of life (HRQOL) scores 
(10 years post-diagnosis) to be significantly lower than their pre-treatment HRQOL 
scores.83,84 The link between symptom burden and QOL is important, as studies among HNC 
patients have reported that QOL domains can predict survival.76-78 A systematic review 
reported improved survival among HNC patients, with less psychosocial distress, high self-
efficacy and physical function.79 
 
Predictors of Symptom Severity 
According to previous literature, age, sex, race, T-stage, tumor subsite, radiation dose, 
fractionation schedule, induction chemotherapy, concurrent systemic therapy, timing of 
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radiation treatment (definitive versus post-surgery or adjuvant) and smoking are some of the 
variables associated with treatment associated toxicity and symptom burden.68,67  
An earlier longitudinal study among HNC patients reported, that pre-treatment MDASI-HN 
scores (coefficient = 0.55, p < 0.001), concurrent chemotherapy (coefficient = 18.77, 
p=0.016), site of primary tumor (coefficient = 5.03, p=0.016) and definitive versus adjuvant 
radiation treatment (coefficient = 15.01, p=0.044) in a multivariate model, were significantly 
associated with MDASI-HN scores at week 5 of radiation treatment.  
As most OPC survivors have long-term survival, minimizing severity of treatment 
related symptoms, are a critical component of OPC treatment today. In our research study we 
assessed the impact of late LCNP on severity of treatment related symptoms among OPC 
survivors. 
 
Severity of treatment related symptoms: for our study was defined as, severity of core 
symptoms common across all cancers and symptoms specific to head and neck cancers and 
would be correlated with functional impairment measured by MDASI-HN interference scores 
experienced by survivors as a consequence of cancer treatment.  
 
General Functional Impairment (GFI) 
General Functional Impairment (GFI) is defined as diminished of ability of a survivor 
to take care of himself or herself, manage the household, work, and indulge in activities for 
relaxation. Thereby GFI can have an adverse impact on the daily lives of cancer survivors.80 
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OPC patients may endure severe treatment related symptoms (symptom severity) overtime, 
which may have a detrimental impact on GFI and symptom interference scores. For some 
patients, the impairment is temporary, and with time they return to their normal activity and 
functional level. But a substantial number of OPC survivors continue to experience these 
limitations, experience disability and may be unable to return to normal activities including 
work leading to decline in income.80 
There is need to understand the impact of long term GFI in the growing pool of OPC 
survivors, as few studies in the past have investigated it and most of the literature related to 
GFI is pertaining to its impact on employment.  
 
According to a previous study about 32.9% and 41.9% of HNC patients experienced 
unemployment and reduction in income respectively.80 Previous studies among HNC patients 
report fatigue, pain, problems in speech, eating and facial appearance as reasons that 
survivors do not return to normal activities including work.80 Likewise, advanced clinical 
stage disease, alcohol exposure, and less education are some of the factors associated with 
disability.89 Among HNC survivors, socioeconomic factors like education and income 
particularly are associated with unemployment.80 Therefore, GFI was a secondary outcome of 
interest and impact of LCNP on GFI was assessed, using mean MDASI-HN scores from the 
interference component. 
 
Confounders  
According to previous literature age, sex, race, T-stage, tumor subsite, radiation dose, 
fractionation schedule, induction chemotherapy, concurrent systemic therapy, surgery, eating 
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solid food at baseline, timing of radiation treatment (definitive versus post-surgery or 
adjuvant) and smoking were some of the variables associated with treatment associated 
toxicity and symptom burden.68,67  
These variables may affect severity of treatment-related symptoms, MDASI-HN scores and 
can act as potential confounders Therefore these variables along with patients eating solid 
food at baseline (control for pre-treatment swallowing dysfunction) and survival time were 
evaluated as confounders and controlled for in multivariate models, to estimate the adjusted 
association between late LCNP and top 5 mean MDASI-HN and mean MDASI-HN 
interference scores. 
 
Effect Modifiers: There was insufficient evidence in literature to suggest any specific effect 
modifiers, and given that late LCNP is rare we did not have enough power to explore effect 
modification in this study; however, exploratory analysis of biologically plausible interaction 
terms between treatment variables, age survival time and smoking were assessed. 
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Research and Methods  
 
Data Collection 
 
Primary Outcome  
Mean MDASI-HN symptom scores, which summarize information from all 22 items 
of core and head and neck specific components, were described in association with late 
LCNP to reflect overall symptom severity. We also identified a cluster of top 5 most severe 
symptoms reported by OPC survivors, to identify most important core and head-neck 
symptoms reported by this population. This methodology was supported by other symptom 
research studies. Some symptoms may be more commonly reported by this population, be 
more severe and may have a greater impact on the life of survivors, whereas others may be 
rare. Thereby overall composite MDASI-HN scores may not be a true reflection of treatment 
related symptom severity in this population.81, 82 
Therefore, mean of Top 5 most severe core and head and neck specific symptoms reported, 
by OPC survivors in this study was the primary outcome to reflect severity of most prevalent 
treatment-related symptoms in this population.  
 
Primary Exposure: Late LCNP among OPC survivors will be the primary exposure for this 
aim. Late LCNP was assessed as described earlier. OPC survivors without late LCNP served 
as the comparison group to test differences in MDASI-HN scores by late LCNP status. 
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Variables  
Covariates for this aim included:  
Demographic variables – Age, Sex, Gender, Race, Education 
Clinical variables - T and N staging, tumor sub-site, treatment modality, RT dose, mode of 
RT, RT fractionation schedule, chemotherapy, surgery, patient eating solid food at baseline, 
smoking and overall modality of treatment. 
Survival time will be defined as the number of years a patient survives after diagnosis and 
will be calculated as the difference between age at diagnosis of OPC and age at time of 
survey 
 
Secondary Outcomes for Aim 2b 
GFI was a secondary outcome of interest, and impact of LCNP on impairment was 
assessed using mean MDASI-HN scores from the interference component. Covariates for this 
outcome as suggested by literature included age, education, race, education, T-stage, survival 
time, alcohol consumption, marital status, BMI and co morbidity.89 Single item scores of the 
top 5 most severe reported core and head and neck specific symptoms were also be assessed, 
and associations of LCNP with these important symptoms were determined. We controlled 
for the same covariates listed above for primary outcome. 
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Power Analysis Aim 2 b 
The power analysis of this aim addressed the specific hypothesis that among OPC 
survivors with late LCNP, there would be higher symptom scores (per mean of top 5 most 
severe core and head and neck specific scores on MDASI-HN survey) than those without late 
LCNP. Multiple linear regression modelling this association would control for 13 variables 
including age, sex, race, education, survival time, tumor subsite, T-stage, radiation dose, 
radiation fractionation schedule, chemotherapy, surgery, smoking, and lack of solid food diet 
prior to treatment.68, 67 We assumed a loss to follow-up and missing data rate of 20%52 for 
our study, therefore we would have a study sample size of 726. Proc Power in SAS with 
assumptions mentioned above testing for a two-sided test with α = 0.05 was used for the 
power calculations. 
Under a fixed effects model and a conservative assumption of R squared of full model 
to be 0.10, we had 98% power to detect a R -squared difference for late LCNP as small as 
0.02, which according to Cohen’s conventions for small, medium and large effects could be 
classified as a small effect. 
Study R square and Cohen’s Conventions for Small, Medium, and Large Effects  
Cohen’s 
Effects 
Cohen’s 
F2 
Cohen’s 
R2 
R2 for 
main 
predictor 
LCNP 
R2 of full 
model in 
study  
Power from 
study 
Small 0.02 0.02 0.02 0.10 0.98 
Medium 0.15 0.13 0.13 0.30 >0.99 
Large 0.35 0.26 0.26 0.30 >0.99 
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Assumptions: Fixed effects model, Loss to follow-up and missing data rate of 20%48, 
sample size n= 726, two-sided test with α = 0.05, main tested predictor late LCNP controlling 
for 13 variables including age, sex, race, education, survival time, tumor subsite, T-stage, 
radiation dose, radiation fractionation schedule, chemotherapy, surgery, smoking and lack of 
solid food diet prior to treatment. 
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Literature Review, Research and Methods for Specific Aim 2 (b): Functional Burden 
Literature Review 
 
Dysphagia and Swallowing-related Quality of Life 
Dysphagia is difficulty in swallowing and is most commonly reported functional 
toxicity among OPC survivors.56,83 This toxicity may occur due to surgery, radiotherapy or 
chemoradiation.56,83 Treatment intensification strategies among HNC in recent times have led 
to enhanced locoregional control and survival.68 But these aggressive treatments may also 
contribute to debilitating treatment related toxicities including dysphagia, which can have a 
devastating impact on the life of HNC patients.84 About 30-50% HNC patients treated with 
aggressive non-surgical treatments report dysphagia.85 
Some patients may develop acute dysphagia which improves overtime, but others 
may report chronic dysphagia with progressive deterioration.85 Dysphagia may occur also 
occur many years after cancer treatment, as a late functional toxicity called late-RAD, 
discussed earlier.19 A pooled analysis of 3 RTOG trials of concomitant chemoradiotherapy 
reported that 35% of OPC survivors reported severe late laryngopharyngeal toxicity.86 
Further, a study using SEER population level data reported 3-year prevalence estimates of 
about 50% for dysphagia among OPC survivors.87 
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Predictors of Dysphagia 
A review among HNC patients reported that total RT dose, fractionation schedule, 
combined treatment modality, subsite, primary tumor size, age and smoking may contribute 
to acute and late dysphagia.84,85 Similarly, another systematic review among OPC patients, 
reported pre-treatment swallowing function, T-stage, base of tongue tumors and adjuvant 
chemoradiation as predictors of swallowing function.56  
Dysphagia-aspiration-related structures (DARS) in the head and neck are vital for 
swallowing function and RT dose to these structures may contribute to swallowing toxicity.85 
Literature suggests that delivery of RT dose to pharyngeal constrictors, suprahyoid muscles 
and larynx is associated with chronic dysphagia.68 It is also suggested that RT dose > 50 Gy 
to the pharyngeal region, may contribute to chronic dysphagia among OPC survivors.68 
Combined modality treatment, concomitant chemotherapy or targeted therapy, surgery after 
radiation including DARS regions and smoking have also been reported to contribute to 
worse swallowing and functional outcomes.85  
 
Swallowing related Quality of Life 
Given the rising numbers of OPC survivors, swallowing outcomes and speech play a 
crucial role in quality of life among these survivors.88 Swallowing impairment among HNC 
patients can lead to increased risk of impaired airway protection, pneumonia, swallowing 
insufficiency, low food intake, extended gastrostomy tube dependence, weight loss and 
malnutrition.88 Patients may have to modify their diet, need extended meal times, feel self-
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conscious to eat in social settings and thereby contribute to social isolation and diminished 
QOL.88 Literature suggests that Dysphagia has high correlation with swallowing and Quality 
of life outcomes over time.53  
LCNP may have a significant impact on dysphagia experienced by OPC survivors, 
many years after treatment and cause extensive functional impairment and result in poor 
swallowing related QOL. The functional impact of LCNP has not been studied in a study 
with substantial numbers of OPC survivors and given that it is an area of concern among 
LCNP patients, we investigated the impact of late LCNP on dysphagia and swallowing 
related QOL among OPC survivors. 
 
Variables in Study 
Survival Time: Long-term survival of OPC patients may contribute to higher chances of 
them developing late toxicities including chronic dysphagia overtime, which may contribute 
to lower swallowing-related QoL scores on MDADI. Earlier reports indicate that age, tumor 
subsite, tumor stage, RT dose and MDADI scores prior to cancer treatment may predict 
MDADI scores at specific time points and longitudinally overtime.53,55,57  Another review 
among OPC patients treated with transoral robotic surgery also reported that pre-treatment 
swallowing function, T-stage, N-stage, primary subsite involving base of tongue and 
adjuvant chemoradiation may predict swallowing outcomes and toxicity.56 Additionally, 
another study among OPC patients treated with bilateral intensity-modulated radiotherapy 
(IMRT) with systemic therapy, on multivariate analysis revealed that older age; as per 5-year 
 
65 
 
increase in age (OR= 1.25; 95% CI = 1.04-1.51), pre-treatment diet restriction (OR= 2.78; 
95% CI = 1.31-5.88), total IMRT dose; as per 5 Gy increase (OR= 5.11; 95% CI = 1.77-
14.81) were significantly associated with increased risk of chronic dysphagia.66 
 
T-Stage: OPC patients withT1 and T2 tumors, have reported significantly better swallowing 
scores as per MDADI (+15.9, p=0.0001 and + 10.9, p=0.0049 respectively) than patients 
with T4 tumors.53 This may be due more aggressive treatment of advanced OPC tumors, 
which may have a detrimental impact on long term toxicities like Dysphagia. 
 
Treatment Intensity: HNC patients treated with non-surgical therapy, have reported that 
treatment intensity i.e. patients treated with less <50 Gy had significantly better swallowing 
scores as per MDADI, than those treated with higher RT dose or chemoradiation (p< 
0.001).57  
 
Combined modality treatment: Concomitant chemotherapy or targeted therapy and surgery 
after radiation including DARS regions have been reported to contribute to worse swallowing 
and functional outcomes.85 
 
Reconstructive Surgery: Oral cancer and OPC patients who had reconstructive surgery for 
primary tumors, have also reported significantly worse composite MDADI scores (58.8 
versus 79.5, p < 0.01) compared to those who did not get treated with reconstructive 
surgery.55 
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Age: Oral cancer and OPC patients younger than 60 years have also reported significantly 
worse physical (65.8 versus 78.4, p = 0.01) and emotional subscale (68.3 versus 82.0, p < 
0.01) scores on the MDADI compared those patients older than 60 years.55 
 
OPC Subsite: OPC patients with base of tongue tumors have also reported significantly 
worse functional subscale scores on MDADI in comparison to patients with oral cancer and 
OPC patients with tonsillar tumors (66.7, 78.8 and 90.0 respectively, p<0.01).55  
 
Current smokers: Among OPC patients, current smokers have reported significantly worse 
swallowing scores as per MDADI (- 9.4 points, p=0.0007) compared to nonsmokers.53 
Further smoking can lead to worse functional outcomes and inferior prognosis overtime, for 
both HPV positive as well as negative disease.53 
 
Pretreatment Swallowing: Among HNC patients, earlier studies have reported that 
swallowing scores prior to treatment explained 13% of the variance in long-term swallowing 
scores. Patient’s not eating solid food at baseline i.e., before treatment, may have some pre-
treatment swallowing dysfunction, which may eventually contribute to long-term swallowing 
impairment and dysphagia. 53, 55-57, 85 
 
Thereby RT dose, Mode of RT, RT fractionation schedule, chemotherapy, surgery, 
combined modality treatment, age, subsite, eating solid food at baseline, and smoking were 
some of the variables that could affect swallowing outcomes and can act as confounders.53, 55-
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57, 85 They were evaluated as confounders and controlled for in multivariate models, to 
estimate the adjusted association between late LCNP and composite MDADI scores. 
 
Effect Modifiers: There was insufficient evidence in literature, to suggest any specific effect 
modifiers and given that late LCNP is rare, we did not have enough power to explore effect 
modification in this study. However exploratory analysis of biologically plausible interaction 
terms between treatment variables, age survival time and smoking were assessed. 
 
Research and Methods 
Data Collection 
Primary Outcome: The primary outcome for this aim was mean composite MDADI score 
reported by OPC survivors and represents swallowing-related QOL. The composite MDADI 
scores was calculated as mean of responses from emotional, physical and functional 
components of the survey and will reflect overall swallowing related quality of life.54, 58-60 
 
Primary Exposure: Late LCNP among OPC survivors was the primary exposure for this 
aim, as the goal was to assess the impact of LCNP on swallowing toxicities reported by OPC 
survivors. Late LCNP was assessed as described earlier. OPC survivors without late LCNP 
served as the comparison group to test differences in MDADI scores by late LCNP status. 
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Covariates  
Covariates for this aim included; 
Demographic Variables – Age, Sex, Gender, Race, Education 
Clinical Variables - T and N staging, tumor sub-site, treatment modality, RT dose, mode of 
RT, RT fractionation schedule, chemotherapy, surgery, patient eating solid food at baseline, 
smoking 
Survival Time was defined as the number of years a patient survives after diagnosis and was 
calculated as the difference between age at diagnosis of OPC and age at time of survey.  
 
Power Analysis  
The power analysis of this aim, addressed the specific hypothesis that among OPC 
survivors with late LCNP, there would be significantly worse swallowing-related QoL (per 
MDADI survey) than those without late LCNP. Multiple Linear regression modelling this 
association would control for 13 variables including age, sex, race, education, survival time, 
tumor subsite, T-stage, radiation dose, radiation fractionation schedule, chemotherapy, 
surgery, smoking and lack of solid food diet prior to treatment.53,55-57,85 We assumed a loss to 
follow-up and missing data rate of 20%53 for our study therefore we would have a study 
sample size of 726.Proc Power in SAS with assumptions mentioned above testing for a two-
sided test with α = 0.05 was used for the power calculations. 
Under a fixed effects model and a conservative assumption of R squared of full model 
to be 0.10, we would have 98% power to detect a R-squared difference for late LCNP as 
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small as 0.02 which according to Cohen’s conventions for small, medium and large effects 
could be classified as a small effect. 
Cohen’s Conventions for Small, Medium, and Large Effects 
Cohen’s 
Effects 
Cohen’s 
F2 
Cohen’s 
R2 
R2 for 
main 
predictor 
LCNP 
R2 of full 
model in 
study  
Power from 
study 
Small 0.02 0.02 0.02 0.10 0.98 
Medium 0.15 0.13 0.13 0.30 >0.99 
Large 0.35 0.26 0.26 0.30 >0.99 
Assumptions: Fixed effects model, Loss to follow-up and missing data rate of 20%48, 
sample size n= 726, two-sided test with α = 0.05, main tested predictor late LCNP controlling 
for 13 variables including age, sex, race, education, survival time, tumor subsite, T-stage, 
radiation dose, radiation fractionation schedule, chemotherapy, surgery, smoking and lack of 
solid food diet prior to treatment. 
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Abstract 
Background 
Lower cranial neuropathy (LCNP) is a rare, but permanent, late effect of radiotherapy 
(RT) and other cancer therapies. LCNP is associated with excess cancer-related symptoms, 
worse swallowing-related quality of life (QoL) and long-term feeding tube dependence, 
aspiration pneumonia, and tracheostomy. The overall objective of this paper is to quantify the 
cumulative incidence of late LCNP and identify clinical predictors of late LCNP among 
long-term oropharyngeal cancer (OPC) survivors. 
Methods  
The study population included 2,021 OPC survivors (median survival: 6.8 years) who 
received primary treatment at MD Anderson Cancer Center from 2000 to 2013. Late LCNP 
events were defined by neuropathy of the glossopharyngeal (IX), vagus (X) and/or 
hypoglossal (XII) nerves ≥3-months after cancer therapy. Cumulative incidence of LCNP 
was estimated using the Kaplan Meir method with adjustment for competing risks using time 
to event as the underlying metric. Log-rank test was used to assess differences between 
groups by LCNP status, and multivariable Cox proportional hazard models were fit.  
Results 
4.4% (n=88) of OPC survivors were diagnosed with late LCNP with median time to 
LCNP onset after treatment of 5.4 (range: 0.3-14.1; IQR: 1.6-8.5) years post-treatment. 
Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI: 0.02-0.03), 0.06 
(95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and 18 years of 
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follow-up, respectively. Multivariable Cox regression identified T4 stage vs T1 stage (HR: 
3.82; 95%CI: 1.85-7.86, p<0.001) and accelerated RT fractionation vs standard RT 
fractionation (HR 2.15, 95%CI 1.34-3.45, p=0.002) independently associated with late LCNP 
status, adjusting for age, subsite, T-stage, smoking, and therapeutic modality.  
Conclusion 
While rare in the population overall, risk of late LCNP progressed over time to 
exceed 10% cumulative risk over survivors’ lifetime. Our prediction model identified OPC 
survivors who had T4 tumors and those who received accelerated fractionation RT treatment 
as having a higher risk of late LCNP. Further efforts are necessary to investigate the risk and 
predictors for this disabling late effect of cancer treatment experienced by growing numbers 
of relatively younger OPC survivors who are expected to survive decades after treatment. 
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INTRODUCTION 
Oropharyngeal cancer (OPC) incidence is increasing by 5% each year, attributable to 
the epidemic of Human Papilloma virus (HPV)-associated OPC.  It is projected that by 2030 
about half of head and neck cancers (HNC) will be OPC.1  In recent decades, HPV-associated 
OPC has dramatically transformed the OPC patient population such that today’s typical OPC 
patients are middle aged, male, white, non-smokers and non-drinkers, have a high 
socioeconomic status, and are often diagnosed at a more advanced stage (per AJCC 7th 
edition).1-4  As a consequence of modern regimens of organ preserving radiotherapy, 
favorable biology, and improved prognosis due to better response to treatment, these patients 
have excellent prognosis and are often expected to live for decades despite advanced stage 
disease at presentation.2-4 HPV associated HNC patients have better 3-year (HPV: 82.0% vs. 
HPV-negative 57.0%) and 5-year (RR=0.40; 95%CI 0.20-1.08) overall survival rates in 
comparison to HPV negative HNC patients.2,3 As the lifespan of OPC survivors increase, 
they are more likely to experience severe side-effects over time due to delayed tumor and 
cancer treatment-related toxicities. For most part, OPC survivors experience excess 
morbidity and disability compared to other cancer survivors.  These late effects may lead to 
debilitating problems in critical physiological functional activities including swallowing, 
eating, breathing, and speaking. In fact, according to a survey study in 2004, 52% of HNC 
patients of mixed sites experienced disability due to cancer treatment and were unable to 
work due to these problems.5 
 
Lower cranial neuropathy (LCNP) is a rare but permanent and potentially devastating 
late effect induced by normal tissue injury due to radiotherapy (RT) or surgery and other 
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HNC therapies. HNC treatment-associated fibrosis of nerve tracts or adjacent soft tissues 
may lead to delayed but progressive neuro-vascular damage and eventually cranial 
neuropathy which over time causes profound functional impairments.6 LCNP can occur 
unilaterally or bilaterally and can affect glossopharyngeal (IX), vagus (X), accessory (XI), 
and hypoglossal (XII) nerves which are crucial for oropharyngeal phase of swallowing 
mechanism, speech production, and shoulder function.6-10 In a large survey study, OPC 
survivors with late LCNP reported significantly worse cancer treatment-related symptoms 
with largest effect size and detrimental impact on swallowing, speech, mucus problems, 
choking, and fatigue.11 Further, survivors with late LCNP reported poor swallowing-related 
quality of life (QoL). Notably, late feeding tube, tracheostomy, and aspiration pneumonia 
events were almost exclusively seen in survivors who developed LCNP compared to their 
LCNP-free counterparts. 12  
It is also postulated that LCNP potentially leads to the accelerated functional decline 
among HNC patients suffering from a severe form of dysphagia which occurs many years 
post-RT called late RT-associated dysphagia (late RAD).9 Late RAD is characterized by 
extreme functional impairment in oropharyngeal phases of swallowing, which causes 
swallowing inefficiency, oropharyngeal residue, and silent aspiration.9 Over time, about 85% 
of OPC survivors with late-RAD develop pneumonia and more than 60% of them require 
long-term gastronomy tube placement.9 Overall, literature suggests substantial functional 
burden including profound impairment in swallowing, speech, voice, and overall low quality 
of life (QoL) in OPC survivors who develop LCNP.6-9  
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The incidence of late LCNP among 59 OPC survivors was 5% at 5.7years according 
to an earlier study, 7 however another cohort study among HNC survivors reported 14% 
cranial neuropathy incidence rates over a 10-year follow-up, suggesting progressively 
increasing LCNP risk over time in this population.14 Further, LCNP has delayed occurrence. 
A previous study among NPC patients reported late LCNP occurrence between 12 to 240 
months post-RT treatment thereby highlighting the need for long-term surveillance of late 
LCNP among HNC and OPC patients.7-9  
Most OPC patients receive either curative RT treatment alone or in combination with 
systemic therapy. Definitive surgery or surgery in combination with adjuvant therapy while 
historically rare is increasing with adoption of transoral robotic surgery methods. Despite this 
rising popularity of primary TORS for OPC, still the vast majority of modern OPC patients 
receive RT as definitive or adjuvant therapy. In practice, cranial nerves are historically 
considered to be relatively resistant to radiation injury but RT-associated cranial nerve injury 
occurs both at acute and late (months and years after RT treatment) recovery intervals.7 It is 
postulated that late LCNP may be caused by peripheral nerve and brainstem injury and RT-
associated peripheral nerve injury may occur by axonal degeneration, suppression of 
Schwann cell proliferation, and fibrosis of connective tissues entrapping nerve fibers. 7 
Total RT dose is most commonly suggested in literature as the chief predisposing 
factor for late LCNP, but the contributing threshold dose is not known.7 It has also been 
suggested that the dose to regions-of interest (ROI) in the RT field including among others 
the superior pharyngeal constrictor (SPC) region, which comprises minor nerve tracts and the 
constrictor and longitudinal pharyngeal muscles, which are important for pharyngeal 
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shortening during swallowing for bolus propulsion into the esophagus may play a more 
pivotal role in late treatment related toxicity than total RT dose.15 Previous literature suggests 
potential risk factors for treatment-associated late LCNP include RT dose, field, mode and 
fractionation, surgery, systemic therapy, smoking, and individual sensitivity to treatment. 7, 
10,16-18 However, previous studies investigating LCNP have predominantly been case series 
among nasopharyngeal cancer (NPC) survivors and few studies have addressed late LCNP 
among OPC survivors. The largest to date comprised only 3 late LCNP cases in a cohort of 
59 OPC survivors. With a rapidly growing pool of OPC survivors who have received 
curative doses of radiotherapy, there is urgent need to investigate this disabling late effect of 
therapy. Late LCNP is a debilitating, permanent condition and can have a profound impact 
on QoL of OPC survivors, yet we know little about risk and predictors of late LCNP in this 
population.  For the growing numbers of OPC survivors at risk for experiencing late LCNP, 
there is need to identify risk profiles of those most vulnerable to late LCNP and subsequent 
late effects to help in the development of more targeted preventive strategies and 
interventions. Therefore, the overall objective of this study was to quantify the cumulative 
incidence of late LCNP and identify clinical predictors for late LCNP among long-term OPC 
survivors. The hypothesis for this study was that that 5-year incidence rate of LCNP would 
approximate 5% and risk of LCNP would correlate with age, tumor subsite and stage, RT 
dose, fractionation schedule, smoking status, and systemic therapy. 
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MATERIALS AND METHODS 
 
Study Design, Eligibility and Consent 
All OPC patients (n=3627) who completed treatment with curative intent at MD 
Anderson Cancer Center (MDACC) between January, 2000 and December, 2013, were 
assessed for eligibility in this retrospective cohort study. All eligible participants were ≥ 18 
years of age at diagnosis, had oropharyngeal squamous cell carcinoma (OPSCC), and at time 
of new patient registration within the institution had consented to future research 
participation. Patients who had recurrent HNC, those treated at other institutions, those 
deceased < 3 months post-treatment, and those with secondary primary malignancy (SPM) or 
persistent/recurrent malignancy of the head and neck < 3 months post-treatment were 
excluded. As this study investigated late LCNP as a treatment-associated late-effect, patients 
with LCNP of any cause at the time of cancer diagnosis or with clinical signs of LCNP 
(n=168) prior to cancer treatment were also excluded. A total of 2,021 OPC survivors were 
included in the final study analysis. Details of study participants inclusion and exclusion are 
presented in Figure 1. 
 
Primary Outcome Variable 
The primary outcome variable for this study was late LCNP. LCNP status among 
patients was assessed by clinical examination of cranial nerves by the head and neck surgeon, 
radiation oncologist, and/or speech pathologist and was recorded in medical charts. Late 
LCNP for this study was defined as swallowing associated neuropathy of glossopharyngeal 
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(IX), vagus (X) and hypoglossal (XII) nerves, which were critical to the oropharyngeal phase 
of swallowing mechanism and speech production.19,20 As CN XI palsy was inconsistently 
recorded in medical charts, it was excluded from LNCP analysis in this study, with the intent 
to focus on swallowing-associated LCNP.  
Late effects of cancer treatment are often defined as severe treatment associated toxicities 
which occur ≥ 3 months post-cancer treatment ,21 therefore, late LCNP was defined as onset 
of swallowing-associated neuropathy of at least one of the glossopharyngeal (IX), vagus (X), 
and hypoglossal (XII) nerves with minimum onset ≥ 3 months after the end of cancer 
treatment. Medical records were reviewed to identify cases of LCNP and case status was 
verified by head and neck specialized physician (R.G.) review. Time to event of LCNP 
diagnosis and information about other competing events were also collected. Details are 
presented in an earlier publication.11  
 
Clinical and Demographic Variables 
Demographic, clinical, treatment-related factors, health behaviors, and HPV status 
were also abstracted from medical charts using a structured study form. Demographic 
variables included age and sex; clinical variables included T and N staging (7th edition 
AJCC), sub-site, HPV status, OPC treatment modality, RT dose, type/mode, and 
fractionation schedule, chemotherapy, surgery, lack of solid food diet at baseline (as a 
surrogate of baseline dysphagia), and smoking status at diagnosis. Survival time was 
calculated as the difference between date of first visit to head and neck clinic and date of 
LCNP diagnosis or competing event diagnosis or date of last follow-up. RT dose, mode and 
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fractionation schedule, chemotherapy, surgery, solid food diet at baseline and smoking were 
some of the variables based on literature review which may influence risk and may act as 
predictors of late LCNP.7, 10,16-18 Thereby, these variables were investigated as potential 
predictors of late LCNP among OPC survivors. 
 
Statistical Analysis 
Descriptive statistics were computed to explore relationship between variables of 
interest. Cumulative incidence of LCNP was calculated using the Kaplan Meier method, with 
adjustment for competing risks for all OPC survivors using time to event as an underlying 
metric.  
Differences in LCNP risk by co-variables of interest were also assessed and Log-rank 
test was used to investigate between group differences by LCNP status. Multivariable Cox 
proportional hazards models were fit regressing LCNP status as the dependent variable on 
clinical and demographic predictors. Model building followed the purposeful variable 
selection method of Hosmer and Lemeshow.22 Univariate analysis was conducted to estimate 
hazard ratios for the crude effect of each variable of interest. Candidate predictors with p < 
0.25 on Wald test along with literature-based a priori defined clinically important covariates 
including age, t-stage, subsite, treatment modality, and smoking were entered into 
multivariable proportional hazards model. Variables that associated with late LCNP (Wald 
test p < 0.05) along with clinically important covariates were entered into the preliminary 
main effects model. Pruned models were compared to full models using partial likelihood 
ratio test; change in hazard ratio estimate ≥10% magnitude for each covariate was the 
threshold for re-entry of variables back into the model. Further, we added variables not 
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selected in earlier steps into model one at a time, checked the Wald statistic or partial 
likelihood ratio test and retained variables that made important contributions. Biologically 
plausible interaction terms and other model building strategies like stepwise regression were 
also explored. Multicollinearity was assessed using variance inflation factors. The 
proportional hazard assumptions of the final model were also assessed and the fit of the final 
model were tested using overall goodness-of-fit χ 2 test. Subgroup analyses were conducted 
among single versus multimodality treatment groups and surgically treated versus non-
surgically treated groups, and those with HPV-associated disease among others. Hazard 
ratios (unadjusted and adjusted) and corresponding 95%confidence interval (CI) were 
estimated. All reported p-values were two-sided and were considered to be statistically 
significant at p <0.05 and statistical analysis was conducted using the STATA software, 
version 14.0 (StataCorp LP, College Station, TX). 
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RESULTS 
Sample Characteristics 
Two thousand twenty-one (n=2,021) eligible OPC survivors with a median survival 
time of 6.8 (range, 0.3-18.4; IQR: 4.3-10.2) years were included in this study. Table 1 
displays the distribution of demographic, tumor, and treatment-related characteristics in the 
study population. Among study participants, median age at diagnosis was 56 (range, 28-86; 
IQR: 50-63) years; 86.1% were male, 93.5% had either tonsil or base of tongue tumors, 72% 
had T1-T2 tumors, 90.3% had nodal involvement, and 89.9% could eat a normal solid-food 
diet prior to treatment. About 99.0% were treated with RT with a median RT dose of 70 Gy 
(range, 40-75; IQR: 66-70 Gy) and 60.7% were treated with intensity-modulated 
radiotherapy split-field technique (IMRT-SF).  
 
Late Lower Cranial Neuropathy 
4.4% (88/2,021) OPC survivors were diagnosed with late LCNP with median time to 
LCNP onset post-treatment of 5.4 years (range, 0.3-14.1; IQR:1.6-8.5). Among LCNP cases, 
median RT dose was 70 (range, 66-73.5; IQR: 66-72) Gy. However, 73.9% (65/88) of LCNP 
cases received an RT dose of ≥70Gy in comparison to 52.9% (1,022/1,933) of those without 
LCNP. 51.1% (45/88) of LCNP cases were treated for T1-T2 tumors, 48.9% (43/88) had T3-
T4 tumors, and 89.8% (79/88) reported eating a solid-food diet prior to treatment. All LCNP 
cases received curative RT, 75% (66/88) were treated with RT in combination with systemic 
therapy, 37.5% (33/88) received IMRT-SF, and 36.4% (32/88) received accelerated RT 
fractionation therapy. In total, 7.6% (154/2021) of all survivors and 21.6% (19/88) LCNP 
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cases received concomitant boost accelerated RT treatment (p <0.001). Lastly, one (1.1%) 
LCNP case underwent transoral robotic surgery to the primary OPC tumor and 29.5% 
(26/88) had neck dissection.  
Among LCNP cases, CN XII (hypoglossal nerve) neuropathy was most common 
(78.4%; 69/88). As isolated CN IX neuropathy was hard to detect; CN X/CN IX palsies were 
combined and 44.3% (39/88) patients had CN X/CN IX neuropathy. Polyneuropathy which 
included CN X/CN IX palsy and CN XII palsy was diagnosed in 22.7% (20/88) of LCNP 
cases. Among LCNP cases, 63.6% (56/88) had ipsilateral nerve damage, 9.1% (8/88) had 
contralateral nerve damage, and 26.1% (23/88) had bilateral nerve damage.  
 
Cumulative Incidence of LCNP 
Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI: 0.02-
0.03), 0.06 (95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and 18 
years of follow-up, respectively. Overall cumulative incidence has been presented in Figure 
2. Table 1 displays the cumulative incidence of late LCNP across demographic, tumor and 
treatment-related characteristics in the study population over an 18-year follow-up period. 
Cumulative Incidence of late LCNP increased proportionally with higher T-stage category 
with highest incidence of 0.26 (95% CI: 0.15-0.42, p=<0.001) among survivors with T4 
tumors.  Among OPC survivors; cumulative incidence of LCNP among those who did not eat 
a solid-food diet prior to treatment was 0.42 (95%CI: 0.12-0.91, p=0.086), those treated with 
multimodality treatment was 0.14 (95%CI: 0.09-0.20, p=0.003), those treated with 
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accelerated RT fractionation treatment was 0.19 (95%CI: 0.13-0.26, p=<0.001) and those 
treated with intensity modulated radiotherapy whole-field technique (IMRT-WF) and 
volumetric-modulated arc therapy (VMAT) was 0.14 (95%CI: 0.09-0.22, p=<0.001).  
 
Risk Factors for LCNP 
Univariate analysis identified smoking status, T-stage, single vs multimodality 
treatment, RT dose, type, and fractionation schedule, and chemotherapy as significantly 
associated with late LCNP status (p<0.05). Multivariable Cox regression identified T4 stage 
(HR: 3.82; 95%CI: 1.85-7.86, p=0.000) and accelerated RT fractionation (HR 2.15, 95%CI 
1.34-3.45, p=0.002) independently associated with late LCNP status, adjusting for age, 
subsite, T-stage, smoking and therapeutic modality. Results of univariate and multivariate 
analysis are summarized in Table 2. Further, statistically significant interaction was 
identified between RT schedule and subsite of primary tumor (p=0.021) but as effect 
estimates of the model with the interaction term were similar to full regression model without 
the interaction term, estimates of final statistical model without interaction were reported for 
ease of clinical interpretation.  
 
Subgroup Analysis: LCNP among those treated with Non-surgical Therapy 
Among non-surgically treated patients, chemotherapy was further investigated as a 
predictor of late LCNP. The majority of non-surgically treated patients (67.6%; 1,342/1,986) 
received RT in combination with systemic therapy and 31.6% (628/1,986) received single 
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modality RT. About 52.5% (1,042/1,986) received concurrent chemotherapy, 31.5% 
(625/1,986) received induction chemotherapy (IC), and 17.3% (344/1,986) received both 
induction and concurrent chemotherapy. Among those who received induction 
chemotherapy, 38.7% (242/625) received Induction TPF (docetaxel, cisplatin, and 
fluorouracil), 5.8% received Induction CTPF (cetuximab, docetaxel, cisplatin, and 
fluorouracil), 20.2% (126/625) received Induction PCC (paclitaxel, carboplatin, cetuximab) 
and the remaining survivors received varied induction chemotherapy regimens. Among non-
surgically treated patients, Induction TPF chemotherapy (HR: 2.37; 95%CI: 1.28-4.38; 
p=0.006) and Induction C-TPF (HR: 4.0; 95%CI: 1.22-13.13, p=0.022) were identified in 
addition to T-stage (model with TPF; HR: 3.72, 95%CI: 1.81-7.65, p=<0.001; model with 
CTPF; HR: 3.97, 95%CI: 1.92-8.21, p=<0.001 ) and accelerated RT fractionation (model 
with TPF; HR: 2.56, 95%CI: 1.55-4.21, p=<0.001, model with CTPF; HR: 2.28, 95%CI: 
1.41-3.68, p=0.001) as significantly associated with late LCNP adjusting for the same 
covariates as the final model. 
 
Validating Model Assumptions 
None of the predictors in the final model violated the proportionality assumption of 
the Cox model except T-stage, but when a Cox model stratified on T-stage was fit, effect 
estimates for predictors in final model remained unchanged. Further, on inclusion of 
previously identified interaction RT schedule and subsite of primary tumor, none of the 
variables violated the proportionality assumption. Therefore, estimates for the unstratified 
Cox model were reported for ease of clinical interpretation. Goodness-of-fit of the final 
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model was assessed using the goodness-of-fit χ 2 test which was not significant (p=0.406) 
and Cox-Snell residuals and in conclusion the final model fit the data well. 
 
DISCUSSION 
Late lower cranial neuropathy is a rare but progressive and functionally devastating 
late toxicity in OPC survivorship.11,12 Late effects are of great concern among an ever-
growing pool of younger OPC survivors with prospects of long-term cure, many of whom are 
expected to survive decades after treatment. This single-center retrospective cohort study is 
to our knowledge the first of its kind. The cohort represents the largest (n=2,021) to date 
among OPC survivors over an 18-year surveillance period and thus provides a high degree of 
precision in estimates of risk of late LCNP in terms of cumulative incidence and 
identification of clinical risk predictors of LCNP. Results of this study suggest that risk of 
late LCNP, though initially small, progressed over time to exceed 10% cumulative risk over 
survivors’ lifetime. Multivariate analysis revealed that T-stage and accelerated RT 
fractionation treatment are significant risk factors of late LCNP. Further, among non-
surgically treated patients, induction TPF chemotherapy with or without cetuximab (C-TPF) 
were additionally identified as significant risk factors of late LCNP.  
The progressively increasing cumulative incidence estimates reported in this study are 
deeply troubling as the majority of OPC survivors in this study were middle-aged at the time 
of diagnosis supported by the 50-63 years interquartile range (IQR) for age at diagnosis 
which is similar to the age distribution of most HPV-positive OPC patients today.23 This 
progressive increase in LCNP risk over time is similar to a study among 59 OPC survivors 
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treated by IMRT, which reported a cumulative risk of 2.1% (95% CI: 0.2-10%), 6.1% 
(95%CI: 0.9%-19%), and 11.0% (95%CI: 2.4%-28%) at 6-year, 7-year, and 8-year follow-
up. 7 Another study among NPC patients also reported a progressive increase in late LCNP 
cumulative incidence of 5.7%, 17.4%, 27.1%, and 37.3% over a 5, 10, 15 and 20-year follow 
up respectively.24-The cumulative incidence estimates in current study are quite precise 
supported by their narrow 95% confidence intervals and risk estimates increased as expected 
by disease severity (as per T-stage), use of RT, use of systemic therapy, neck dissection, and 
increase in treatment intensity with use of multimodality treatment including chemoradiation 
and accelerated RT fractionation. Tight confidence intervals and expected performance in 
subgroup stratifications support both accuracy and validity of these cumulative incidence 
estimates.  
The progressive trajectory of LCNP has long-term clinical implications on the 
functional status of HNC survivors as was suggested by a prospective study among 3 OPC 
survivors with LCNP, which suggested that LCNP cases could experience severe decline in 
function over time, as per multiple functional metrics.7 Long-term deterioration of 
swallowing function was noted using  both patient-reported MDADI scores and clinician-
rated modified barium swallow (MBS) scores as per validated Dynamic Imaging Grade of 
Swallowing Toxicity (DIGEST) criteria, as well as diet score rated on the Performance Status 
Scale of Head and Neck Cancer (PSS-HN).7 In fact, survivors with LCNP may be compelled 
to modify their diet, need extended meal times, feel self-conscious to eat in social settings, be 
socially isolated, and experience poor QOL.26 The investigators have previously reported 
worse cancer treatment-related symptoms, poor swallowing-related QoL, and worse 
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functional status metrics including long-term feeding tube dependence, lack of normalcy of 
diet, dietary restrictions in public, weight loss, aspiration pneumonia, and tracheostomy 
among long-term OPC survivors with late LCNP.11,12 Further, the devastating impact of 
cranial neuropathy on the life of LCNP cases was reflected by their qualitative remarks in the 
present study which suggested, profound distress and suffering with loss of swallowing 
function to an extent where these patients regretted pursuing any OPC treatment at all. It is 
also worrisome, that a recent report indicated that OPC incidence is now rising among the 
older population.27 These patients are likely to have comorbidities and experience more side-
effects with multimodality treatment including concurrent chemoradiation and are also likely 
to experience bigger deficits in swallowing function overtime and even more 
poor/diminished QoL. These findings altogether suggest that as OPC survival probabilities 
continue to improve, the number of survivors at risk of substantial functional morbidity 
associated with late LCNP grows too. These survivors eventually transition from oncologic 
management to care of primary care physicians and there is need for increased surveillance to 
assess and treat late effects. 
The results from this multivariate analysis suggest, on an average, OPC patients with 
T4 stage tumors were 3.8 times more likely to develop late LCNP than those with T1 tumors 
after adjusting for age, subsite, smoking, therapeutic modality, and RT fractionation 
schedule. Identification of T-stage as a predictor in this study is plausible given that locally 
advanced OPC tumors are bulky tumors. As per AJCC 7th edition TNM staging in this study, 
T3 tumors are > 4cm with possible extension to lingual epiglottis, whereas T4 tumors are 
even bigger with T4a tumors being moderately advanced invading other head neck sites 
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possibly including the larynx/tongue muscles/hard palate/ mandible and T4b tumors 
including very advanced extensive tumors invading the lateral pterygoid muscles, lateral part 
of the nasopharynx and even the skull base and carotid artery (AJCC 7th edition). In case of 
larger tumors, the RT treatment planning target volume is more extensive, requiring a 
relatively larger gross tumor volume, clinical target volume (to incorporate subclinical 
disease), and additional marginal area (to account for errors).28 These larger irradiation fields 
may include neurovascular structures including cranial nerves and adjacent normal tissues, 
the injury of which  may precipitate cranial neuropathy. Additionally patients with T4 tumors 
may have also have a greater risk of subclinical baseline neve injury by compression of nerve 
tracts by large tumors.29-31 According to previous literature primary tumor size among other 
clinical variables may also contribute to acute and late dysphagia including late-RAD among 
HNC patients 32,33 and tumor stage may predict swallowing function (as per MDADI scores) 
at specific time points and longitudinally.34-36  Another prospective study among 529 HNC 
patients treated with curative RT which reported T3-T4 vs T1-T2 stage (OR:2.38, 95%CI: 
1.36-4.19, p=0.003) was positively significantly associated with grade 2-4 RTOG 
swallowing dysfunction at 6 months post-treatment.37 Therefore, tumor stage can not only 
contribute to late LCNP but also potentially play a role in development of late functional 
toxicities including late RAD. 
Advanced stage cancers are also treated more intensely/aggressively with 
multimodality treatment regimens including either chemoradiotherapy (CRT) or surgery 
followed by CRT or chemotherapy. Chemoradiotherapy is regarded as standard of care for 
locally advanced OPSCC but multimodality treatment regimens can result in acute and 
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persistent tissue changes and lead to severe acute and late treatment-related toxicities.38,39 A 
trial in France demonstrated that multimodality treatment was associated with an increase in 
grade 3 or 4 acute toxicity though these findings were not statistically significant.40 Thus, 
collectively among patients with T4 tumors larger irradiation fields and greater treatment 
intensification may contribute to higher risk of late LCNP.  
In this study, OPC patients treated with accelerated RT fractionation were 2.2 times 
more likely to develop late LCNP than those who received standard RT fractionation after 
adjusting for age, subsite, smoking, T-stage, and therapeutic modality. Accelerated RT 
fractionation treatment regimens incorporate several RT fractions in a day with the goal to 
shorten total treatment time and also to overcome tumor cell regeneration/repopulation 
during RT treatment.41,42 Thereby, accelerated RT fractionation therapy may also include an 
increase in average RT dose per week above the standard 10 Gy dose per week of 
conventional RT fractionation which may contribute to an increase in late effects of RT 
treatment.28 Further, regeneration/repair in some normal tissues maybe slower and as a 
consequence of longer half-time for repair; these tissues may be more susceptible to RT-
induced injury.28 Lastly, an increase in RT dose per week may contribute to an increase in 
early tissue injury like mucositis or other severe and extensive/protracted acute effects which 
may result in chronic normal tissue injury and consequential late effects.28 
Pure acceleration, split-course treatment acceleration, accelerated hyper-fractionation, 
and concomitant boost are some of the strategies used in accelerated RT fractionation 
therapy.42 In this study, more than 20% LCNP cases received concomitant boost accelerated 
RT treatment. Concomitant boost RT technique incorporates initial irradiation of gross tumor 
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volume and clinical target volume, followed by a second boost RT dose delivered to a 
smaller clinically identifiable tumor area to ensure the highest RT dose is given to the 
smallest region to reduce potential of late RT-associated toxicity/morbidity. 42 In this 
institution concomitant boost RT strategy includes a total RT dose of 72 Gy, given in 42 
fractions during 6 weeks.42,44 During the last/final two weeks of RT treatment, the patient 
receives twice a day treatment with the second dose administered as boost RT dose.42,44 
However, in a previous phase II Radiation Therapy Oncology Group Trial (RTOG 99-14), 
advanced HNC patients treated with concomitant boost accelerated RT regimen/strategy with 
cisplatin had better survival but endured severe acute toxicity and alarmingly higher rates of 
late toxicities including late gastrostomy tube dependence.43 Another randomized trial among 
NPC patients also reported, accelerated hyper-fractionation therapy was associated with 
significantly higher risk of RT-associated central nervous system injury including damage to 
cranial nerves, temporal lobe, and brainstem.44 
Some patients (n=8) in this study also received Danish Head and Neck Cancer Group 
(DAHANCA) moderate accelerated RT fractionation strategy which incorporated 6 instead 
of 5 weekly radiation fractions during RT.45 A previous randomized trial among patients with 
glottic cancer reported that patients treated with the DAHANCA regimen suffered more 
frequently from severe acute mucositis even though frequency of late effects were 
comparable among patients treated with 6 vs 5 RT fractions.45 It was postulated that 
effectiveness of RT treatment may be influenced by inherent radio-sensitivity of cells, 
hypoxia of the tumor microenvironment, and regeneration of stem cells during RT 
treatment.45 Another randomized trial among NPC patients, also reported that accelerated 
hyper-fractionation radiation treatment was associated with higher late LCNP incidence than 
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conventional fractionation (13.0% vs 8.7%) over a median follow-up of 59.2 months.44 
Finally, the effect estimates in this study for accelerated RT are robust and similar to a 
previous study among NPC, which reported RT fractionation schedule (RR: 2.91, 95%CI: 
1.07-7.91, p=0.036) as a significant predictor of upper cranial nerve neuropathy and but not 
as a significant predictor of lower cranial nerve neuropathy.24  In summary, accelerated RT 
fractionation treatment regimens can contribute to an increase in risk of nerve fibrosis and 
cranial nerve injury. 
   Among non-surgically treated patients, the present study identified Induction TPF and 
Induction C-TPF followed by chemoradiotherapy or RT as risk factors associated with late 
LCNP. Chemotherapy drugs are cytotoxic and modify radiation sensitivity of cells either by 
altering their cell-cycle phase or by interfering with repair of radiation initiated double-strand 
DNA breaks.46,47 Thus, while enhancing tumor control, they can also contribute to late 
toxicity like LCNP. A prior study among NPC patients reported that chemotherapy was 
significantly associated with development of cranial neuropathy (RR=1.42, p=0.021).24 
Another clinical trial among stage III and stage IVB NPC patients revealed that late cranial 
neuropathy was significantly increased among patients treated with RT and concurrent 
adjuvant chemotherapy (p=0.042) than those treated with RT only.48 Similarly, in a previous 
study 6.3% of HNC patients, who received intra-arterial Cisplatin therapy developed cranial 
neuropathy shortly after treatment.49 Thus, while various authors have associated concurrent 
chemotherapy with LCNP after NPC radiotherapy, the results of this study are, to our 
knowledge, the first to link induction chemotherapy to elevated risk of LCNP in OPC.  
 
 
93 
 
Induction chemotherapy (IC) is a treatment alternative for patients with locally 
advanced head and neck squamous cell carcinoma (HNSCC) with goals of shrinking tumors, 
reducing risk of distant metastasis, and organ preservation for operable and inoperable 
tumors. 51-53 Induction TPF is considered the gold-standard evidence-based IC treatment 
regimen and is considered superior to PF (cisplatin combined with 5-FU).52,53 However, the 
use of IC in case of unresectable disease followed by RT or chemoradiation (CXRT) is 
controversial. 52,53  TPF may also be more toxic than concurrent chemoradiotherapy and 
contribute to greater morbidity and death, as some trials have reported IC toxicity-related 
death rates of 2%-7%.52 The TPF regimen in the United States includes a combination of 3 
drugs, including 3 cycles of docetaxel 75 mg/m2 combined with cisplatin 100 mg/m2 and 
1000 mg/m2 5FU infusion for 4 days, for every 3 weeks.53 Each one of these drugs has it’s 
individual toxicity profile. Cisplatin can contribute to neuropathy, hearing problems, renal 
toxicity, and cardiovascular adverse events, 5FU can result in severe mucositis and 
hematological problems, docetaxel can also contribute to neuropathy, erythema and 
hypotension.53 In case of CTPF, the cetuximab component can additionally contribute to 
severe anaphylactic toxic reactions.53 Therefore, in combination these drugs may contribute 
to late effects like LCNP. Lastly, IC therapy including drugs like Cisplatin may lead to 
increased radio-sensitivity to subsequent RT which in turn can play a role in development of 
late treatment-related toxicity and late LCNP.54 
The results from this study are of paramount importance in the realm of OPC 
survivorship as they have the potential to inform/advocate for long-term screening and 
surveillance recommendations to monitor and treat late effects like LCNP, inform future late 
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effects research, and advise the development and implementation of targeted risk-reduction 
and preventive interventions. These strategies could be implemented early and be 
personalized via risk stratification methods to meet individual needs for symptom 
management and psychosocial support to allow for more strategic allocation of resources and 
potentially lower health care cost. Risk-based OPC treatment planning, use of targeted 
therapies, nerve-sparing RT planning to decrease irradiation of vital structures which play an 
important role in swallowing, or sequential chemoradiotherapy may help to alleviate late 
effects like LCNP and improve function among survivors. Knowledge about predictors of 
late LCNP and its consequent impact on swallowing function and overall symptom severity 
may also allow more effective delineation of de-escalation targets.  
With more than 2,000 OPC survivors, this is to our knowledge, the largest 
retrospective cohort study to date to estimate risk of late LCNP and identify clinical 
predictors of late LCNP. However, there are limitations to acknowledge. Study participants 
had varying survival time and may be susceptible to survival bias. As a consequence of the 
long latency period for late LCNP development, risk would be highest among survivors with 
greater survival time. Nonetheless, consistently precise and robust effect estimates on late 
LCNP were identified which varied across clinical and demographic covariates as expected. 
The low event rate of late LCNP and loss-to-follow-up among survivors may also have 
contributed to low statistical power to identify additional potential predictors like RT dose 
among others. But the substantial study sample of OPC survivors, allowed for identification 
of possibly the most impactful predictors of LCNP. There may be some misclassification of 
study variables due to the retrospective study design but as study results varied as would be 
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expected by clinical and demographic variables their impact on study results is likely to be 
minimal. HPV testing had also not been conducted in about half of the cohort, therefore 
accurate estimates of risk based on HPV status in study population could not be assessed. 
However, sensitivity analysis of study results by HPV status did not have an impact on effect 
estimates for late LCNP, suggesting study results were valid and accurate. As this study was 
conducted at a tertiary care cancer center and there were small numbers of surgical patients 
there may be some limitations to generalizability of study results to more diverse 
populations. Further, late LCNP risk may have been underestimated in this study, as LCNP 
diagnosis was primarily via clinical signs of loss of motor function only and did not take into 
account loss of sensory function. Further, CN XI palsy was excluded to focus on swallowing 
associated late LCNP only. Isolated CN IX palsies were not detected in this study. Therefore, 
actual risk of LCNP among OPC survivors may most likely be higher than reported in our 
study. Lastly, individual susceptibility and impact of genetic predictors on LCNP could not 
be assessed and should be addressed by future studies assessing the risk of late LCNP. 
It is of utmost importance going forward to investigate evidence-based risk 
identification and early risk reduction strategies for late effects detection and management. 
Effective screening interventions, may consider the use of patient-reported outcomes tools 
like MD Anderson Dysphagia Inventory (MDADI) and MD Anderson Symptom Inventory – 
Head and Neck module (MDASI-HN) among others for surveillance and detection of late 
effects. Potential treatment for late LCNP also needs to be investigated in prospective clinical 
trials. Future studies need to further assess the role of dose to organs at risk (including the 
salivary glands, pharyngeal constrictors, cricopharyngeal muscle, base of tongue, supraglottic 
and glottic larynx and other critical structures), induction chemotherapy, and transoral 
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robotic surgery in development of late effects like LCNP.55 Further, it is crucial that HNC 
treatment selection must take into account long-term treatment-related morbidity and should 
be prioritized based on individual patient preferences to reduce disease burden due to late 
effects. Better RT techniques need to be developed to modify dose delivery and less toxic 
chemotherapy agents need to be investigated. Treatment de-intensification strategies need to 
be explored which maintain cure and prevent late effects. 
 
CONCLUSION 
While rare in the population overall, quantitative estimates of lifetime risk of late 
LCNP over an almost 18-year follow-up into OPC survivorship demonstrate that one out of 
10 OPC survivors middle-aged at time of diagnosis are likely to develop late LCNP. The 
progressively increasing risk of late LCNP of 2%, 6%, and 10% at 5, 10, 18-year follow-up 
also indicates that risk of LCNP overtime is much higher than previously believed. The 
potential impact of late LCNP on the life of OPC survivors is devastating as late LCNP and 
accompanying late-RAD is refractory to treatment, life-long, and permanent. In this study 
patients with big bulky tumors had large irradiation fields possibly including cranial nerves, 
they were likely to be treated most aggressively with multimodality treatment regimens 
including, IC, RT, and systemic therapy, thereby they were more likely to develop late 
LCNP. In summary, the long-term treatment-related burden of OPC is becoming more 
apparent, there is urgent need to find ways to treat cancer, minimize late effects like LCNP 
and improve QoL among OPC survivors. 
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TABLES 
Table 1: Patient Characteristics (N=2,021) 
Variables All patients 
(n=2021) 
LCNP 
(n=88) 
No LCNP 
(n=1,933) 
P-
value** 
Cumulative Incidence Log rank 
Test p 
value 
Age at diagnosis, median 
(range), IQR 
56 (28-86), 
(50-63) 
57(33-80) 
(51-63) 
55(28-86) 
(50-63) 
0.734   
Survival time, median 
(range), IQR yrs 
6.8(0.3-18.4) 
(4.3-10.2) 
5.4(0.3-14.1) 
(1.6-8.5) 
6.8(0.3-18.4) 
(4.4-10.3) 
< 0.001   
RT Dose, Gy median 
(range), IQR 
70(40-75), 
(66-70) 
70(66-73.5) 
(66-72) 
70(40-75) 
(66-70) 
< 0.001   
RT Fractions (range), IQR 33(15-44), 
(28-43) 
33(30-43) 
(32-40.5) 
33(15-44) 
(30-33) 
< 0.001   
Sex    0.429  0.399 
 Female 281(13.9) 15(5.3) 266(94.7)  0.096 (0.055-0.165)  
 Male 1740(86.1) 73(4.2) 1667(95.8)  0.098 (0.073-0.132)  
Primary Site     0.453  0.6418 
Tonsil 944(46.7) 40(4.2) 904(95.8)  0.101 (0.0678-0.152)  
Base of Tongue 945(46.8) 45(4.8) 900(95.2)  0.100 (0.070- 0.142)  
Others 132(6.5) 3(2.3) 129(97.7)  0.039 (0.012-0.128)  
T classification    < 0.001  < 0.001 
1 686(33.9) 18(2.6) 668(97.4)  0.046(0.027-0.077)  
2 770(38.1) 27(3.5) 743(96.5)        0.087 (0.049-0.151)  
3 358(17.7) 20(5.6) 338(94.4)  0.178 (0.109-0.283)  
4 207(10.2) 23(11.1) 184(88.9)  0.259 (0.154-0.417)  
N classification (AJCC 7th 
Ed) 
   0.212  0.0445 
N0 196(9.7) 6(3.1) 190(96.9)  0.082 (0.031-0.207)  
N1+2a 510(25.2) 16(3.1) 494(96.9)  0.052 (0.030-0.088)  
2b+3 968(47.9) 46(4.8) 922(95.2)  0.127 (0.084-0.188)  
2c 347(17.2) 20(5.8) 327(94.2)  0.127 (0.075- 0.211)  
HPV status    0.007  0.681 
Negative 110(5.4) 6(5.5) 104(94.6)  0.142 (0.054-0.345)  
Positive 817(40.4) 22(2.7) 795(97.3)  0.080 (0.033-0.175)  
Unknown 1094(54.2) 60(5.4) 1034(94.5)  0.098 (0.073-0.131)  
Smoking    0.559  0.087 
Never 861(42.6) 39(4.5) 822(95.5)  0.101 (0.065-0.154)  
Former 842(41.7) 33(3.9) 809(96.1)  0.088 (0.059-0.131)  
Current 294(14.6) 16(5.4) 278(94.6)  0.131 (0.070-0.240)  
Missing 24(1.2) 0(0) 24(100.0)  0.000  
Solid Food pre-Tx      0.086 
Yes 1816(89.9) 79(4.4) 1737(95.6) 1.000 0.092 (0.070-0.121)  
No 205(10.1) 9(4.4) 196(95.6)  0.421 (0.116- 0.912)  
Treatment Group    0.102  0.003 
Single Modality 647(32.0) 21(3.3) 626(96.8)  0.060 (0.038-0.094)  
Multimodality 1374(68.0) 67(4.9) 1307(95.1)  0.136 (0.090-0.201)  
Treatment Group    0.397  0.029 
RT alone 628(31.1) 21(3.3) 607(96.7)  0.061 (0.039-0.095)  
Surgery alone 19(0.9) 0(0.0) 19(100.0)  0.000  
RT plus systemic 1342(66.4) 66(4.9) 1276(95.1)  0.136 (0.091-0.201)  
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Variables All patients 
(n=2021) 
LCNP 
(n=88) 
No LCNP 
(n=1,933) 
P-
value** 
Cumulative Incidence Log rank 
Test p 
value 
Surgery +adjuvant RT 
&Chemo 
32(1.6) 1(3.1) 31(96.9)  0.032 (0.005-0.208) 
 
 
Radiotherapy    1.000  0.447 
No 21(1.0) 0(0.0) 21(100.0)  0.000  
Yes 2000(99.0) 88(4.4) 1912(95.6)  0.099 (0.075-0.128)  
Chemotherapy    0.082  0.002 
No 656(32.4) 21(3.2) 635(96.8)  0.060 (0.038-0.093)  
Yes 1365(67.5) 67(4.9) 1298(95.1)  0.136 (0.091-0.201)  
Surgery    1.000  0.865 
No 1986(98.3) 87(4.4) 1899(95.6)  0.098 (0.075-0.128)  
Yes- Robotic 35(1.7) 1(2.9) 34(97.1)  0.029 (0.004-0.191)  
Neck Dissection    0.454  0.779 
No 1500(74.2) 62(4.1) 1438(95.9)  0.091 (0.067-0.123)  
Yes 521(25.8) 26(5.0) 495(95.0)  0.110 (0.067-0.175)  
RT Schedule    < 0.001  < 0.001 
Standard Fractionation 1681(83.2) 56(3.3) 1625(96.7)  0.071 (0.047-0.107)  
Accelerated  319(15.8) 32(10.0) 287(90.0)  0.187 (0.132-0.260)  
Missing (Pt. Without RT) 21(1.0) 0(0.0) 21(100.0)  0.000  
RT Type    < 0.001  < 0.001 
3d Conformal 234(11.6) 24(10.3) 210(89.7)  0.174 (0.118-0.251)  
IMRT-SF  1227(60.7) 33(2.7) 1194(97.1)  0.073 (0.041-0.129)  
IMRT- WF+VMAT 377(18.7) 25(6.6) 352(93.4)  0.136 (0.085-0.215)  
Proton 36(1.8) 2 (5.6) 34(94.4)  0.056 (0.014-0.204)  
 IMRT Ipsi 126(6.2) 4 (3.2) 122 (96.8)  0.052 (0.018-0.145)  
 Missing (Pt. without RT) 21(1.0) 0(0.0) 21(1.0)  0.000  
 
Abbreviations: IQR, interquartile range, T, tumor; RT, radiotherapy; IMRT-SF, Intensity modulated 
radiotherapy split-field technique; IMRT-WF, Intensity modulated radiotherapy whole-field 
technique; IMRT-Ipsi, Intensity modulated radiotherapy ipsilateral treatment; VMAT, Volumetric-
modulated arc therapy 
Bold denotes statistical significance at p value < 0.05 
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TABLE 2: Univariate & Multivariate Cox Proportional Hazards models for Late 
LCNP (N=2021)  
Variables Univariate 
Analysis HR 
(95%CI) 
P Value  Multivariate Analysis 
HR (95%CI) 
P Value 
Age at diagnosis, median (range) 1.02 (1.00- 1.04) 0.117 1.02 (0.99-1.04) 0.163 
RT Dose, Gy median (range) 1.24 (1.14- 1.36) < 0.001   
RT Fractions 1.11 (1.07- 1.16) < 0.001   
Sex  0.412   
Female Reference  Reference  
 Male 0.79 (0.45-1.37) 0.400   
Primary Site   0.624   
Others Reference  Reference  
Tonsil 1.42 (0.44-4.58) 0.560 1.89 (0.58-6.17) 0.292 
Base of Tongue 1.62 (0.50-5.21) 0.420 1.85 (0.57-6.05) 0.309 
T classification, AJCC 7th Ed  < 0.001   
1 Reference  Reference  
2 1.53 (0.84-2.78) 0.161 1.12 (0.60-2.10) 0.727 
3 2.72 (1.44-5.14) 0.002 1.59 (0.76-3.31) 0.218 
4 6.10 (3.29-11.33) < 0.001 3.82 (1.85-7.86) < 0.001 
N classification, AJCC 7th Ed.  0.040   
N0 Reference  Reference  
N1+2a 0.85 (0.33-2.17) 0.733   
2b+3 1.56 (0.67-3.66) 0.302   
2c 2.01 (0.81-5.00) 0.134   
HPV status  0.706   
Negative Reference  Reference  
Positive 0.67 (0.27-1.66) 0.386   
Unknown 0.72 (0.31-1.67) 0.439   
Smoking  0.038   
Never Reference  Reference  
Former 0.85 (0.53-1.35) 0.493 0.76 (0.47-1.22) 0.253 
Current 1.74 (0.97-3.11) 0.064 1.57 (0.86-2.86) 0.143 
Solid Food pre-Tx  0.117   
Yes Reference  Reference  
No 1.82 (0.91-3.66) 0.091 1.16 (0.56-2.41) 0.685 
Treatment Group  0.002   
Single Modality Reference            Reference  
Multimodality 2.09 (1.27-3.44) 0.004 1.35 (0.77-2.37) 0.299 
Treatment Group  0.018   
RT alone Reference  Reference  
Surgery alone 0.00 1.000   
RT plus systemic 2.06 (1.25-3.39) 0.004   
Surgery +adjuvant RT &Chemo 2.02 (0.27-15.09) 0.494   
Chemotherapy  0.002   
No Reference  Reference  
Yes 2.13 (1.30-3.50) 0.003   
Surgery  0.868   
No Reference    
Yes- Robotic 1.19 (0.16-8.57) 0.865   
Neck Dissection  0.780   
No Reference    
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Variables Univariate 
Analysis HR 
(95%CI) 
P Value  Multivariate Analysis 
HR (95%CI) 
P Value 
Yes 1.07 (0.67-1.69) 0.779   
RT Schedule  0.000   
Standard Fractionation Reference  Reference  
Accelerated  2.53 (1.63-3.92) 0.000 2.15 (1.34-3.45) 0.002 
RT Type  < 0.001   
3d Conformal Reference    
IMRT-SF  0.32 (0.19-0.55) < 0.001   
IMRT- WF +VMAT 0.96 (0.54-1.70) 0.888   
Proton 1.33 (0.31-5.77) 0.701   
IMRT Ipsi 0.33 (0.11-0.94) 0.039   
 
Abbreviations: IQR, interquartile range, T, tumor; RT, radiotherapy; IMRT-SF, Intensity modulated 
radiotherapy split-field technique; IMRT-WF, Intensity modulated radiotherapy whole-field 
technique; IMRT-Ipsi, Intensity modulated radiotherapy ipsilateral treatment; VMAT, Volumetric-
modulated arc therapy 
Statistical significance p value < 0.25 after Univariate Analysis 
Statistical significance p value < 0.05 after Multivariate Analysis 
Bold denotes statistical significance at p value < 0.05 
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Figure 1. Consort flow chart showing study participant screening and eligibility criteria  
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Figure 1. Consort flow chart showing study participant screening and eligibility criteria. 
Abbreviations: 
OPC, oropharyngeal carcinoma, SCC, squamous cell carcinoma, OSH, outside hospital; SPM, second 
primary malignancy; LRR, locoregional recurrence; RRR, regional recurrence; DM, distant 
metastasis; NED, no evidence of disease; LCNP, lower cranial neuropathy. 
 
Figure 2: Overall Cumulative Incidence of Late LCNP in OPC survivors over an 18-year 
surveillance period (n=2,021) 
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Figure 3: Adjusted Risk of Late LCNP stratified by T-Stage 
 
Figure 3.  Adjusted Risk of Late LCNP stratified by RT T-Stage. Regression model adjusted for age, 
subsite, T-stage, smoking and therapeutic modality. Abbreviations: T, tumor; LCNP, lower cranial 
neuropathy. 
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Figure 4: Adjusted Risk of Late LCNP stratified by RT Fractionation 
 
Figure 4.  Adjusted Risk of Late LCNP stratified by RT Fractionation. Regression model adjusted for 
age, subsite, T-stage, smoking and therapeutic modality. Abbreviations: RT, radiotherapy; LCNP, 
lower cranial neuropathy. 
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Key Points 
Question What is the impact of late lower cranial neuropathy (LCNP) on severity of cancer 
treatment-related symptoms and general functional impairment (GFI) among long-term 
oropharyngeal cancer (OPC) survivors? 
Findings In this large cross-sectional survey (n=889), OPC survivors with late LCNP 
reported significantly worse cancer treatment-related symptoms. 
Meaning Further efforts are necessary to lessen symptom burden associated with this 
disabling late effect of cancer treatment experienced by OPC survivors. 
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Abstract 
IMPORTANCE: Lower cranial neuropathy (LCNP) is a rare but potentially disabling late 
effect of radiotherapy (RT) and other head and neck cancer therapies. Survivors who develop 
late LCNP may experience profound functional impairment with deficits in swallowing, 
speech, and voice. 
OBJECTIVE: To investigate the impact of late LCNP on severity of cancer treatment-
related symptoms and their subsequent impact on general functional impairment (GFI) 
among oropharyngeal cancer (OPC) survivors. Impact of late LCNP on single item scores of 
the most severe symptoms was also assessed. We hypothesized that late LCNP status among 
OPC survivors would be associated with significantly worse symptom scores and GFI.  
DESIGN: Cross-sectional survey analysis among 889 OPC survivors nested within a 
retrospective cohort of OPC survivors treated during January 2000 -December 2013. 
SETTING:  MD Anderson Cancer Center 
PARTICIPANTS: Eligible survey participants were disease-free and completed OPC 
treatment ≥1-year prior to survey. 
EXPOSURE: Late LCNP defined by onset ≥3-months after cancer therapy. 
MAIN OUTCOME: The primary outcome variable was the mean of the top 5 most severely 
scored symptoms from MD Anderson Symptom Inventory Head and Neck Cancer Module 
(MDASI-HN) out of all 22 core and HNC-specific symptoms. Secondary outcomes included 
mean MDASI-HN interference scores and single item scores of the most severe symptoms. 
Multivariate models regressed MDASI-HN scores on late LCNP status adjusting for clinical 
covariates. 
RESULTS: Overall, 4% (n=36) of 889 OPC survivors (median survival time: 7 years) 
 
113 
 
developed late LCNP. 
Late LCNP was significantly associated with worse mean top 5 MDASI-HN symptom scores 
(coefficient, 1.54; 95%CI, 0.8, 2.2) adjusting for age, survival time, sex, therapeutic modality, 
T-stage, subsite, type of radiotherapy, smoking, and normal diet prior to treatment. Late 
LCNP was also associated with single item scores for difficulty swallowing/chewing 
(coefficient, 2.25; 95%CI, 1.3, 3.1), mucus (coefficient, 1.97; 95%CI, 1.0, 2.9), fatigue 
(coefficient, 1.35; 95%CI, 0.4, 2.2), choking (coefficient, 1.53; 95%CI, 0.6, 2.4), and voice/ 
speech symptoms (coefficient, 2.3; 95%CI, 1.6, 3.0) in multivariable models. However late 
LCNP was not significantly associated with mean interference scores after correction for 
multiple comparisons. 
CONCLUSION AND RELEVANCE: In this large survey study, OPC survivors with late 
LCNP reported significantly worse cancer treatment-related symptoms demonstrating the 
impact of late LCNP on both symptom severity and burden.
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Introduction 
The incidence of oropharyngeal cancer (OPC) is increasing by 5% annually in the 
United States.
1 It is projected that by 2030 half of head and neck cancers (HNC) will be 
OPC.
1
This phenomenon is attributable to the epidemic of human papillomavirus (HPV)-
associated OPC, which is usually diagnosed in middle age.
1-4 HPV-disease is biologically 
favorable with excellent prognosis for long-term survival despite advanced-stage cancer.
2-4 
Despite excellent prognosis, survivors may experience severe side-effects of cancer treatment 
impacting critical functions like speech, breathing, and swallowing. 
 Late lower cranial neuropathies (LCNP) are a rare, but potentially severe late effect 
induced by damage due to radiotherapy (RT) and other cancer therapies. Lower cranial 
nerves include glossopharyngeal (IX), vagus (X), accessory (XI) and hypoglossal (XII) 
nerves, which are critical to the oropharyngeal phases of swallowing, shoulder function, and 
speech, respectively.
5-9 Fibrosis of nerve tracts or adjacent soft tissues can lead to delayed, 
typically progressive, neuro-vascular damage and eventually neuropathy which over time 
causes profound functional impairments.
5 
According to a recent single institution report, the 
incidence of delayed LCNP among 59 OPC survivors was 5% at 5.7 years.
6
 
Although a rare late effect, case reports suggest profound functional impairments and 
overall low quality of life (QOL) among LCNP cases.5-8Symptom burden is defined as 
severity of symptoms experienced by patients and the impact of those symptoms on day-to-
day life.
10 Patients may experience symptoms due to disease, recurrence, or as a consequence 
of treatment-related toxicity.
10 Late toxicities, such as late LCNP, conventionally persist or 
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occur ≥ 3 months after treatment completion but may develop even years later.11 
 General functional impairment (GFI) is defined as a diminished ability to take care of 
oneself, manage the household, work, and indulge in activities for relaxation.
12 Thus, GFI 
can adversely impact the daily lives of survivors.
12 Treatment-related symptoms may have 
detrimental impact on GFI marked by symptom interference scores. For some patients, the 
impairment is temporary, and with time they return to normal activity and function. However, 
a substantial number of OPC survivors continue to experience limitations, disability, and may 
be unable to return to normal activities including work leading to a long-term economic 
impact.12-13 
  Previous studies examining late radiation-associated LCNP have been case reports or 
small case series or cohorts of predominantly nasopharyngeal cancer (NPC) survivors. In 
OPC, severe symptoms have been described among LCNP cases, but the late LCNP and 
symptom relationship has yet to be quantified, nor has impact on GFI.7, 8 For the growing 
numbers of OPC survivors at risk for experiencing LCNP, it is critical to quantify the impact 
of late LCNP on severity of cancer treatment-related symptoms and GFI to inform 
development and implementation of targeted strategies for late effect surveillance and 
management. 
 The purpose of this analysis was to investigate the severity of cancer treatment-
related symptoms (per primary endpoint of top 5 MDASI-HN symptom mean) and their 
subsequent impact on GFI (per secondary endpoint of mean MDASI-HN interference score) 
by late LCNP status among OPC survivors. Impact of late LCNP on overall mean symptom 
burden single item scores of most severe symptoms, and categorical ratings of top 5 
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symptoms was also assessed to explore impact on diverse symptom metrics. We 
hypothesized that late LCNP status would be associated with significantly worse symptom 
scores and GFI. 
 
Methods 
 
Patient Eligibility 
 An IRB-approved cross-sectional patient-reported outcome (PRO) survey was 
conducted among survivors of a retrospective cohort of OPC survivors treated at MD Anderson 
Cancer Center (MDACC) between January, 2000 and December, 2013. Eligible participants 
were ≥ 18 years of age at diagnosis, completed OPC treatment ≥ 1 year prior to survey, and 
consented to future research participation at new patient registration within the institution. 
Deceased patients, those who had a secondary primary malignancy (SPM) or recurrent 
malignancy of the head and neck prior to survey, and those whose primary language was not 
English were excluded. Patients with LCNP of any cause at the time of cancer diagnosis or 
with clinical signs of LCNP before starting cancer treatment were also excluded. Details of 
survey administration and response have been published previously.
14  
 
OPC Treatment    
  Institutional practices regarding OPC treatment during the time period of this study 
have been previously described.15 Standard of care treatment during the current study time 
period for stage I/II OPC was definitive radiation and for patients with locally advanced OPC 
 
 
117 
 
(III/IV) was definitive chemoradiation.15-17 During 2000-2006, both IMRT and 3D conformal 
radiation technique were routinely used, but after 2006 IMRT became the primary modality 
of treatment.15 The recommended radiation dose for small volume primary tumors was 66 Gy 
and for more advanced tumors was 70-72 Gy.15 For treatment of primary tumors and nodes in 
the upper neck region predominantly IMRT approach was used, whereas for nodes in the 
lower neck anterior beam technique with laryngeal and or full midline block was used. 
Further, for treatment of primary tumors and the neck region when split-field IMRT was not 
possible whole-field IMRT technique was used. Individual extent of primary disease and pre-
existing comorbidities were taken into account to decide whether patients would receive 
systemic therapy or not. Definitive surgery via transoral resection to primary site was rare but 
after 2009, a small number of patients were treated with Transoral robotic surgery (TORS) 
with adjuvant therapy based on pathologic features.15-17 
  
            Demographic and Clinical Variables 
 Age at diagnosis, sex, race, education, smoking history, and HPV/p16 status were 
abstracted from electronic medical records. Clinical and treatment data abstracted included 
subsite of primary OPC tumor, tumor and nodal stage (AJCC version VII), treatment 
modality, RT dose, modality and fractionation, surgery, chemotherapeutic regimen, and 
ability to eat solid food at baseline (surrogate for baseline dysphagia). Survival time was 
calculated as the difference between age at diagnosis and age at time of survey. 
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Survey Items 
 The MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-
HN) is a 28-item validated PRO instrument that evaluates symptom severity and interference 
in HNC patients. MDASI-HN includes 13 questions to assess core symptoms common across 
all cancers and 9 questions to assess HNC-specific symptoms. MDASI-HN symptom severity 
item scores range from 0 “not present” to 10 “as bad as you can imagine.” MDASI-HN also 
includes 6 interference questions to assess the impact of symptoms on daily function with 
respect to general activity, walking, work, mood, relations with other people, and enjoyment 
of life. These item scores range from 0 “do not interfere” to 10 “interfere completely,” such 
that higher scores indicate more limitations and lower QOL.
14-21 Symptom and interference 
scores are commonly classified as: 0 “no symptom”; 1-3 “mild”; 4-6 “moderate” and 7-10 
“severe” symptoms.
22
Mean subscale scores have been shown to be internally consistent 
(Cronbach alpha: 0.72-0.92).
14-21
 
 
Primary Exposure 
 Late LCNP was assessed during surveillance and rehabilitation visits by clinical 
examination of cranial nerves by head and neck surgeons, radiation oncologists, and speech 
pathologists, and recorded in medical charts. Late LCNP was defined as onset of swallowing-
associated neuropathy of at least one of the glossopharyngeal (IX), vagus (X), and 
hypoglossal (XII) nerves with minimum onset ≥ 3 months after the end of cancer treatment. 
Three months is considered the start of late toxicity interval as per the NCI – Common 
Toxicity Criteria Manual, “Late radiation effects are defined as effects that occur 90 days and 
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onwards after initiation of RT treatment.”11 For this reason, we elected to code any onset of 
LNCP after 3 months and up until the survey response as a late LCNP. Polyneuropathy was 
present in some patients with LCNP but there was no standard method to document degree of 
neuropathy in medical charts. Medical records were reviewed to identify LCNP cases. 
Physical examination reports were reviewed in detail. Objective methods such as endoscopy 
and radiographic swallow studies were not universally available for such a large study 
sample but were reviewed in detail when available. CT and MRI were used to verify LCNP, 
but they were not a requirement for case status assessment. Case status was verified through 
independent review of a head and neck surgeon with review of surveillance CT and MRI to 
rule out malignancy or other sources of neuropathy. Electromyography was not routinely 
used. 
 
Primary Outcome: The primary outcome variable for this study was the mean of the top 5 
most severely scored symptoms out of all 22 core and HNC-specific symptoms. This 
methodology, reported in the MDASI user guide and previous symptom research studies, 
serves as an estimate of the severity of the most impactful and prevalent symptoms reported 
by this population.23-26 
  
            Secondary Outcome: Results of the MDASI-HN can be summarized in various ways. 
Therefore, four secondary outcomes of the MDASI-HN were evaluated to fully explore the 
impact of late LCNP on symptom burden. Secondary outcomes included: 1) overall mean of 22 
symptom items, 2) mean interference, 3) single item scores of the top 5 most severe symptoms, 
and 4) categorical ratings of top 5 symptoms.  
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 Overall mean symptom scores summarize all 22 items of core and HNC- specific 
symptoms to reflect overall symptom severity. Mean interference serves as a marker of GFI 
with sub-domains of activity-related interference (using item scores related to general activity, 
work, and walking) and psychosocial-related interference (using item scores related to mood, 
relations with other people and enjoyment of life). Single item scores of the top 5 most severe 
symptoms, while extant in our primary endpoint (mean of top 5) were evaluated to reflect 
impact of LCNP on individual symptoms to provide insight on particular functional domains 
where LCNP had the greatest negative impact that might be helpful to focus supportive care 
efforts for this population. Finally, categorical ratings were examined to allow ease of clinical 
interpretation to identify proportions of patients experiencing high grade symptoms 
(supplementary analysis).22 
 
Statistical Analysis 
Descriptive and univariate analyses were first performed. For the primary outcome, 
mean top 5 MDASI-HN symptoms, multiple linear regression was next used to investigate 
associations between LCNP status and MDASI-HN scores, controlling for age, sex, race, T-
stage, subsite, RT dose, fractionation, and modality, chemotherapy, surgery, eating solid food 
at baseline, survival time, and smoking, which according to previous literature, are co-factors 
that associate with toxicity and symptom burden.
27, 28
 
Model building followed the purposeful variable selection method of Hosmer and 
Lemeshow.
29
Candidate predictors with p < 0.25 on univariate Wald test were entered into 
multivariable models and removed stepwise (p > 0.2). Age, T-stage, subsite, treatment 
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modality, and smoking were a priori retained as clinically important covariates and included 
in all models. Coefficients (unadjusted and adjusted) and corresponding 95% confidence 
interval (CI) were estimated. Impact of late LCNP on secondary outcomes were evaluated 
using multiple regression methods adjusting for the same variables as the primary outcome 
analysis. All data were analyzed without imputation for missing information. Given our 
consideration of multiple MDASI-HN parameters as symptom burden outcomes, analysis of 
all twelve primary and secondary outcomes including top5 mean, overall 22-item mean, 
mean interference including activity-related and psychosocial domains, individual scores for 
top 5 symptoms, voice and categorical ratings was corrected for multiple comparisons. After 
Bonferroni correction (α=0.05/12), statistical significance was conferred at p < 0.004. 
Statistical analysis was conducted using the STATA software, version 14.0 (StataCorp LP, 
College Station, TX). 
 
Results 
 
Sample Characteristics 
 889 eligible survivors were included in the final analytic sample with a median 
survival duration at time of survey of 7.0 years (range: 1-16). OPC survivors were mostly 
white (92%, 821/889), male (84%, 753/889), and had higher than high school education 
(72%, 637/889). Almost all were treated with RT (99%, 881/889), and few were treated with 
definitive surgery (3%, 24/889).  
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Late Lower Cranial Neuropathy 
 
 Overall, 4% (n=36) of OPC survivors were diagnosed with late LCNP and these 
cases had longer survival (median, 10.5 years). The median time to onset among LCNP cases 
in our study was 5.25, (range: 0.25 to 12.3) years after RT. Among late LCNP cases, 58% 
(22/36) had T1-T2 tumors, 42% (15/36) received accelerated RT, 25% (9/36) were treated 
with 3-D conformal RT and 64% (23/36) received IMRT-SF and almost all could 
functionally eat a normal diet prior to treatment. 
 Median RT Dose among respondents with LCNP was slightly higher (70 Gy, range: 
60-72 Gy) in comparison to those without late LCNP (69.3 Gy, range: 40-73 Gy). 68% 
(605/889) of respondents received chemotherapy and rate of LCNP was slightly higher 
among respondents who received chemotherapy (risk difference; 0.26, 95% CI: -2.6, 3.0) in 
comparison to those who did not. 
 
Treatment-related Symptom Burden (Mean of Top 5 symptoms) 
 The mean of each of the top 5 most severe symptoms reported by OPC survivors are 
summarized in Table 1 and included in descending order: dry mouth (mean 3.9± 2.9), 
swallowing/chewing (mean 2.6±2.8), mucus (mean 2.3±2.4), fatigue (mean 2.0± 2.5), and 
choking (mean 2.0± 2.6). Overall treatment-related symptom burden among all survivors was 
low (mean 2.6, median 2.0, range 0-10).  Late LCNP cases reported significantly worse mean 
treatment-related symptom scores compared to those without LCNP (LCNP: 4.5 vs. no 
LCNP: 2.5, mean difference; -2.0; 95%CI, -2.7, -1.3). 
.  
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 Unadjusted univariate analyses showed survival time, T-classification, therapeutic 
modality, chemotherapy, RT dose, fractionation, and modality, and smoking had significant 
associations with mean scores. Multiple linear regression identified that late LCNP was 
significantly associated with worse mean top 5 MDASI-HN symptom scores (Coefficient, 
1.54; 95%CI, 0.8, 2.2, adjusted R2, 0.08) adjusting for age, survival time, sex, therapeutic 
modality, T-stage, subsite, RT modality, smoking, and normal diet prior to treatment. 
 
Overall Mean (22-item) MDASI-HN 
 LCNP cases reported significantly worse mean overall 22-item mean scores 
compared to those without LCNP (LCNP: 2.4 vs. no LCNP: 1.4, mean difference; -1.0; 
95%CI, -1.5, -0.5). Late LCNP remained significantly associated with worse overall 22-item 
mean scores (Coefficient, 0.75; 95%CI, 0.2, 1.2,) after multivariable adjustment. 
 
GFI/ Mean Interference 
 Late LCNP was not significantly associated with worse mean interference scores 
after multivariable adjustment and correction for multiple testing. Impact of late LCNP on 
individual domains of interference scores categorized as activity-related and psychosocial-
related was also not statistically significant after correction for multiple comparison. 
 
Individual Top 5 Symptoms and Voice/Speech Symptom 
 Individual symptoms that were most severe among late LCNP cases, in rank order of 
means, included difficulty swallowing/chewing (LCNP: 5.5 vs. no LCNP: 2.5, mean 
difference;-2.9; 95%CI, -3.9,-2.0), dry mouth (LCNP: 4.9 vs. no LCNP: 3.8, mean difference; 
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-1.0; 95%CI, -2.0,-0.4), mucus (LCNP: 4.7 vs. no LCNP: 2.3, mean difference; -2.5; 95%CI, 
-3.4,-1.5), voice/speech (LCNP: 4.4 vs. no LCNP: 1.3, mean difference; -3.1; 95%CI, -3.9,-
2.3) and choking (LCNP: 4.1 vs. no LCNP: 1.9, mean difference; -2.1; 95%CI, -3.0,-1.3). 
  
 Late LCNP was significantly associated with worse mean swallowing/chewing scores 
(coefficient, 2.25; 95%CI, 1.3, 3.1adjusted R2, 0.10), mucus problems (coefficient, 1.97; 
95%CI, 1.0, 2.9, adjusted R2, 0.07), fatigue (coefficient, 1.35; 95%CI, 0.4, 2.2, adjusted R2, 
0.03), and choking/coughing (coefficient, 1.53; 95%CI, 0.6, 2.4, adjusted R2, 0.07) adjusting 
for the same variables as the primary outcome analysis. However, late LCNP was not 
significantly associated with worse dry mouth after multivariable adjustment. As late LCNP 
can include vocal cord paralysis and/or lingual paralysis (with associated impact on voice and 
speech production), the impact of late LCNP on voice/speech was assessed in exploratory 
post hoc analysis despite its exclusion from the top 5 items in the overall sample. Late LCNP 
was independently associated with worse mean MDASI-HN voice scores (Coefficient, 2.3; 
95%CI, 1.6, 3.0, adjusted R2 – 0.17) after multivariable adjustment. 
 Among LCNP cases, a higher proportion reported severe (LCNP: 20% vs no LCNP: 
5%) and moderate (LCNP: 40% vs no LCNP: 15%) symptoms. Additionally, among LCNP 
cases, severe scores (≥7) were reported by 43% (15/35) for swallowing/chewing symptoms 
and 37% (13/35) for voice/speech problems. Among 35 late LCNP cases, 6 patients rated 
difficulty swallowing, 4 rated voice/speech problems, 4 rated choking, and 3 rated mucus as 
10 of 10 severity, the worst possible score on MDASI-HN (Supplementary Figure 1).  
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Discussion 
 This large cross-sectional survivorship survey yields a comprehensive, quantitative 
assessment of the significant impact of late LCNP on cancer treatment-related symptoms and 
their subsequent impact on GFI among OPC survivors. Survey results in almost 900 OPC 
survivors treated during 2000-2013 indicated that, although overall treatment-related 
symptom burden among all survivors was low, the small subgroup of late LCNP cases (4%) 
reported significantly worse treatment-related symptom severity. While the impact of late 
LCNP is clinically recognized, prior studies have yet to quantitatively estimate the burden of 
this late effect. 
  
 Our results suggest, on average, mean of top 5 MDASI-HN items is 1.54 points worse 
among survivors with LCNP compared to those without LCNP, even after adjusting for age, 
survival time, sex, therapeutic modality, T-stage, subsite, RT modality, smoking, and normal 
diet prior to treatment. This reflects a moderate effect size of LCNP on most prevalent 
symptoms in this survivor population. The adjusted R
2 of the model suggested that late 
LCNP explained 8% of the variation in top 5 MDASI-HN mean after accounting for the 
effects of other covariates. This modest/moderate adjusted R
2 for a single exposure may 
reflect the variability of nerve paresis effects on symptoms among survivors due to their 
cross-sectional sampling along the continuum of nerve paresis (partial through complete 
denervation) as progressive deterioration over time is characteristic of late LCNP.
30 That is, 
LCNP cases responded to the survey from 2 to 16 years after treatment, a timeframe during 
which the clinical course of LCNP was likely to vary. This observation is consistent with 
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previous case reports suggesting that functional status of cases approximated the trajectories 
of their neuropathies.
7 That is, as late LCNP remained clinically stable, physiologic 
impairment remained steady and, as late LCNP progressed, coincident severe decline in 
function and body weight occurred.
7
 
 
 OPC treatment may lead to multiple local symptoms in the treatment field including 
dry mouth, dysphagia, mucositis, choking, speech problems, and lack of taste, among others, 
which can contribute to excessive distress and lower QOL.
27, 31
The top 5 symptom means 
reported by our study population predominantly featured similar local head and neck specific 
side effects (4/5, except fatigue). Given their central role in daily functioning, it is not 
surprising that late LCNP cases also reported higher levels of GFI that highly correlated with 
symptom severity but this relationship was not statistically significant after multiple 
comparison correction. Interestingly, among individual components of the interference 
domain, late LCNP seemed to be more strongly associated with activity-related interference 
but not psychosocial-related scores, but this relationship was not statistically significant. 
These findings may perhaps suggest a more lasting impact of LCNP on activity as opposed to 
emotional distress. It is speculated that psychosocial distress associated with late effects may 
attenuate over time as patients learn to cope with the emotional distress associated with 
physical impairment. Similarly, a previous study investigating QOL among oral cancer 
patients per the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) 
demonstrated significantly improved emotional scores in the same time that functional scores 
deteriorated between 1 month and 6 months after treatment.
32
The authors attributed this to a 
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“response shift” which they described as emotional adaptation to decline in physical 
functioning and improved coping with the “new normal” level of functioning.32 These trends 
are  also consistent with results of a study among HNC patients using the MD Anderson 
Dysphagia Inventory (MDADI), which reported better scores for the emotional versus 
functional component.
33
 
 
 Overall, late LCNP most strongly associated with worse swallowing/chewing and 
speech/voice symptoms, with LCNP explaining 10% and 17% of the variation in these 
scores, respectively. These findings agree with those reported by a longitudinal study among 
57 OPC survivors wherein 3 LCNP cases experienced severe decline in swallowing function 
over time, as per patient-reported MDADI scores, clinician-rated radiographic dysphagia 
grades (DIGEST), and standard diet scales (PSS-HN).
6 Late LCNP also strongly associated 
with worse mucus and choking scores in the present survey, which may reflect symptoms 
associated with swallowing effects of LCNP. Inefficient swallows described previously in 
LCNP cases impact the ability to effectively clear food and liquids through the oropharynx, 
including mucus.
7 Mucus accumulation can lead to unpleasant symptoms of gagging and 
choking. This may also reflect aspiration of food and liquids during swallowing as previously 
reported in 100% of cases with neuropathy mediated late radiation-associated dysphagia 
(late-RAD) comprised largely of long-term OPC survivors >5-years post-treatment.
34
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 Lower cranial nerves are critical to the oropharyngeal phase of swallowing as well as 
voice and speech production. 
5-9 CN IX palsy may lead to swallowing problems by way of 
loss of function of the stylopharyngeus muscle and loss of pharyngeal sensation, whereas CN 
X injury can cause paralysis of the pharyngeal constrictors and/or vocal cords (depending on 
the branch), and thereby contribute to dysphagia as well as voice impairment. Neuropathy of 
CN XII results in tongue paresis, atrophy, and fibrillations with implications also to 
swallowing and speech precision.
5-9 Therefore, the specific patterns of symptom burden 
detected in this survey align with the clinical impact of specific LCNPs among OPC patients. 
 Fatigue is widely prevalent in HNC survivors but was also reported with greater 
severity among LCNP cases, which may be because of late LCNP-associated mucus 
problems that could exacerbate sleep disturbance.
35 LCNP-associated swallowing 
dysfunction can also contribute to long-term micronutrient deficiency and complications like 
anorexia, malnutrition, anemia, and cachexia. Cachexia especially has been linked in past 
studies to functional limitations and fatigue.
36 Furthermore, lack of association between late 
LCNP and dry mouth is expected, given that dry mouth is not a consequence of lower cranial 
nerve injury and is instead caused by RT-induced hypofunction of salivary glands.
37
 
With approximately 900 OPC survivors, this study is the first to quantitatively 
estimate the impact of late LCNP on treatment-related severity of symptoms. There are, 
however, limitations to acknowledge. Cross-sectional survey administration led to 
respondents with varying survival time and survival bias. Given the long latency period for 
late LCNP development, risk is highest among responders with greater survival time. For this 
reason, survival time was accounted for in all regression models. The small number of events 
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is a limitation inherent to studies of LCNP, as it is known to be a rare late effect. 
Nonetheless, consistently robust effect estimates on study outcomes were identified that 
reflect expected outcomes from clinical observations. This study was conducted in a tertiary 
care cancer center making it subject to referral bias that can limit generalizability of results to 
other hospitals and communities, but sample characteristics are common of modern OPC in 
the US, therefore, impact of this issue is expected to be negligible. The largest threat to 
validity is the possibility of misclassification. Late LCNP ascertainment may be incomplete 
due to loss to follow-up, missing chart details, or differential follow-up among patients 
displaying mild cranial neuropathy symptoms insufficient to merit return to clinic for late 
LCNP. Therefore, exposure misclassification in this study would most likely lead to under-
reporting of LCNP and consequently to underestimation of LCNP impact on symptom 
burden. Thus, if misclassification was substantial, actual coefficients for LCNP and symptom 
burden may be higher than reported in this study. With cross-sectional survey, degree or time 
course of LCNP was not standard in all cases. There was, for instance, no standard method to 
document degree of neuropathy in medical records. Likewise, the impact of LCNP on diet 
and other functional parameters was not assessed and will be investigated in future 
publications. We also did not obtain detailed validated measures of anxiety and depression 
and therefore the impact of late LCNP on these domains need to be investigated in future 
studies using other more robust measures. 
Symptom burden can be reflected by many parameters of the MDASI-HN. Each of 
the MDASI-HN outcomes we report in this analysis is described in the MDASI user guide as 
options to report findings from the instrument. It is important to acknowledge, however, that 
the top 5 mean MDASI-HN metric has not been evaluated for validity in a dedicated 
 
 
130 
 
publication. It is, however, supported by both the MDASI user manual and by expected 
performance relative to clinical and demographic classifiers in this report and other 
publications. 23-26Evaluation of individual items as a secondary endpoint also suggested that 
late LCNP had a greatest negative impact on difficulty swallowing, speech, mucus problems, 
choking, and fatigue symptoms among OPC survivors. For this reason, the functional 
translation of late LCNP may lead to placement of feeding tubes, tracheostomy tubes, 
aspiration, and pneumonia, as has been described in smaller series with more objective 
metrics.6-8Smaller series, however, fail to include non-LCNP controls such that effect sizes 
from these more objective metrics are not available in current literature. It is our hope that 
these survey-based quantifications offer initial progress toward quantifying the impact of this 
rare but devastating late effect of treatment. 
This research can inform development of supportive care interventions among OPC 
survivors to target these symptom domains through personalized speech and swallowing 
therapy and nutritional consultations and such implications need to be assessed in future 
studies. Given the high degree of symptom burden, the authors support the integration of 
interdisciplinary supportive care early to potentially attenuate or slow the functional impact 
of LCNP. Diverse symptoms likely merit involvement of speech pathologists, oral 
oncologists, physiatrists, physical therapists, nutrition, and oncology nursing among others to 
optimize outcomes. Targeted and individualized treatments must take into consideration 
patient perspectives and routine symptom screening using validated PROs such as MDASI-
HN in patients with LCNP may also be of value to prioritize areas for intervention.
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 Conclusions 
In this large survey study, late LCNP cases reported significantly worse cancer 
treatment-related symptoms, and worse symptoms associated with motor functions of the 
upper aerodigestive tract (swallowing, voice), demonstrating the relevance of late LCNP to 
both symptom severity and QOL. Among LCNP cases, a higher proportion reported severe 
(LCNP: 20% vs no LCNP: 5%) and moderate (LCNP: 40% vs no LCNP: 15%) symptoms. 
There is a clear need for long-term surveillance of late LCNP among HNC and OPC patients, 
particularly in light of epidemiologic trends that suggest growing numbers of OPC survivors 
at risk of late effects in immediate years ahead.6-8 Further, efforts are necessary to lessen 
symptom burden associated with this disabling late effect among OPC survivors. 
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Table 1: Patient Characteristics 889 (N=889), Top 5 mean MDASI-HN: 
Variables No. of Patients LCNP Rate (%) Top 5 mean MDASI-
HN Score (+/-Standard 
Deviation) 
All patients (n=906) 
Age at diagnosis, 
median (range) 
  56 (32-84) 
Survival time, median 
(range) 
  7(1-16) 
Radiation Dose, Gy. 
median (range) 
  70 (40-73) 
Sex    
Female 136 (15.3) 5(3.7) 2.81 ± 2.3 
Male 753 (84.7) 31(4.1) 2.57 ± 2.1 
Education    
≥Highschool 168(18.9) 8(4.8) 2.95 ± 2.4 
>Highschool 637(71.7) 27(4.2) 2.49 ± 2.1 
Missing 84(9.4) 1(1.2) 2.86 ± 2.3 
Race    
Others 59(6.6) 3(5.0) 2.79 ±2.7 
White 821(92.4) 32(3.9) 2.60 ± 2.1 
Missing 9(1.0) 1(11.1) 2.44 ± 1.7 
Primary Site    
Tonsil 438(49.3) 17(3.8) 2.58 ± 2.2 
Base of Tongue 451(50.7) 19(4.2) 2.64 ± 2.2 
T classification    
1 334(37.6) 8(2.4) 2.37 ±2.1 
2 345(38.8) 13(3.8) 2.52 ±2.1 
3 131(14.7) 8(6.1) 2.89 ±2.3 
4 79(8.9) 7(8.9) 3.56 ±2.5 
N classification    
N0 81(9.1) 3(3.7) 2.58 ±2.3 
N1+2a 236(26.5) 7(2.9) 2.48 ±2.2 
2b+3 429(48.3) 19(4.4) 2.50 ±2.0 
2c 143(16.1) 7(4.9) 3.16 ±2.4 
HPV status    
Negative 56(6.3) 2(3.6) 2.37 ±1.9 
Positive 429(48.3) 9(2.1) 2.46 ±2.1 
Unknown 404(45.4) 25(6.2) 2.80 ±2.3 
Smoking    
Never 409(46.0) 16(3.9) 2.49 ±2.1 
Former 422(47.5) 17(4.0) 2.64 ±2.1 
Current 58(6.5) 3(5.2) 3.22 ±2.5 
Solid Food pre-Tx    
Yes 879(98.9) 35(4.0) 2.56 ±1.8 
No 10(1.1) 1(10.0) 2.61 ±2.2 
Treatment Group    
Single Modality 278(31.3) 11(4.0) 2.34 ±2.1 
Multimodality 611(68.7) 25(4.1) 2.73 ± 2.2 
Treatment Group    
RT alone 270(30.4) 11(4.1) 2.38 ±2.1 
Surgery alone 8(0.9) 0 0.80 ±0.7 
RT plus systemic 596(67.0) 23(3.9) 2.73 ±2.2 
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Surgery plus adjuvant 15(1.7) 2(13.3) 2.64 ±2.3 
Radiotherapy    
No 8(0.9) 0 0.80 ±0.8 
Yes 881(99.1) 36(4.1) 2.62 ±2.2 
Chemotherapy    
No 284(32.0) 11(3.9) 2.34 ±2.1 
Yes 605(68.0) 25(4.1) 2.73 ±2.2 
Surgery    
No 865(97.3) 34(3.9) 2.63 ±2.2 
Yes 24(2.7) 2(8.3) 1.91 ±2.0 
Neck Dissection    
No 665(74.8) 27(4.1) 2.64 ±2.2 
Yes 224(25.2) 9(4.0) 2.52 ±2.2 
RT Schedule    
Standard Fractionation 778(88.3) 21(2.7) 2.54 ±2.1 
Accelerated  95(10.8) 15(15.8) 3.40 ±2.4 
Missing 8(0.9) 0 1.76 ±1.9 
RT Type    
3d Conformal 50(5.7) 9(18.0) 4.34 ±2.6 
IMRT-SF  675(76.6) 23(3.4) 2.63 ±2.1 
IMRT- WF 33(3.8) 1(3.0) 2.72 ±2.3 
Proton 23(2.6) 1(4.4) 2.14 ±1.6 
IMRT Ipsilateral 100(11.3) 2(2.0) 1.8 ±1.6 
Abbreviations: T, tumor; RT, radiotherapy; MDASI-HN, MD Anderson Symptom Inventory Head 
and Neck Cancer Module (MDASI-HN 
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Table 2. Top 5 MDASIHN Univariate and Multivariate Regression (n=889) 
Variables Univariate Analysis Coefficient 
(95%CI) 
Multivariate Analysis Coefficient 
(95%CI) 
Late LCNP   
No Reference Reference 
Yes 2.00 (1.28, 2.72) *** 1.54 (.82, 2.27) *** 
Age at diagnosis 0.001 (-.02, .02) 0.007 (-.01, .02) 
Survival Time 0.06 (.02, .09) * 0.02 (-.03, .06) 
Radiation Dose 0.10 (.04, .15) *  
Sex   
Female Reference Reference 
Male -0.24 (-.64, .16) -0.32 (-.71, .08) 
Education   
≤Highschool Reference Reference 
>Highschool -0.46 (-.83 -.09) *  
Missing -0.09 (-.66, .48)  
Race   
Others Reference Reference 
White -0.20 (-.78, .39)  
Missing -0.35 (-1.87, 1.18)  
Primary Site   
Tonsil Reference Reference 
Base of Tongue  0.07 (-.22, .36) -0.08 (-.38,.23) 
T classification   
1 Reference Reference 
2 0.15(-.17, .48) 0.007 (-.33,.35) 
3 0.52 (.08, .96) * 0.06 (-.42, .54) 
4 1.19 (.65, 1.73) *** 0.73 (.16,1.30) ** 
Smoking   
Never Reference Reference 
Former 0.14 (-.15, .44) 0.12 (-.18,.41) 
Current 0.73 (.12, 1.33) * 0.62 (.03, 1.22) ** 
Solid Food pre-Tx   
Yes Reference Reference 
No 0.06 (-1.29, 1.42) 0.60 (-.64,1.85) 
Treatment Group   
Single Modality Tx. Reference Reference 
Multimodality Tx. 0.40 (.09, .71) * 0.17 (-.20, .53) 
Radiotherapy   
No Reference  
Yes 1.83 (.32,3.33) *  
Chemotherapy   
No Reference Reference 
Yes 0.40 (.09, .70) *  
Surgery   
No Reference Reference 
Yes,  -0.72 (-1.61, .18)  
Neck Dissection   
No Reference Reference 
Yes -0.11 (-.46,.22)  
RT Schedule   
Standard Fractionation Reference Reference 
Accelerated  0.85 (.39, 1.32) ***  
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Missing -0.77 (-2.27, .74)  
RT Type   
3d Conformal Reference  
IMRT-SF  -1.71 (-2.33, -1.10) *** -1.34 (-2.02, -.66) *** 
IMRT- WF -1.62 (-2.55, -.68) * -1.33 (-2.29, -.38) ** 
Proton -2.20 (-3.25, 1.15) *** -1.76 (-2.89, -.63) ** 
IMRT-Ipsilateral -2.54 (-3.27, -1.81) *** -2.06 (-2.89, -1.23) *** 
Abbreviations: T, tumor; RT, radiotherapy; MDASI-HN, MD Anderson Symptom Inventory Head 
and Neck Cancer Module (MDASI-HN) 
* Statistical significance p value < 0.05 after Univariate Analysis 
** Statistical significance p value < 0.05 after Multivariate Analysis 
*** Statistical significance p value < 0.001  
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FIGURE 1: Consort flow chart 
 
 
Figure 1. Consort flow chart showing study participant recruitment and eligibility criteria. 
Abbreviations: SPM, second primary malignancy; LRR, locoregional recurrence; DM, distant 
metastasis; LCNP, lower cranial neuropathy; MDASI-HN, MD Anderson Symptom Inventory Head 
and Neck Cancer Module (MDASI-HN). 
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Figure 2: Crude/Unadjusted Difference in means of individual MDASI-HN symptom 
severity by Late LCNP status. 
 
 
 
 
Figure 2. Crude/Unadjusted Difference in means of individual MDASI-HN symptom severity by Late 
LCNP status. Darkened circles represent estimate of difference in means and bars represent 95% 
Confidence Intervals. * Denotes statistical significance conferred if 95% confidence for the estimate 
did not include the null value. Abbreviations: MDASI-HN, MD Anderson Symptom Inventory Head 
and Neck Cancer Module (MDASI-HN); LCNP, lower cranial neuropathy. 
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Difference in means by Late LCNP status and 95% Confidence Interval 
Appetite 1.26 (0.5, 1.9) *
Choking/Coughing 2.15 (1.3, 3.0) *
Constipation 0.45 (-0.2, 1.1)
Disturbed Sleep 0.89 (0.1, 1.7) *
Drowsy 1.14 (0.4, 1.9) 
*
Fatigue 1.47 (0.6, 2.3) *
Memory 0.09 (-0.7, 0.9)
Mucus 2.48 (1.6, 3.4) *
Numbness 1.35 (0.5, 2.2) *
Sad 0.39 (-0.3, 1.1)
Shortness of Breath 0.68 (0.02, 1.3) *
Skin 0.24 (-0.2, 0.7)
Vomiting 0.1 (-0.1, 0.4)
Dry mouth 1.02 (0.04, 2.0) *
Nausea 0.25(-0.1, 0.6)
Pain 0.58 (-0.1, 1.3)
Swallowing/Chewing 2.94 (2.0, 3.9) *
Taste 0.8 (-0.1, 1.7)
Voice/Speech 3.1 (2.3, 3.9) *
Sores 0.04 (-0.5, 0.5)
Teeth 0.26 (-0.6, 1.1)
Upset 0.7 (0.02, 1.4) *
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Figure 3: Multivariate Adjusted Coefficients for Late LCNP and MDASI-HN Scores. 
 
 
 
 
 
 
Figure 3.  Multivariate Adjusted Coefficients for Late LCNP and MDASI-HN Scores. 
All regression models adjusted for age, survival time, sex, therapeutic modality, T-stage, subsite, RT 
modality, smoking, and normal diet prior to treatment. * Denote statistically significant in 
multivariate model before multiple comparison correction. ** Denote statistically significant in 
multivariate model after multiple comparison correction (p < 0.004). Abbreviations: MDASI-HN, 
MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN); LCNP, lower 
cranial neuropathy. 
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Abstract 
Background: The purpose of this study was to quantify the association of late lower cranial 
neuropathy (late LCNP) with swallowing-related quality of life (QOL) and functional status 
among long-term oropharyngeal cancer (OPC) survivors. 
Methods: Eight hundred eighty-nine OPC survivors (median survival time: 7 years) who 
received primary treatment at a single institution between January, 2000 – December, 2013 
completed a cross-sectional survey (56% response rate) that included the MD Anderson 
Dysphagia Inventory (MDADI) and self-report of functional status. Late LCNP events ≥3-
months after cancer therapy were abstracted from medical records. Multivariate models 
regressed MDADI scores on late LCNP status adjusting for clinical covariates.  
Results: Overall, 4.0% (n=36) of respondents developed late LCNP with median time to 
onset of 5.25 years post-treatment. LCNP cases reported significantly worse mean composite 
MDADI (LCNP: 68.0 vs. no LCNP: 80.2, p<0.001). Late LCNP independently associated 
with worse mean composite MDADI (β= -6.7, p=0.015, 95%CI: -12.0, -1.3) as well as all 
MDADI domains after multivariate adjustment. LCNP cases were more likely to have a 
feeding tube at time of survey (OR= 20.5; 95%CI, 8.6 to 48.9), history of aspiration 
pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), and tracheostomy (OR= 26.9; 95%CI, 6.0 to 
121.7). 
Conclusions: In this large survey study, OPC survivors with late LCNP reported 
significantly poorer swallowing-related QOL and had significantly higher likelihood of poor 
 
 
147 
 
functional status. Further efforts are necessary to optimize swallowing outcomes to improve 
QOL in this subgroup of survivors.  
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INTRODUCTION 
Swallowing is a complex and multifaceted neuromuscular process that involves 5 
cranial nerves (CN) and almost 30 muscles in the upper aero-digestive tract. Patients with 
oropharyngeal cancer (OPC) receive local treatments, radiotherapy (RT), and/or surgery, to 
this functionally critical region that can cause chronic dysphagia with adverse impact on 
swallowing-related quality of life (QOL). 1-6 Dysphagia is one of the most impactful and 
prevalent functional toxicities reported in approximately 30-50% of survivors. 7-10 Prior 
analysis of this OPC survivorship found that, among 22 symptoms queried, the severity of 
dysphagia symptoms most strongly associated with decisional regret about cancer 
treatment.11 The rising incidence of highly curable HPV-associated OPC leads to greater 
numbers of OPC survivors at risk of dysphagia with great impetus to understand factors that 
associate with poor swallowing outcomes and adversely impact QOL in this growing 
population. Dysphagia also leads to excessive morbidity, negatively impacting functional 
status and health of OPC survivors. Impaired airway protection can lead to aspiration 
pneumonia, and inefficient bolus clearance may result in low food intake, extended 
gastrostomy tube dependence, weight loss, and malnutrition.12 Patients with dysphagia often 
modify their diet, need extended meal times, feel self-conscious to eat in social settings, and 
thereby experience social isolation and diminished QOL.12  
Radiation-associated dysphagia is typically linked with soft tissue injuries including 
inflammation, edema, fibrosis, and stricture.13 Acute tissue injury results from cell depletion 
and inflammation that contribute to edema, erythema, and mucositis of the oropharyngeal 
region.13,14  Late RT injury is defined classically as 3 months or more after cancer treatment, 
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and may represent persistence of early injury (i.e., “consequential late effects”) or new 
damage linked to excessive collagen accumulation, microvascular damage, and 
overproduction of pro-fibrotic growth factors β (TGF-β1) resulting in fibrosis and 
atrophy.14,15 The superior pharyngeal constrictor (SPC) region comprises minor nerve tracts 
and the constrictor and longitudinal pharyngeal muscles, which are important for pharyngeal 
shortening and constriction during swallowing for safe and efficient bolus propulsion into the 
esophagus.16 Irradiation to this region, specifically the mean SPC region dose, has been 
reported in numerous studies to be associated with chronic and late radiation associated 
dysphagia (late-RAD).16-19 Thereby dysphagia may occur as consequence of reduced base of 
tongue retraction and elevation of larynx, inadequate retroflexion of epiglottis, pharyngeal 
transit delay, and inadequate swallowing muscle action.14  
Surgical treatment for OPC including tongue resection involving geniohyoid or 
mylohyoid muscles, mandibulotomy-related genioglossus injury and loss of occlusion, lateral 
soft palate resection may also cause muscle and nerve injury and contribute to dysphagia.13 
Site and extent of tumor resection thereby contribute to severity of dysphagia.13 Reports also 
suggest that head and neck (HNC) patients treated with surgery followed by post-operative 
RT may experience cumulative effects and more accelerated effects of RT.6, 13, 20 This may 
contribute to additional decline in swallowing function due to diminished oropharyngeal 
swallow efficiency. 6, 13, 20  
Lower cranial neuropathies (LCNP) are a rare, but permanent late effect of HNC 
treatment that injures the glossopharyngeal (IX), vagus, (X), accessory (XI), and/or 
hypoglossal (XII) nerves.1, 21-24 These nerves (except XI) play a pivotal role in the 
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oropharyngeal swallowing mechanism and thereby their damage can contribute to profound 
functional impairment in terms of dysphagia often with co-existing problems in speech and 
voice and shoulder impairment. 1, 16, 21-25 A previous study among 59 OPC survivors treated 
with intensity modulated radiotherapy (IMRT) reported a 5% incidence rate of late LCNP at 
median follow-up of 5.7 years (range: 4.6-7.6 years).1 Among LCNP cases, onset of 
neuropathy preceded quantifiable, clinically significant decline in both patient-reported (per 
MD Anderson Dysphagia Inventory; MDADI) and clinician-rated (per Modified Barium 
Swallow Study; MBS) swallowing function.1 Likewise, the investigators recently published a 
large survey of 889 long-term OPC survivors in which LCNP was significantly associated 
with excess symptom burden and had the greatest impact on swallowing/ chewing and 
voice/speech symptoms among the 22 symptom items rated using the MD Anderson 
Symptom Inventory Head and Neck Cancer Module (MDASI-HN), a validated multi-
symptom survey instrument.26  
Previous literature also specifically implicates LCNP as a major contributor to late 
radiation associated dysphagia (late-RAD).21, 22 Patients with late RAD often have clinically 
detectable LCNP with unilateral paralysis, muscle wasting leading to atrophy of lingual and 
pharyngeal musculature with clinical series supporting a prominent role of nerve injury in the 
functional decline experienced by these patients.25 A series of 29 HNC survivors with late-
RAD reported that 48% of cases had clinically-detectable cranial neuropathies, and cranial 
nerve XII and X palsies were most common.25 Several small published series and case 
reports consistently describe severe problems in swallowing, eating, and extreme functional 
impairment in pharyngeal phase of swallowing among survivors with late LCNP, with 
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associated swallowing inefficiency, pharyngeal residue, and silent aspiration. 1, 16, 21-25 
Consequently, about 85% of OPC survivors with late-RAD develop pneumonia and more 
than 60% require long-term gastrostomy tube placement highlighting the possible extreme 
functional relevance of late LCNP if it indeed is a driver of late dysphagia.16, 22 
The previous literature and prior analysis of symptom burden suggests a strong 
association between late LCNP and the severity of dysphagia, however the nature of this 
association has not been comprehensively evaluated or quantified in a large population of 
survivors. Few studies have addressed late LCNP among OPC survivors, as most of the 
published literature on LCNP has been comprised of case reports or studies primarily 
conducted among nasopharyngeal cancer (NPC) survivors.27, 28 Studies suggest that risk of 
cranial nerve damage increases over time 1, 22, 28 and as survival probabilities improve for 
OPC, there is an ever-growing pool of OPC survivors who have received surgery and/or 
curative doses of radiotherapy sufficient to induce LCNP. Therefore, there is urgent need to 
understand to our fullest ability the functional impact of this disabling late effect of therapy. 
Thus, the purpose of this analysis was to quantify the association of late LCNP with 
swallowing-related QOL using the MDADI and functional status metrics. We hypothesized 
that late LCNP among OPC survivors would be associated with significantly worse 
swallowing-related QOL (per MDADI survey scores) and LCNP status would relate to 
differences in functional status metrics. 
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MATERIALS AND METHODS 
 
Study Design, Eligibility and Consent 
This cross-sectional survey was conducted in 2015 among a cohort of OPC survivors 
who received primary cancer treatment at MD Anderson Cancer Center (MDACC) between 
January, 2000 and December, 2013. An institutional review board-approved patient-reported 
outcome (PRO) survey was administered to eligible OPC survivors in the cohort who were ≥ 
18 years of age at diagnosis, completed their treatment at least 1 year prior to survey 
administration, and consented to the study. Exclusion criteria were: patients who were 
deceased, those with second primary malignancy (SPM) or recurrent head and neck cancer 
tumors preceding survey, and those whose primary spoken language was not English. For 
this analysis, patients diagnosed with LCNP or with clinical signs of LCNP prior to initiation 
of OPC treatment were excluded. The survey items included in this analysis were the 
MDADI, a patient-reported adaptation of the Performance Status Scale for Head and Neck 
cancer (PSS-HN) with questions on normalcy of diet and public eating, as well as self-report 
of aspiration pneumonia, current feeding tube status, and current weight. A previous 
publication provides details of survey administration and response.7 
 
MD Anderson Dysphagia Inventory (MDADI)  
The MD Anderson Dysphagia Inventory (MDADI) is a 20-item validated patient 
reported outcomes (PRO) instrument that quantifies perceived limitations in swallowing 
ability and their impact on day to day activities.29 MDADI provides subscale scores which 
are comprised of emotional (6 questions), physical (8 questions), and functional components 
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(5 questions). It also estimates a global summary score (based on 1 question- “My 
swallowing limits my day to day activities”) and a composite score (based on 19 questions 
excluding the global item).29-32  
 
Scoring of MDADI: The questions related to swallowing function are Likert scaled 
with the options of ‘strongly agree’, ‘agree’, ‘no opinion’, ‘disagree’, or ‘strongly disagree’, 
scored on a scale of 1-5, respectively, with the exception of two questions (E7 and F2) for 
which reverse scoring is calculated. After summation of response scores, mean is estimated 
and multiplied by 20 to estimate total score.33 Total scores range from 20-100 with higher 
scores reflecting higher perceived swallowing-related QOL. 12, 29, 32, 33   MDADI scores can 
be analyzed as continuous or categorical variables with scores classified in the following 
categories:  ≥80 as optimal, 60-79 as adequate and <60 as poor.10 MDADI was validated 
among HNC patients and has internal consistency scored by Cronbach’s alpha of 0.96 and 
was documented to have test-rest reliability correlations ranging from 0.69 to 0.88.29  
 
Performance Status Scale for Head and Neck (PSS-HN) Adaptation 
An adapted version of the PSS-HN, a validated, clinician-rated interview-based 
measure of performance status among HNC patients was included in the survey instrument.1 
The scale was adapted for patient-reported administration and comprised of questions 
pertaining to the survivor’s diet level and public eating experience.1 Normalcy of diet options 
included the following: full diet no restriction, full diet with liquid assist, solid food but avoid 
some hard to eat foods, soft chewable foods, non-chewable or pureed foods, drink warm and 
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cold liquids only, or nothing orally only use a feeding tube. Public eating was coded as the 
following: no restriction of place, food, or companion, no restriction of place, restrict diet in 
public, eat only in the presence of selected person in selected places, only eat at home with 
selected persons, or always eat alone. 
 
Primary and Secondary Outcomes 
The primary outcome for this study was mean composite MDADI score which serves 
as an estimate of overall swallowing-related quality of life.29-33 The secondary outcomes for 
analysis included the emotional, physical and functional subscale and the global MDADI 
scores as well as self-reported functional status metrics including current feeding tube status, 
normalcy of diet, public eating, history of aspiration pneumonia, current weight, 
understandability of speech, and current tracheostomy. Chart abstracted functional data 
included baseline weight to calculate percent change in weight between weight at time of 
survey and pre-treatment weight, and history of dilations due to presence of stricture. Current 
feeding tube status, aspiration pneumonia history, and current tracheostomy were coded as 
binary variables. Change in weight was calculated as baseline weight minus current weight 
and percent change in weight was calculated as change in weight divided by baseline weight. 
Survey questions on functional status metrics have been listed in Appendix 2. 
 
Primary Exposure 
Late LCNP was the primary exposure for this analysis. Late LCNP case status was 
ascertained by detailed review of medical records of survivors as previously described.26 For 
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this study late LCNP was defined as clinical evidence of neuropathy of at least one of the 
glossopharyngeal (IX), vagus (X), and hypoglossal (XII) nerves ≥ 3 months after the end of 
cancer treatment.26 The time period was defined considering the NCI-Common Toxicity 
Manual’s definition of late radiation effects as occurring 90 days and onwards after RT 
therapy initiation.34  
 
Clinical and Demographic Variables 
Demographic variables including age at diagnosis, sex, race, and education, and 
clinical variables including primary tumor subsite, tumor and nodal staging (AJCC version 
VII), treatment modality, chemotherapy, surgery, neck dissection, RT dose, fractionation, 
and modality were abstracted from the electronic medical records. Pre-treatment diet (ability 
to eat solid foods) was also collected as a surrogate variable for presence of baseline 
dysphagia. Survival time for this population was estimated as the difference between age of 
diagnosis and age at the time of the survey. History of pharyngoesophageal dilation was used 
as a surrogate variable for stricture which can contribute to dysphagia and act as a 
confounder in our analysis. 
 
Statistical Analysis 
Demographic, clinical, and treatment variables and distribution of MDADI scores by 
these variables were summarized using descriptive statistics and univariate analysis. With a 
rare event leading to small case numbers for our primary exposure (LCNP), imputation of 
MDADI scores was conducted to minimize loss of statistical power due to skipped or 
missing MDADI items. Imputation used the mean of responses to MDADI items among 
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those patients who responded to that specific item (mean score among non-missing on that 
item).35 Post-hoc sensitivity analysis was conducted to assess the impact of imputed, missing 
MDADI responses on study results. 
 
Multiple linear regression was used to investigate the association between late LCNP 
and MDADI scores controlling for confounders following model building strategies using the 
purposeful variable selection method.36 Age, subsite, T-stage, treatment modality and 
smoking based on previous literature were defined a priori as clinically important variables 
and retained for adjustment in all models. Variance inflation factor was used to assess 
collinearity among variables. Biologically plausible interaction terms were also assessed 
using the likelihood ratio tests and were considered statistically significant when p-values 
were < 0.05. Adequacy and fit of model were assessed using R squares, adjusted R squares, 
and Chi-square goodness of fit tests. Coefficients (univariate and multivariate adjusted) for 
impact of late LCNP on MDADI scores and their 95% confidence intervals (CI) were 
estimated. As secondary analyses, the relationships between late LCNP and functional status 
metrics were assessed according to their distributions using the Fisher’s exact test, Wilcoxon 
rank-sum test, and Kruskal Wallis test. All reported p-values are two-sided and considered 
statistically significant at p-value of ≤ 0.05. Statistical analysis was conducted using the 
STATA software, version 14.0 (StataCorp LP, College Station, TX). 
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RESULTS 
Sample Characteristics 
A total of 889 eligible OPC survivors with a median survival time 7.0 (range, 1-16) 
years were included in the analysis. Table 1 displays the distribution of demographic, tumor, 
and treatment-related characteristics in the study population. The patient characteristics of 
this study population have been described fully in an earlier publication.19 Briefly, 84.7% 
were male, 92.4% were white, 71.7% were educated beyond high school, 76.4% had been 
treated for T1-T2 tumors, 98.9% could eat a normal solid-food diet prior to treatment, 99.1% 
were treated with RT of which 76.6% were treated with intensity-modulated radiotherapy 
split-field technique (IMRT-SF), and median radiation dose was 70 Gy (range, 40-73 Gy). 
Definitive surgery was rare (2.7%). 
 
Late Lower Cranial Neuropathy 
Overall, 36 (4.0%) OPC survivors were diagnosed with late LCNP with median time 
to LCNP onset after treatment of 5.3 (range, 0.3-12.3) years. Among them, 21 (58.3%) of 
LCNP cases had been treated for T1-T2 tumors, 35 (97.2%) reported eating a normal solid-
food diet prior to treatment, all 36 of them received RT, 23 (63.9%) were treated with RT in 
combination with systemic treatment, 2 (5.6%) had surgery to the primary OPC tumor, 9 
(25.0%) had neck dissection, and 23 (63.9%) were treated with IMRT-SF. Median time from 
LCNP onset to survey completion was 2.7 (range, 0.1-14.0) years. Among patients without 
LCNP, composite MDADI scores had a mean of 80.1±16.3 and median of 83.2, (range, 26.3-
100) whereas LCNP cases had a mean of 68.0±17.4 and median of 67.4 (range, 36.8-97.9). 
Among LCNP cases, CN XII palsy was most common and present in 86.1% (31/36) of 
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LCNP cases. Isolated IX nerve palsy was difficult to ascertain, rather those with pharyngeal 
paresis were included as CN IX/X nerve palsy and 50% (18/36) of LCNP cases had CN IX 
or/and CN X neuropathy. Polyneuropathy was also present among 36.1% (13/36) of LCNP 
cases.  
 
MDADI composite scores 
The MDADI composite scores reported by OPC survivors are summarized in Table 1. 
Lowest (worse) scores were reported by patients with T4 tumors (68.7 ± 18.9) and those 
treated with 3-dimensional conformal RT technique (67.8 ± 20.4), whereas the highest 
(better) scores were reported by patients who did not receive RT (89.9 ± 9.4) and those 
treated with proton therapy (87.5 ± 11.3). Unadjusted univariate analyses demonstrated that 
survival time, education, T-classification, smoking, therapeutic modality, chemotherapy, RT 
dose, fractionation, and modality, and stricture had significant associations (p<0.25) with 
composite MDADI scores. Composite MDADI scores were also significantly different based 
on patient-reported diet levels at the time of survey (p< 0.001). 
 
Late LCNP cases reported significantly worse composite MDADI scores compared to 
those without LCNP (LCNP: 68.0 ± 17.4, 95%CI, 62.1 to 73.9 vs. no LCNP: 80.2 ± 16.3, 
95%CI, 79.1 to 81.3, p< 0.001). Multiple linear regression identified that late LCNP was 
significantly associated with lower (worse) composite MDADI scores (coefficient, -6.7; 
95%CI, -12.0 to -1.3; p value = 0.015; adjusted R2, 0.13) after adjusting for age, survival 
time, sex, education, subsite, T-stage, smoking, therapeutic modality, RT modality, solid 
food diet prior to treatment, and stricture. These results have been summarized in Table 2. 
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When MDADI composite scores were categorized, 38.9% (14/36) LCNP cases had poor 
swallowing scores (MDADI<60) in comparison to 12.9% (110/853) patients without LCNP 
(OR= 4.3; 95%CI, 2.2 to 8.6).  
 
MDADI Subscale Scores 
Late LCNP cases reported significantly lower (worse) scores on all MDADI 
subscales and on global MDADI scores. The associations remained significant in multiple 
linear regression models after adjusting for significant covariates. These results are 
summarized in Table 3. Additionally, global MDADI scores were also highly correlated with 
composite MDADI scores (Spearman's rho = 0.8, p<0.001). 
Figure 1 summarizes multivariate adjusted coefficients for late LCNP and MDADI Scores 
We also compared composite MDADI scores among patients without LCNP, LCNP IX/X 
only, LCNP XII only and polyneuropathy illustrated in Figure # 2. Lowest (worst) mean 
scores and least variability of scores were reported by LCNP cases with polyneuropathy 
which may be suggestive of worsening swallowing function with more cranial nerve injury 
indicating a dose-response relationship. Of great concern was that LCNP cases with 
polyneuropathy, reported a drop of 18.2 in mean scores in comparison to patients without late 
LCNP with about half of them reporting poor composite scores indicating a clinically 
meaningful reduction in MDADI scores but this was not statistically significant. 
Sensitivity analysis was also conducted including RT dose and HPV status in final 
models for all MDADI scores and as the effect estimates for late LCNP remained unchanged 
therefore these variables were excluded. Results are presented in Appendix Table 2 and 
Table 3. 
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Functional status metrics 
LCNP status also significantly associated with (p ≤0.001) worse functional outcomes 
and health metrics reported by the patient or chart abstracted at the time of survey as detailed 
in Table 4.  LCNP cases were more likely to have a current feeding tube (OR= 20.5; 95%CI, 
8.6 to 48.9), history of aspiration pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), tracheostomy 
(OR= 26.9; 95%CI, 6.0 to 121.7), and were more likely to have undergone dilation for 
stricture (OR= 12.3; 95%CI, 4.2 to 36.3) than patients without LCNP. LCNP cases were also 
more likely to report restricted oral diets at the time of survey (LCNP: OR= 3.5; 95%CI, 1.5 
to 8.3). Mean percentage of reported weight loss from baseline weight to weight at time of 
survey was also significantly higher among LCNP cases than patients without LCNP (LCNP: 
mean 11.7% vs. no LCNP: 6.0%, p=0.002).  
 
DISCUSSION 
Late LCNP is rare with reports of incidence ranging from 3.7% to 25.6%. However, 
another cohort study reported 14% incidence of LCNP in 10-year survivors of HNC, 
suggesting that risk increases over time.37Our previous report confirmed high symptom 
burden among OPC survivors who developed LCNP, with largest effect sizes (coefficient, 
2.3 of 10) on swallowing-related symptoms.26 This phenomenon is also clinically recognized, 
but previous work has failed to quantify the impact of LCNP on individual swallowing 
domains and functional metrics. This large single-center cross-sectional survivorship survey 
study among OPC survivors provides a comprehensive evaluation and found significant 
associations with moderate effect size between late LCNP and overall swallowing-related 
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quality of life, domain-specific swallowing function, as well as functional status metrics 
related to swallowing.  
 
Overall, swallowing-related quality of life among all 889 OPC respondents suggested 
most survivors perceived acceptable levels of functioning (as per composite MDADI means 
of 79.7 ± 16 and 55.2% of survivors reported composite scores ≥80), but the small group of 
survivors (n=36) with late LCNP reported a clinically meaningful reduction of > 10 points 
difference relative to survivors without LCNP in univariate analyses.38 This meaningful 
reduction was observed for all summary and domain-specific MDADI scores.  After 
multivariate adjustment for clinical covariates, on an average, composite MDADI scores 
were 6.7 points lower (worse) among late LCNP cases versus those without late LCNP. The 
adjusted R2 demonstrated that late LCNP explained 13% of the variation in composite 
MDADI scores after accounting for the effect of other covariates, which according to 
Cohen’s criteria is a moderate effect.39   This moderate effect size is consistent with effect 
estimate for the impact of LCNP on patient-reported MDASI-HN swallowing/chewing 
symptoms (coefficient, 2.3 of 10) reported in an earlier study and may in part reflect the 
subjective nature of PROs that likely vary with individuals’ overall contentment and 
satisfaction with life and functional abilities.12, 13, 40  
 
Late LCNP was also significantly associated with all domain-specific MDADI 
subscale scores. Late LCNP cases experienced the greatest deterioration of physical subscale 
scores which represent patient perception of swallowing ability; LCNP explained 10% of the 
variation in this domain controlling for important confounders. Previous studies have also 
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reported lowest MDADI scores on the physical subscale among HNC patients.10, 38 Further, 
among late LCNP cases, the least impact of nerve injury was on the emotional subscale 
scores. Emotional subscale scores reflect psychological response to diminished swallowing 
ability and functional subscale scores reflect the impact of swallowing impairment on daily 
functioning and activities.32 Previous studies among HNC patients have reported the highest 
subscale scores in the functional domain and substantial recovery of emotional MDADI 
scores over time.10, 40 This may be indicative of adjustment and adaptation to a decline in 
swallowing function overtime.40 
 
It is generally believed that PRO instruments may underestimate the prevalence of 
dysphagia.41, 42 For this reason, we also explored the relationship between LCNP with other 
functional status measures of swallowing ability. As expected, late LCNP status was also 
significantly associated with worse functional status metrics including current feeding tube 
status, normalcy of diet, public eating, self-reported history of aspiration pneumonia, weight- 
loss since diagnosis, understandability of speech, tracheostomy, and esophageal dilations due 
to presence of stricture. Thereby late LCNP was consistently associated with substantial 
functional morbidity among OPC survivors. These results are not surprising given the degree 
of swallowing dysfunction previously reported among long-term OPC survivors in earlier 
case reports that suggested that treatment-related LCNP may play a major role in late RAD, 
and precipitate delayed but extreme oropharyngeal impairment as recorded by MBS studies.1, 
21, 22 These observations also align to numerous reports of significant swallowing dysfunction 
caused by lower cranial nerve deficits among populations due to traumatic injury, vascular 
causes, and infection, documented primarily in case reports.43-47 
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Approximately one-third (28.6%) of late LCNP patients in our study, reported having 
a feeding tube at the time of survey. High rates of gastrostomy dependence among LCNP 
cases again support a high prevalence of dysphagia in this population. In an earlier study 
among OPC patients with advanced stage treated with concurrent RT and chemotherapy, 
feeding tube use had the maximum impact on QOL (-30 points compared to controls) 
evaluated by SF36 and HNQOL.48 Late LCNP cases also had significantly higher rates of 
aspiration pneumonia (32.3% LCNP versus 2.0% no LCNP ), which support association with 
high dysphagia-related morbidity. Similarly, a study using SEER data among HNC patients 
treated with chemoradiation reported 23.8% five-year rates of aspiration pneumonia.49 
Additionally, as late LCNP occurs many years after treatment with a tendency for silent 
aspiration, symptoms of LCNP may be missed due to lack of adequate surveillance among 
OPC survivors. This may further enhance risk of aspiration pneumonia and contribute to 
debilitating functional morbidity with increased feeding tube dependence, hospitalization, 
weight loss, and life-threatening complications. 
 
Overall, late LCNP with accompanying dysphagia is a clinical condition of great 
concern as it does not typically respond well to treatment. With progressive long-term 
functional decline with aspiration and recurring aspiration-pneumonia, long-standing feeding 
tube dependence and elective laryngectomy may be required.1, 16, 21, 22, 50 Therefore, risk-
reduction and management of late effects like LCNP, late-RAD and associated functional 
toxicities need to be prioritized in contemporary OPC treatment and management. That is, 
providers should be alerted that survivors found to have a new IX, X, or XII nerve palsy in 
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routine surveillance likely merit return to the speech pathologist for instrumental swallowing 
evaluation, counseling, and therapy as well as interdisciplinary consideration of risk 
reduction strategies for aspiration that preserve oral intake but diminish pneumonia risk.  
This research may also help to provide benchmarks for novel interventions and surveillance 
efforts. Routine PRO administration coupled with instrumental examination using fiberoptic 
endoscopic evaluation of swallowing (FEES) and MBS may also help identify patients in 
need of more intense, targeted therapy.50 Multi-disciplinary supportive treatment including 
routine swallowing and speech assessment, risk-based treatment planning, swallowing and 
nutritional therapy, counselling to improve coping skills, and guidance in effective meal 
preparation may help to attenuate the impact of late LCNP-associated swallowing 
impairment, diminish life-threatening complications, and enhance swallowing-related QOL.50 
 
This study is the first to quantify the association between late LCNP and swallowing-
related quality of life in a study population of almost 900 OPC survivors finding the 
hypothesized significant associations. However, there are limitations to acknowledge. 
Complete case analysis was not feasible as 126/889 (14.2%) respondents returned surveys 
with skipped or missing MDADI items. Thus, complete case analysis would have contributed 
to attrition of approximately one-third of LCNP cases that would have substantially 
diminished power in our study that focused on a rare event like LCNP. Therefore, we 
imputed missing MDADI scores for 27% (10/36) of late LCNP patients. The validity of our 
imputed results is supported by sensitivity analyses finding similar effect size estimates using 
imputed vs non-imputed data (Appendix: Table 1). Imputed composite MDADI scores and 
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non-imputed composite MDADI scores by LCNP status have also been presented as 
Supplementary figure # 1 and their distribution is similar which was expected given 
imputation was conducted using scores from non-missing items only. Post-imputation, 
unadjusted means and accompanying standard deviations of composite, global, emotional, 
physical, and functional scores were similar to estimates of means and standard deviations of 
an earlier study among HNC patients.38 Further, consistency of results with previous 
literature was demonstrated as survivors in our study treated with multimodality treatment 
versus single modality, those who did not receive chemotherapy versus those who did, those 
treated with accelerated RT versus standard fractionation, those who received conventional 
3D conformal RT versus IMRT/ proton therapy and current smokers versus never smokers 
reported significantly worse composite scores and those with early stage versus more 
advanced stages reported significant positive trend for better swallowing scores 5, 8-10, 33, 50 
These results indicate that our primary outcome variable, composite MDADI variable 
consistently performed well and showed expected variation across clinical and tumor-related 
factors. Large and statistically significant differences in functional metrics by LCNP status 
also support our findings of high functional morbidity among LCNP cases. Our study results 
also support a previous survey analysis in this study population, which used complete case 
analysis of MDASI-HN, with low attrition of cases due to missing data and demonstrated a 
strong impact of LCNP on swallowing, choking, mucus, fatigue, and voice symptoms.26 
 
Our study may also be subject to limitations inherent to cross-sectional PRO survey 
collection including survival bias, which we tried control by including survival time in all our 
multivariate models. MDADI and PSS-HN scores prior to late LCNP diagnosis were not 
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available to fully control for subtle differences in baseline function. Rather, oral diet at 
baseline was included as a covariate in analysis; among LCNP cases all but one could eat a 
solid food diet pre-treatment suggesting functional baseline swallow in the vast majority of 
LCNP cases. Further, chart abstraction of the LCNP case status precluded the ability to 
identify sensory deficits associated with LCNP as clinical documentation focused on motor 
deficits. We suspect that inclusion of sensory deficits of late LCNP might have led to higher 
number of late LCNP cases detected. Several factors may limit generalizability of these 
results. Given that few patients in our study received definitive surgery, our study results may 
have less application to OPC patients treated with primary surgery. Our study population was 
treated at a single tertiary cancer care institution and thus demographic characteristics may 
limit generalizability to other more varied populations. However, the study population 
demographics are similar to those expected among OPC patients across the US. Finally, it 
was beyond the scope of this work to identify predictors of late LCNP as would be necessary 
avoid this severe late functional toxicity. However, a recent cohort study among 10-year 
survivors identified an association between primary tumor site, RT dose, chemotherapy, and 
post-RT neck dissection as clinical predictors of cranial neuropathy on univariate analysis.37 
Predictors of LCNP will be addressed in future work by the authors, as well. 
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CONCLUSIONS 
In this large cross-sectional analysis, OPC survivors with late LCNP had significantly 
lower (worse) swallow-related QOL as per MDADI scores with significantly higher 
likelihood of adverse functional status metrics like dietary restrictions, nutritional 
impairment, weight-loss, decline in public food consumption with possible consequences of 
social isolation, aspiration pneumonia, long-term feeding tube dependence, and 
tracheostomy. These data support and quantify the detrimental relationship of late LCNP 
with swallowing-related measures.  
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Table 1: Patient Characteristics (N=889), late LCNP rate, and mean composite MDADI 
scores 
 
  Composite MDADI Score ± 
Standard Deviation) 
Variables All Patients 
(n=889) 
Patients with 
LCNP (n=36) 
All patients 
(n=889) 
P-value a, b 
Continuous Variables    P-value a 
Age at diagnosis, median 
(range) 
56 (32-84) 57 (42-72) rho = -0.034 0.306 
Survival time, median 
(range) 
7 (1-16) 10.5 (2-16) rho = -0.076 0.023 
Radiation Dose, Gy. 
median (range) 
70 (40-73) 70 (60-72) rho = -0.201 < 0.001 
Categorical Variables All Patients 
n (%) 
n (%) Patients 
with LCNP 
All patients 
(n=889) 
P-value b 
Sex    0.443 
Female 136 (15.3) 5(3.7) 78.3 ±17.5  
Male 753 (84.7) 31(4.1) 79.9 ±16.3  
Education    < 0.001 
≤Highschool 168(18.9) 8(4.8) 75.6 ±16.7  
>Highschool 637(71.7) 27(4.2) 80.9 ±15.9  
Missing 84(9.4) 1(1.2) 78.6 ±18.9  
Race    0.983 
Others 59(6.6) 3(5.0) 78.5 ±20.0  
White 821(92.4) 32(3.9) 79.8 ±16.2  
Missing 9(1.0) 1(11.1) 78.4 ±19.3  
Primary Site    0.200 
Tonsil 438(49.3) 17(3.8) 80.3 ±16.4  
Base of Tongue 451(50.7) 19(4.2) 79.1 ±16.6  
T classification    < 0.001 
1 334(37.6) 8(2.4) 82.6 ±15.2  
2 345(38.8) 13(3.8) 80.8 ±15.7  
3 131(14.7) 8(6.1) 75.8 ±17.0  
4 79(8.9) 7(8.9) 68.7 ±18.9  
N classification    0.007 
N0 81(9.1) 3(3.7) 79.9 ±16.1  
N1+2a 236(26.5) 7(2.9) 81.8 ±14.7  
2b+3 429(48.3) 19(4.4) 80.1 ±16.4  
2c 143(16.1) 7(4.9) 74.7 ±18.9  
HPV status    0.033 
Negative 56(6.3) 2(3.6) 80.9 ±16.8  
Positive 429(48.3) 9(2.1) 81.0 ±15.9  
Unknown 404(45.4) 25(6.2) 78.1 ±17.0  
Smoking     < 0.001 
Never 409(46.0) 16(3.9) 81.4 ±16.2  
Former 422(47.5) 17(4.0) 79.0 ±16.3  
Current 58(6.5) 3(5.2) 72.5 ±17.9  
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  Composite MDADI Score ± 
Standard Deviation) 
Variables All Patients 
(n=889) 
Patients with 
LCNP (n=36) 
All patients 
(n=889) 
P-value a, b 
Solid Food pre-Tx    0.846 
Yes 879(98.9) 35(4.0) 79.9 ±14.0  
No 10(1.1) 1(10.0) 79.7 ±16.5  
Treatment Group    < 0.001 
Single Modality 278(31.3) 11(4.0) 83.2 ±14.3  
Multimodality 611(68.7) 25(4.1) 78.1 ±17.2  
Treatment Group    0.001 
RT alone 270(30.4) 11(4.1) 83.0 ±14.4  
Surgery alone 8(0.9) 0 89.9 ±9.4  
RT plus systemic 596(67.0) 23(3.9) 78.1 ±17.3  
Surgery plus adjuvant 15(1.7) 2(13.3) 78.4 ±14.2  
Radiotherapy     0.068 
No 8(0.9) 0 89.9 ±9.4  
Yes 881(99.1) 36(4.1) 79.6±16.5  
Chemotherapy     < 0.001 
No 284(32.0) 11(3.9) 83.0 ±14.3  
Yes 605(68.0) 25(4.1) 78.1 ±17.2  
Surgery     0.403 
No 865(97.3) 34(3.9) 79.6 ±16.6  
Yes 24(2.7) 2(8.3) 83.0 ±13.8  
Neck Dissection    0.431 
No 665(74.8) 27(4.1) 79.9 ±16.5  
Yes 224(25.2) 9(4.0) 79.0 ±16.5  
RT Schedule     0.002 
Standard Fractionation 778(88.3) 21(2.7) 80.3 ±16.1  
Accelerated  95(10.8) 15(15.8) 73.5 ±18.3  
Other 8(0.9) 0 78.3 ±24.3  
RT Type     < 0.001 
3d Conformal 50(5.7) 9(18.0) 67.8 ±20.4  
IMRT-SF  675(76.6) 23(3.4) 79.6 ±16.1  
IMRT- WF 33(3.8) 1(3.0) 74.7 ±17.8  
Proton 23(2.6) 1(4.4) 87.5 ±11.3  
IMRT Ipsilateral 100(11.3) 2(2.0) 84.9 ±14.3  
Dilation/ Stricture    < 0.001 
No 873 (98.2) 31(3.6)  80.0 ± 16.3  
Yes 16 (1.8) 5(31.3) 61.0 ± 14.6  
Abbreviations: T, tumor; RT, radiotherapy; MDADI, MD Anderson Dysphagia Inventory (MDADI); 
rho, Spearman rho; pre-Tx, pre-treatment; 3d Conformal, Three Dimensional (3D) Conformal 
Radiation Therapy; IMRT-SF, Intensity-modulated radiation therapy with split field technique; 
IMRT-WF, Intensity-modulated radiation therapy with whole field technique. a P-value for 
Continuous Variables and Composite scores calculated using Spearman Test. b P-value for 
Categorical Variables and Composite scores calculated using Kruskal Wallis Test. 
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Table 2: Univariate and Multivariate Regression: Composite MDADIa (N=889) 
Variables 
 
Univariate Analysis 
Coefficient (95%CI) 
P value Multivariate 
Analysis 
Coefficient 
(95%CI) 
P value 
Late LCNP     
No Reference  Reference  
Yes -12.2 (-17.6, -6.7) < 0.001 -6.6 (-12.0, -1.3) 0.015 
Age at diagnosis -0.1 (-0.2, 0.1) 0.328 -0.1 (-0.2, 0.1) 0.275 
Survival Time -0.4 (-0.7, -0.1) 0.009 -0.2 (-0.6, 0.1) 0.151 
Radiation Dose -1.1 (-1.5, -0.7) < 0.001   
Sex     
Female Reference  Reference  
Male 1.6 (-1.4, 4.6) 0.305 2.3 (-0.6, 5.2) 0.119 
Education     
≤Highschool Reference  Reference  
>Highschool 5.3 (2.5, 8.1) < 0.001 4.2 (1.5, 6.9) 0.002 
Missing 3.0 (-1.3, 7.3) 0.167 2.8 (-1.4, 7.0) 0.196 
Race     
Others Reference    
White 1.3 (-3.1, 5.7) 0.556   
Missing -0.1 (-11.7, 11.5) 0.987   
Primary Site     
Tonsil, soft palate, & 
pharyngeal wall 
Reference  Reference  
Base of tongue & GPS -1.2(-3.4, 1.0) 0.282 -1.1 (-3.4, 1.2) 0.334 
T classification     
1 Reference  Reference  
2 -1.8 (-4.2, 0.6) 0.139 -1.1 (-3.6, 1.5) 0.407 
3 -6.9 (-10.1, -3.6) < 0.001 -3.3 (-6.8, 0.3) 0.069 
4 -14.0 (-17.9, -10.0) < 0.001 -9.9 (-14.1, -5.8) < 0.001 
Smoking     
Never Reference  Reference  
Former -2.4 (-4.6, -0.1) 0.039 -1.6 (-3.8, 0.5) 0.141 
Current -8.9 (-13.4, -4.3) < 0.001 -7.0 (-11.4, -2.7) 0.001 
Solid Food pre-Tx     
Yes Reference  Reference  
No -0.2 (-10.5, 10.1) 0.965 -2.1 (-12.0, 7.8) 0.675 
Treatment Group     
Single modality Tx.  Reference  Reference  
Multimodality Tx. -5.1 (-7.4, -2.8) < 0.001 -2.7 (-5.4, -0.1 0.046 
Radiotherapy     
No Reference    
Yes -10.4 (-21.9, 1.1) 0.077   
Chemotherapy     
No Reference    
Yes -4.9 (-7.2, -2.6) < 0.001   
Surgery     
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Variables 
 
Univariate Analysis 
Coefficient (95%CI) 
P value Multivariate 
Analysis 
Coefficient 
(95%CI) 
P value 
No Reference    
Yes,  3.5 (-3.2, 10.1) 0.310   
Neck Dissection     
No Reference    
Yes -0.9 (-3.4, 1.6) 0.497   
RT Schedule     
Standard Fractionation Reference    
Accelerated  -6.9 (-10.4, -3.4) < 0.001   
Missing -2.0 (-13.5, 9.4) 0.731   
RT Type     
3d Conformal Reference  Reference  
IMRT-SF  11.8 (7.2, 16.4) < 0.001 8.1 (3.1, 13.1) 0.002 
IMRT- WF 6.9 (-0.2, 14.0) 0.057 5.9 (-1.3, 13.0) 0.107 
Proton 19.7 (11.7, 27.7) < 0.001 14.4 (6.0, 22.9) 0.001 
IMRT-Ipsilateral 17.1 (11.6, 22.5) < 0.001 9.9 (3.8, 16.0) 0.002 
Stricture/Dilation     
No Reference    
Yes -19.0 (-27.1, -10.9) < 0.001 -13.1 (-21.1, -5.2) 0.001 
Abbreviations: T, tumor; RT, radiotherapy; MDADI, MD Anderson Dysphagia Inventory (MDADI); 
rho, Spearman rho; pre-Tx, pre-treatment; 3d Conformal, Three Dimensional (3D) Conformal 
Radiation Therapy; IMRT-SF, Intensity-modulated radiation therapy with split field technique; 
IMRT-WF, Intensity-modulated radiation therapy with whole field technique. Statistical significance 
p value < 0.25 after Univariate Analysis. Statistical significance p value < 0.05 after Multivariate 
Analysis. aMissing values imputed.  
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Table 3: MDADI Scores by late LCNP Status (N=889) 
 Mean ± SD  
(95%CI) 
 Analysis Coefficient (95%CI)  
MDADI 
SCORESa 
Patients with 
LCNP 
 (n=36) 
Patients 
without 
LCNP 
(n=853) 
P value Univariate 
(95%CI) 
 
Multivariate 
(95%CI) 
P value 
Composite 68.0 ± 17.4 
(62.1 to 73.9) 
80.2 ±16.3 
(79.1 to 81.3) 
 
< 0.001 
 
-12.2 (-17.6 to -6.7) - 6.7 (-12.0 to -1.3) 0.015 
Global 65.1 ± 28.9 
(55.3 to 74.8) 
81.3 ± 23.2 
(79.8 to 82.9) 
 
< 0.001 
 
-16.3 (-24.1 to -8.4) -9.1 (-17.0 to -1.3) 0.023 
Emotional 70.1±19.2 
(63.6 to 76.5) 
81.0±16.4 
(79.9 to 82.1) 
 
< 0.001 
 
-10.9 (-16.5 to -5.4) -5.9 (-11.4 to -0.3) 0.038 
Physical 62.5±18.0 
(56.4 to 68.6) 
75.9±19.0 
(74.6 to 77.2) 
 
< 0.001 
 
-13.5 (-19.8 to -7.1) -7.7 (-14.0 to -1.3) 0.018 
Functional 74.4±20.7 
(67.4 to 81.4) 
86.0±16.1 
(84.9 to 87.1) 
 
< 0.001 
 
-11.6 (-17.1 to -6.1) -6.0 (-11.4 to -0.6) 0.028 
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial 
neuropathy. Multiple linear regression models adjusted covariates including, age, survival time, sex, 
education, subsite, T-stage, smoking, therapeutic modality, RT modality, solid food diet prior to 
treatment, and stricture. The regression model for global scores adjusted for an additional variable, 
neck dissection. aMissing values imputed.  
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Table 4: Functional Status Metrics by late LCNP status (n=889) 
Variables Patients with 
LCNP  
n (%) 
Patients without 
LCNP n (%) 
P-value Crude OR 
(95%CI) 
Current Feeding Tube   < 0.001  
No 25 (71.4) 819 (98.1)  Reference 
Yes 10 (28.6) 16 (1.9)  20.5 (8.6 to 48.9) 
Normalcy Diet    < 0.001  
Full Diet no restrictions  6 (18.2) 357 (43.7)  Reference 
Full Diet with liquid assist  8 (24.2) 315 (38.5)  3.5 (1.5 to 8.3) 
Solid food but avoid some hard to eat foods  10 (30.3) 96 (11.7)   
Soft chewable foods  2 (6.1) 33 (4.0)   
Non-chewable or pureed foods  1 (3.0) 3 (0.4)   
Warm and cold liquids  2 (6.1) 10 (1.2)   
Not eat or drink anything by mouth  4 (12.1) 4 (0.5)   
Public Eating   < 0.001  
No restriction of place/ food/companion  8 (25.8) 582 (70.3)  Reference 
No restriction of place, but restrict diet in 
public  
14 (45.2) 191 (23.1)  6.8 (3.1 to 15.1) 
In presence of selected person in selected 
places  
7 (22.6) 36 (4.3)   
Only eat at home with selected persons  1 (3.2) 14 (1.7)   
Always eat alone 1 (3.2) 5 (0.6)   
Aspiration Pneumonia   < 0.001  
No 21 (67.7) 741 (98.0)  Reference 
Yes 10 (32.3) 15 (2.0)  23.5 (9.6 to 57.6) 
Weight loss   0.050  
No 4 (11.4) 202 (24.4)  Reference 
Yes 31 (88.6) 626 (75.6)  2.5 (0.9 to 6.9) 
Change in Weight; mean, median (range)a 22.9, 
16.8(14.2,87.8) 
13.3,  
9.4(103.1,164.6) 
0.005 
 
 
% Change in Weight; mean ± SD, median, 
(range)b 
11.7±10.4, 
9.9(-7.9,33.4) 
6.0 ±10.7, 
5.1(-96.4, 43.4) 
0.002  
Understandability of Speech   < 0.001  
Always understandable 6 (17.6) 528 (63.3)  Reference 
Understandable most of the time  16 (47.1) 269 (32.3)  8.1 (3.4 to 19.2) 
Usually understandable  3 (8.8) 19 (2.3)   
Difficult to understand  8 (23.5) 17 (2.0)   
Never understandable 1 (2.9) 1 (0.1)   
Tracheostomy   0.001  
No 31 (91.2) 834 (99.6)  Reference 
Yes 3 (8.8) 3 (0.4)  26.9(6.0 to 121.7) 
Dilation/ Stricture   < 0.001  
No 31 (86.11) 842 (98.71)  Reference 
Yes 5 (13.89) 11 (1.29)  12.3 (4.2 to 36.3) 
P values estimated by Fishers Exact Test. a, b P values estimated by Wilcoxon Rank-Sum Test. Odds 
Ratio for normalcy of diet calculated with full diet no restrictions as reference category and all other 
categories collapsed. Odds Ratio for public eating calculated with no restriction of place/ 
food/companion as reference category and all other categories collapsed. Odds Ratio for 
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understandability of speech calculated with always understandable as reference category and all other 
categories collapsed.  
 
Figure 1: Multivariate Adjusted Coefficients for Late LCNP and MDADI scores 
 
 
 
Figure 1.  Multivariate Adjusted Coefficients for Late LCNP and MDADI Scores. Multiple linear 
regression models adjusted for age, survival time, sex, education, subsite, T-stage, smoking, 
therapeutic modality, RT modality, solid food diet prior to treatment, and stricture. The regression 
model for global scores adjusted for an additional variable, neck dissection.  
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial 
neuropathy. 
 Late LCNP worse MDADI Late LCNP better  
-7.7 (-14.0 to -1.3) * 
-9.1 (-17.0 to -1.3) * 
-6.0 (-11.4 to -0.6) * 
-5.9 (-11.4 to -0.3) * 
-6.7 (-12.0 to -1.3) * 
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FIGURE 2: Imputed composite MDADI scores by Type of LCNP 
 
Figure 2. Imputed composite MDADI scores among patients without LCNP, LCNP IX/X only, LCNP 
XII only and polyneuropathy. Polyneuropathy included LCNP cases with both CN XII and CN IX/X 
palsy. Patients without LCNP had higher (better) scores than LCNP cases, but lowest (worst) mean 
scores and least variability of scores were reported by LCNP cases with polyneuropathy.  
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial 
neuropathy; IX/X, Glossopharyngeal or Vagus Nerve; XII Hypoglossal Nerve. 
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CONCLUSION 
The results of this study clearly establish late LCNP as a serious treatment-related 
toxicity among long-term OPC survivors and was associated with significantly worse cancer 
treatment-related symptoms and significantly worse swallow-related QOL. 
While rare in the population overall, quantitative estimates of lifetime risk of late LCNP over 
an almost 18-year follow-up into OPC survivorship demonstrate that one out of 10 OPC 
survivors middle-aged at time of diagnosis are likely develop late LCNP. The progressively 
increasing risk of late LCNP of 2%, 6%, and 10% at 5, 10, 18-year follow-up also indicates 
that risk of LCNP overtime is much higher than previously believed. The potential impact of 
late LCNP on the life of OPC survivors is devastating as late LCNP and accompanying late-
RAD is refractory to treatment, life-long, and permanent. Our prediction model enabled 
identification of OPC survivors who had T4 tumors and those who received accelerated 
fractionation RT treatment as having higher risk of late LCNP. In this study patients with big 
bulky tumors, had large irradiation fields possibly including cranial nerves, were likely to be 
treated most aggressively with multimodality treatment regimens including, IC, accelerated 
RT, and systemic therapy, thereby they were more likely to develop late LCNP.  
In the large cross-sectional survey analysis, late LCNP cases reported significantly 
worse cancer treatment-related symptoms, and worse symptoms associated with motor 
functions of the upper aerodigestive tract (swallowing, voice), demonstrating the relevance of 
late LCNP to both symptom severity and QOL. Among LCNP cases, a higher proportion 
reported severe (LCNP: 20% vs no LCNP: 5%) and moderate (LCNP: 40% vs no LCNP: 
15%) symptoms. 
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OPC survivors with late LCNP also reported had worse swallow-related QOL as per 
MDADI scores with significantly higher likelihood of adverse functional status metrics like 
dietary restrictions, nutritional impairment, weight-loss, decline in public food consumption 
with possible consequences of social isolation, aspiration pneumonia, long-term feeding tube 
dependence, and tracheostomy. 
Future studies need to further assess the role of dose to ROI (regions of interest 
involving critical structures), IC, and transoral robotic surgery in development of late effects 
like LCNP. Better RT techniques need to be developed to modify dose delivery and less toxic 
chemotherapy agents need to be investigated. Treatment de-intensification strategies need to 
be explored which maintain cure and prevent late effects. There is also a clear need for long-
term surveillance of late LCNP among HNC and OPC patients, particularly in light of 
epidemiologic trends that suggest growing numbers of OPC survivors at risk of late effects in 
immediate years ahead.6-8 Further, efforts are necessary to address severity of treatment-
related symptoms and optimize swallowing outcomes to improve QoL among growing 
numbers of relatively younger OPC survivors, who are expected to survive decades after 
treatment. Finally, the long-term treatment-related burden of OPC is becoming more 
apparent, there is need to find ways to treat cancer and minimize toxicity. 
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APPENDIX 
FIGURES 
Journal Article 2  
Supplementary Figure 1: MDASI-HN Scores for Swallowing/Chewing, Voice/Speech and 
Choking/Coughing for late LCNP cases (n=35) 
 
 
Supplementary Figure 1.    MDASI-HN Scores for Swallowing/Chewing, Voice/Speech and 
Choking/Coughing for late LCNP cases (n=35). Symptom are classified as: 0 “no symptom”; 1-3 
“mild”; 4-6 “moderate” and 7-10 “severe” Abbreviations: MDASI-HN, MD Anderson Symptom 
Inventory Head and Neck Cancer Module (MDASI-HN); LCNP, lower cranial neuropathy. 
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Journal Article 3 
SUPPLEMENTARY FIGURE 1: Imputed composite MDADI scores and non-imputed 
composite MDADI scores by LCNP status 
 
Supplementary Figure 1: Imputed composite MDADI scores and non-imputed composite MDADI 
scores by LCNP status. Distribution of imputed composite and non-imputed composite MDADI 
scores by LCNP status was very similar which was expected given that imputation was conducted 
using scores from non-missing items only. Further, there was expected decline in both imputed 
composite and non-imputed composite MDADI scores among LCNP cases in comparison to those 
without LCNP. This along with our sensitivity analysis in Appendix 1, Table 1 show that imputed and 
non-imputed MDADI scores were similar and our study results are valid. 
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TABLES 
Journal Article 3 
Table 1: Sensitivity Analysis Comparing Imputed Versus Non-Imputed MDADI Scores 
 IMPUTED MDADI SCORES NON-IMPUTED MDADI SCORES 
MDADI SCORE Multivariate 
Analysis Coefficient 
(95%CI) 
P Value Multivariate 
Analysis Coefficient (95%CI) 
P Value 
Composite - 6.7 (-12.0 to -1.3) 0.015 -4.8 (-11.3 to 1.6) 0.142 
Global -9.1 (-17.0 to -1.3) 0.023 -10.6 (-18.9 to -2.4) 0.012 
Emotional -5.9 (-11.4 to -0.3) 0.038 -5.6 (-11.7 to 0.6) 0.077 
Physical -7.7 (-14.0 to -1.3) 0.018 -7.8 (-15.0 to -0.6) 0.033 
Functional -6.0 (-11.4 to -0.6) 
 
0.028 -5.3 (-11.1 to 0.5) 0.073 
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI) 
Comment: Other than Composite scores all effect estimates are not very different. 
 
Table 2: Sensitivity Analysis Comparing Final Model with and without RT Dose 
 Final Model with RT Dose Final Model without RT Dose 
 
MDADI SCORE Multivariate Coefficient 
for late LCNP (95% CI) 
P Value Multivariate Coefficient 
for late LCNP (95% CI) 
P Value 
Composite -6.6 (-12.0 to -1.2) 0.016 - 6.7 (-12.0 to -1.3) 0.015 
Global -9.1 (-17.0 to -1.3) 0.022 -9.1 (-17.0 to -1.3) 0.023 
Emotional -5.8 (-11.3 to -0.3) 0.039 -5.9 (-11.4 to -0.3) 0.038 
Physical -7.6 (-13.9 to -1.2) 
 0.019   
-7.7 (114.0 to -1.3)  0.018 
Functional  -6.0 (-11.4 to -0.6) 0.029 -6.0 (-11.4 to -0.6) 0.028 
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); RT Dose (Radiation Dose) 
Comment: Effect estimates for all MDADI scores for LCNP are similar.  
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Table 3: Sensitivity Analysis Comparing Final Model with and without HPV 
 Final Model with HPV status Final Model without HPV status 
 
MDADI SCORE Multivariate Coefficient 
for late LCNP (95% CI) 
P Value Multivariate Coefficient for 
late LCNP (95% CI) 
P Value 
Composite -6.7 (-12.1 to -1.3) 0.015 - 6.7 (-12.0 to -1.3) 0.015 
Global -9.2 (-17.0 to -1.4) 0.022 -9.1 (-17.0 to -1.3) 0.023 
Emotional -5.9 (-11.4 to -0.4) 0.037 -5.9 (-11.4 to -0.3) 0.038 
Physical -7.7 (-14.0 to -1.4) 0.017 -7.7 (114.0 to -1.3)  0.018 
Functional  -6.0 (-11.4 to -0.7) 0.028 -6.0 (-11.4 to -0.6) 0.028 
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); HPV (Human Papilloma 
Virus) 
Comment: Effect estimates for all MDADI scores for LCNP are similar.  
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APPENDIX 2: Functional Status Metrics Survey Questions 
Current Feeding Tube Status 
1) Do you currently have a feeding tube?  
Yes  
No  
 
Normalcy of Diet 
2) What kinds of foods you are able to eat? (Mark one)  
Please mark the item that represents the highest level of foods or liquids you eat. If you have 
a feeding tube, but also eat by mouth, please mark the highest level of foods you eat in 
addition to your tube feedings.  
7. I eat whatever I would like (full diet no restriction).  
6. I eat whatever I would like, but require more liquids than usual with meals (full diet 
with liquid assist).  
5. I eat solid food but avoid some hard to eat foods (like meats, raw vegetables/ fruits).  
4. I eat soft chewable foods (like pasta, cooked vegetables, fish, dry foods).  
3. I eat non-chewable or pureed foods.  
2. I drink warm and cold liquids.  
1. I do not eat or drink anything by mouth; I only use a feeding tube. 
 
Public Eating 
3) Select the statement that best reflects if and how you eat in public:  
I eat out at any opportunity with no restriction of place, food, or companion.  
I eat out with no restriction of place, but I restrict my diet when in public.  
I eat only in the presence of selected person in selected places.  
I only eat at home with selected persons.  
I always eat alone.  
 
Understandability of Speech 
4) How well are you understood when speaking to other people?  
My speech is always understandable.  
My speech is understandable most of the time, I am occasionally asked to repeat 
myself.  
My speech is usually understandable, but face-to-face contact is necessary.  
My speech is difficult to understand.  
My speech is never understandable.  
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Aspiration Pneumonia 
5) Since your cancer treatment, has a doctor or other health professional told you that you 
have: 
  
Yes 
 
No 
 
Don’t Know 
 
 
Pneumonia? 
   
 
 
Tracheostomy 
6) Do you currently have a tracheostomy tube (or breathing tube)?  
Yes  
No  
 
7) Since your cancer treatment, has a doctor or other health professional told you that you 
have: 
  
Yes 
 
No 
 
Don’t Know 
 
Stricture of the throat or esophagus? 
(Stricture is a narrowing or tightness of the 
food tube that may cause sticking or 
obstruction of food.)  
   
 
But we did not use this variable we abstracted EGD/Dilation Variable from the Charts. 
 
Current Height and Weight 
8) What are your current height and weight?  
a) Height: _____ ft. _____in.  
b) Weight: _________lbs. 
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